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ABSTRACT.
Enforced expression of c-myc in many cell types is associated with inhibition of 
terminal differentiation. However, the mechanism by which this occurs remains 
unclear. In order to address this issue we therefore exploited the ability of c-Myc to 
block differentiation in the 3T3-L1 cell line, a well characterised in vitro model of 
adipogenesis.
Analysis of 3T3-L1 lines constitutively expressing an avian c-myc transgene 
revealed an inability to undergo morphological changes or accumulate cytoplasmic 
triglyceride, which was dependent upon the integrity of the Myc leucine zipper. In 
order to define the point at which adipogenesis was inhibited we analysed patterns 
of gene expression during the differentiation programme. This study demonstrated 
that the Myc block was associated with repression of the late stage markers 
C/EBPa, PPARy2, aP2 and SCD1. C/EBPa and PPARy2 are key transcriptional 
regulators of adipogenesis that co-ordinate the expression of genes required for 
lipid metabolism, including aP2 and SCD1. Hence, repression of these factors 
provides a molecular basis for the inability of Myc-expressing cell lines to undergo 
morphological differentiation. Interestingly, a 3T3-L1 clone that had spontaneously 
lost the ability to differentiate displayed a similar profile of gene expression. 
However, subtle differences indicated that this block occurred via a different 
mechanism.
Surprisingly, low levels of c-Myc were sufficient to inhibit 3T3-L1 
differentiation and this was not associated with transformation or the capacity to 
undergo apoptosis. Additionally, the continued presence of c-Myc did not alter the 
ability of the 3T3-L1 line to undergo a number of defined cell cycle events during 
the early phases of the differentiation programme. Hence, inhibition of 
adipogenesis was unlikely to reflect altered cell cycle control.
It had been proposed that c-Myc inhibits adipogenesis by preventing entry 
into a differentiation-specific growth arrest (Go) that is both irreversible and a 
prerequisite for terminal differentiation. However, we were unable to characterise 
the Gd state by either conventional criteria or by analysis of factors known to 
mediate cell cycle withdrawal in other differentiation systems. Indeed, irreversible 
cell cycle exit was only apparent in mature adipocytes, suggesting this was a 
consequence of terminal differentiation rather than the driving force. Thus, c-Myc 
did not inhibit adipogenesis by precluding entry into Gd-
Finally, treatment with 10% foetal calf serum (FCS) was sufficient to rescue 
Myc-mediated inhibition of adipogenesis but had no effect on the differentiation- 
defective clone. Abrogation of the Myc block was associated with restoration of 
the late stage markers, accounting for the ability of the Myc-expressing lines to 
accumulate lipid in the presence of FCS. Whilst the active component(s) present in 
FCS have yet to be fully defined, it is likely that growth hormone may be partly 
responsible for this phenomenon.
We therefore conclude that c-Myc inhibits adipogenesis by repressing the 
expression of master transcription factors. However, this effect is dependent upon 
external factors, since FCS rescues the phenotype.
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INTRODUCTION.
INTRODUCTION.
CHAPTER 1: Adipocyte Development.
1.1 Biological Function of Adipose Tissue.
The primary role of white adipose tissue (WAT) is to store energy in the form of 
triglycerides during times of caloric excess, and to mobilise this reserve during 
periods of energy deprivation. Mature adipocytes possess all the necessary 
enzymes required for de novo lipogenesis and lipolysis, and these processes are 
maintained under tight hormonal control (Stryer, 1988). In contrast, brown adipose 
tissue (BAT) has a somewhat specialised function, the dissipation of stored energy 
as heat, which is achieved by uncoupling mitochondrial electron transport from the 
production of ATP (Darnell et al, 1990). This response, known as non-shivering 
thermogenesis, is of particular importance in neonates, cold-adapted animals and 
hibernating vertebrates. Finally, there is currently a large body of evidence 
accumulating to suggest that adipose may also perform an endocrine function 
(McGarry, 1995). This is discussed in Section 1.6.
1.2 Adipocyte Development in vivo.
The adipocyte lineage derives from a multipotent embryonic stem cell of 
mesodermal origin, that can also give rise to cartilage and muscle cell precursors. 
Preadipocytes appear relatively late in embiyogenesis, undergoing massive 
expansion and differentiation during the neonatal period when the acquisition of an 
energy reserve becomes essential to survival (Ailhaud et al, 1992). Some species, 
including humans, have macroscopic WAT deposits at birth, whilst in rodents 
WAT does not develop until the post-natal period. Mature adipocytes represent 
between one and two-thirds of the total WAT cell population, the remainder 
comprising the stromal vascular fraction, which in addition to blood and 
endothelial cells, contains the preadipocyte population. These preadipocytes retain
l
the potential to differentiate in response to external cues throughout the life-span of 
the animal.
BAT is present in most mammalian species at birth and is thought to be a specific 
organ, distinct from WAT. However, the developmental relationship between the 
two tissues is not clear. The existence of distinct precursor cells is generally 
assumed, but a common progenitor can not be ruled out. Alternatively, it has been 
suggested that BAT may be the default pathway of adipocyte development and that 
WAT arises by transdifferentiation of pre-existing BAT depots (Ailhaud et al,
1992).
1.3 Cell Culture Models of Adipogenesis.
The study of adipocyte development has been greatly facilitated by the availability 
of established preadipocyte cell lines. These can be broadly sub-divided into two 
classes: (1) multipotent stem cell lines and (2) lines committed to the adipocyte 
lineage.
1.3.1 Multipotent Stem Cell Lines.
Multipotent cell lines, such as 10T1/2 (Reznikoff et al, 1973) and Balb/c 3T3 
(Sparks et al, 1986), have not undergone the commitment phase, but may be 
induced to do so. Thus, treatment of 10T1/2 cells with 5-azacytidine, an inhibitor 
of DNA methylation, generates a number of stable, determined lineages: 
preadipocytes, premyocytes and prechondrocytes (Taylor and Jones, 1979; 
Konieczny and Emerson, 1984). Additionally, transfection of 10T1/2 cells with 
large segments of hypomethylated genomic DNA derived from 5-azacytidine 
treated cells was found to result in myogenic conversion at a frequency suggesting 
that a single gene was responsible for commitment to this lineage (Lassar et al, 
1986). This seminal work led to the isolation of the MyoD family of basic helix-
2
loop-helix (bHLH) transcription factors, thought to be master regulators of muscle 
development (reviewed in Olson and Klein, 1994). However, this approach has so 
far proven unsuccessful in the identification of genes that control adipocyte 
determination.
1.3.2 Preadipocyte Cell Lines.
Preadipocyte cell lines have passed through the commitment phase and when 
appropriately stimulated can differentiate into cells resembling mature adipocytes. 
The properties of some of these cell lines are described below. Whilst these lines 
display many similar characteristics, their responsiveness to both positive and 
negative regulators of adipogenesis varies widely. This probably reflects stage- 
specific differences which relate to the point in development at which the lines 
were derived.
A. 3T3-L1 and 3T3-F442A Cell Lines. These cell lines are probably the most 
extensively characterised cell culture models for preadipocyte development. They 
were originally selected from the murine embryonic Swiss 3T3 M cell line for their 
ability to spontaneously accumulate triglyceride (Green and Kehinde, 1974; Green 
and Kehinde, 1976). The differentiation defective 3T3-C2 cell line was also 
derived from the same source. Prior to differentiation these cell lines resemble the 
fibroblastic preadipocyte cells found in WAT stroma. Although both the 3T3-L1 
and F442A lines can differentiate spontaneously, protocols have been developed 
that induce rapid adipogenesis at high frequency (Student et al, 1980). For the 
3T3-L1 cell line, the most widely used agents are dexamethasone, supra- 
physiological levels of insulin and methyl isobutylxanthine (MIX), a cyclic AMP 
(cAMP) phosphodiesterase inhibitor, whilst 3T3-F442A cells are responsive to 
insulin and growth hormone.
3
B. Ob 17 Cell Line. The Ob 17 preadipocyte cell line was derived from the stromal 
cells of epididymal fat pads from C57/BL/6J ob/ob (genetically obese) mice 
(Negrel et al, 1978). Various sub-lines with high adipogenic capacity have since 
been derived from Ob 17, (e.g. Ob 1771), which can be induced to differentiate in 
serum-free medium containing insulin, growth hormone, triiodothyronine and 
either agents that elevate intracellular cAMP concentrations or glucocorticoid.
C. TA1 Cell Line. This cell line was derived from 10T1/2 cells treated with 5- 
azacytidine in order to pass through the commitment phase (Chapman et al, 1984). 
Differentiation is induced with dexamethasone or indomethacin, a prostaglandin 
synthesis inhibitor.
D. HIB-1B Cell Line. The HIB-1B cell line represents a model for BAT 
development. Originally derived from a cultured murine brown cell tumour 
(hibernoma), this line differentiates in response to insulin, triiodothyronine, MDt, 
hydrocortisone and indomethacin (Ross et al, 1992). The unique feature of this cell 
line is that, once differentiated, it is competent to express the uncoupling protein 
(UCP/thermogenin), which is responsible for uncoupling respiration from oxidative 
phosphorylation. Expression of UCP is induced by p-adrenergic agents.
1.3.3 Validity o f Cell Culture Models for the Study o f Adipogenesis.
Considerable evidence exists to suggest that preadipocyte cell lines do, indeed, 
represent valid models for adipogenesis. Sub-cutaneous injection of 3T3-F442A 
cells into Balb/c athymic mice, at anatomical sites usually devoid of adipose, 
results in the formation of apparently normal fat pads at the site of injection (Green 
and Kehinde, 1979). Additionally, detailed histological and electron microscopic 
studies of mature 3T3-L1 cells revealed structural and ultra-structural features 
indistinguishable from adipocytes in situ (Novikoff et al, 1980). Fully
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differentiated cells from these lines are also found to mimic the metabolic 
properties of WAT-derived adipocytes. Hence, they display appropriate hormone 
sensitivity and responsiveness to metabolic effectors, and express the full range of 
proteins required for effective lipid metabolism. In addition, studies employing 
primary preadipocytes from a variety of sources suggest that such cells are 
responsive to the same group of effectors that initiate adipogenesis in established 
cultures (Ramsay et al, 1989a; Ramsay et al, 1989b). Finally, with the advent of 
transgenic and nullizygous animal technology, it is likely that many of the 
conclusions drawn from cell culture systems will be verified in vivo.
1.4 Modulators of Adipogenesis.
Efficient differentiation of the preadipocyte cell lines is achieved by treatment with 
external inducers. The most commonly used factors are described below, whilst the 
reader is referred to reviews by Smyth et al (1993) and Cornelius et al (1994) for a 
comprehensive list of agents that both positively, and negatively, affect 
adipogenesis.
1.4.1 Insulin, Insulin-like Growth Factor-1 and Growth Hormone.
Whilst growth hormone and high levels of insulin are known to promote 
adipogenesis, it is now apparent that both hormones exert many of their effects 
through the insulin-like growth factor-1 (IGF-1) receptor, and that physiological 
doses of IGF-1 can substitute for insulin and growth hormone in some cell lines 
(Smith et al, 1988). Preadipocytes possess large numbers of IGF-1 receptors, but 
relatively few insulin receptors. Thus, when present at supra-physiological levels, 
insulin is able to bind to the IGF-1 receptor, and so mimic the effects of IGF-1. In 
contrast, growth hormone acts by initiating an autocrine/paracrine loop, whereby 
signalling via the growth hormone receptor stimulates increased expression and
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secretion of IGF-1, which subsequently binds and signals through its own receptor 
(Zezulak and Green, 1986; Kamai et al, 1996).
The IGF-1 receptor is a member of the receptor tyrosine kinase family, which signal 
through the Ras pathway in order to transmit extracellular signals to the nucleus 
(see Figure 1). Ligand stimulated activation of the IGF-1 receptor results in the 
activation of Ras, a small GTP/GDP binding protein, which in turn stimulates a 
cascade of serine/threonine kinases, including Raf-1 and the mitogen activated 
protein kinase (MAPK), ultimately influencing the expression of a number of target 
genes (Khosravi-Far and Der, 1994; Maruta and Burgess, 1994). Evidence for an 
involvement of the Ras signal transduction pathway in adipogenesis comes from 
several sources. Liao and Lane (1995) demonstrated that over-expression of a 
phosphotyrosine phosphatase, HA2, in 3T3-L1 preadipocytes effectively blocked 
differentiation, whilst treatment with the phosphatase inhibitor, vanadate, reversed 
this effect. Additionally, over-expression of a constitutively active Ras allele in the 
3T3-L1 system resulted in differentiation in the absence of inducing hormones 
(Benito et al, 1991), as did constitutive activation of Raf-1, (Porras et al, 1994). 
Conversely, blocking Raf-1 function with a dominant negative allele inhibited 
differentiation (Porras et al, 1994).
An important function of insulin in adipocyte differentiation is the facilitative up­
take of glucose by specific transport proteins. Whilst Ras mediates the insulin- 
stimulated translocation of the ubiquitous transporter, GLUT1, it has no effect on 
GLUT4, the major glucose transport protein active during adipogenesis (Hausdorff 
et al, 1994; van den Berghe et al, 1994). Insulin-stimulated glucose uptake is now 
thought to be mediated by phosphatidylinositol 3-kinase (Okada et al, 1994), which 
is linked to insulin receptor activation via the insulin receptor substrate 1 (IRS-1) 
protein (Holman and Cushman, 1994). However, recent studies suggest that whilst
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Figure 1. Signal Transduction Pathways Implicated 
in Adipogenesis.
Ras and phosphatidylinositol 3-kinase activity are necessary to mediate the various 
effects of insulin, they are not in themselves sufficient to promote the full 
adipogenic response, suggesting a requirement for other signal transduction 
pathways (Wiese et al, 1995).
This hypothesis is further supported by studies using growth hormone. 3T3-F442A 
preadipocytes require growth hormone for differentiation when grown in serum 
supplemented conditions, as shown by immunodepletion studies. However, in this 
system IGF-1 can not substitute for growth hormone (Nixon and Green, 1984). 
Additionally, the obi771 cell line has a requirement for growth hormone that can 
not be met by IGF-1. This suggests that growth hormone functions by more than 
one mechanism. Indeed, the growth hormone receptor is a member of the cytokine 
receptor superfamily, which has recently been shown to signal via a novel route, the 
so called JAK/STAT pathway (Figure 1). Members of the Janus (JAK) kinase 
family of soluble tyrosine kinases associate with the cytokine receptor and are 
rapidly activated by tyrosine phosphorylation following ligand binding. The 
activated JAKs then phosphorylate members of the Signal Transducers and 
Activators of Transcription (STAT) family of transcription factors, which 
translocate into the nucleus, where they activate transcription of specific target 
genes (Ihle and Kerr, 1995; Watanabe and Arai, 1996). Growth hormone binding 
to its receptor has been shown to activate JAK2 (Argetsinger et al, 1993), and 
STATs 1, 3 and 5 (Ram et al, 1996). With respect to the role of growth hormone in 
promoting adipogenesis, it is also of interest to note that there may be considerable 
cross-talk between the Ras and JAK/STAT signalling pathways (Ihle, 1996; 
Winston and Hunter, 1996) and that JAK2 may also be involved in IRS-1 activation 
(Argetsinger et al, 1995).
1.4.2 Glucocorticoid and cAMP.
Differentiation of obi771 preadipocytes is potentiated by glucocorticoid. 
Glucocorticoids stimulate the expression of the enzyme, phospholipase A2, 
resulting in the release of arachidonic acid for prostaglandin biosynthesis. 
Increased levels of prostaglandins in turn lead to an increase in the intracellular 
levels of the second messengers, cAMP and Ca , which presumably act via the 
protein kinase A and C pathways respectively (Vassaux et al, 1992). However, in 
some cell lines, including TA1, arachidonic acid and its metabolites inhibit 
adipogenesis (Serrero et al, 1992). In this case, treatment with dexamethasone is 
thought to induce an inhibitor of phospholipase A2, whilst indomethacin inhibits 
the activity of cyclo-oxygenase, the enzyme which catalyses the initial breakdown 
of arachidonic acid. In addition, both dexamethasone and MIX, which increases 
cAMP levels by inhibiting the cAMP phosphodiesterase, elevate the expression of 
two transcription factors thought to be involved in the early stages of the 
differentiation programme: the CCAAT/enhancer binding proteins (C/EBP) 8 and 
(3, respectively (Yeh et al, 1995a). The role of these factors in adipogenesis is 
discussed in Chapter 2. Finally, cAMP is also implicated in the positive regulation 
of at least one gene involved in lipid metabolism, the fatty acid binding protein, 
aP2/422 (Yang et al, 1989).
1.4.3 Fatty Acids and Peroxisome Proliferators.
Treatment of preadipocytes with long chain fatty acids stimulates the expression of 
several genes involved in lipid metabolism (Distel et al, 1992; Abumrad et al, 
1993) and induces differentiation. More recently, it has been demonstrated that 
peroxisome proliferators, a diverse class of amphipathic compounds, including 
certain herbicides and hypolipidaemic drugs, can induce adipogenesis in the 3T3- 
L1 cell line with varying degrees of efficacy (Chawla and Lazar, 1994). Natural 
fatty acids and the peroxisome proliferators appear to function by a common
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mechanism (Tontonoz et al, 1995a; MacDougald and Lane, 1995a), viz. stimulation 
of members of a sub-group of the nuclear hormone receptor family of transcription 
factors, the peroxisome proliferator activated receptors (PPARs). Two PPARs are 
implicated in adipogenesis thus far: PPARy2 (Tontonoz et al, 1994a) and the fatty 
acid activated receptor (FAAR/PPAR5/Nucl), which was recently cloned by Amri 
and co-workers (1995). These factors are discussed in Chapter 2.
1.4.4 Inhibitors o f Adipogenesis.
The adipogenic programme may be inhibited by a variety of substances, including 
growth factors, cytokines, and the product of the c-myc oncogene (Smyth et al,
1993). The mode of action of many of these anti-adipogenic agents remains 
unclear. However, in the case of growth factors, inhibition of differentiation is 
likely to be an indirect consequence of stimulating proliferation. Both epidermal 
growth factor (EGF) and transforming growth factor a  (TGFa) are able to inhibit 
adipogenesis in vitro and studies with TGFa transgenic mice demonstrate a 50% 
reduction in total body fat when compared with non-transgenic controls (Luetteke 
et al, 1993). Similarly, sub-cutaneous injection of EGF into neonatal rats decreased 
fat pad weight due to a reduced differentiation potential of the adipocyte precursors 
(Serrero and Mills, 1991).
The cytokine, tumour necrosis factor a  (TNFa), is able to inhibit differentiation of 
the TA1 cell line in the presence of inducing agents (Torti et al, 1985). In addition, 
treatment of mature adipocytes with TNFa suppresses the expression of a sub-set 
of fat-specific genes and is associated with marked delipidation and morphological 
changes, a phenomenon known as dedifferentiation. The genes affected by TNFa 
appear to be predominantly targets of the transcription factor, C/EBPa, whilst the 
expression of other genes such as lipoprotein lipase and malic enzyme is not 
obviously deregulated (Weiner et al, 1991) It is now clear that at least some of the
10
inhibitory effects of TNFa may be mediated by c-myc (Ninomiya-Tsuji et al, 1993). 
The role of the Myc oncoprotein as a negative regulator of adipogenesis is 
described in detail in Chapter 3.
1.5 The Differentiation Programme.
Adipose cell differentiation is a multistep process, the key features of which are 
outlined below and summarised in Figure 2.
1.5.1 Determination.
As described in Section 1.3.1, 5-azacytidine treatment of multipotent stem cell lines 
results in the generation of three determined lineages, including preadipocytes 
(Taylor and Jones, 1979). This suggests that demethylation is an important trigger 
for differentiation, and various mechanisms are proposed to account for this 
activity. Firstly, hypomethylation may alter the chromatin structure and so unmask 
putative czs-acting regulatory elements. Alternatively, based on the 10T1/2 model 
for myogenic determination, expression of a unique transcription factor may 
commit the mesodermal stem cell to the adipocyte lineage. Transfection of 
genomic DNA derived from 3T3-F442A or human fat cells into the differentiation 
defective 3T3-C2 cell line resulted in adipogenic conversion when cultured in the 
presence of insulin (Chen et al, 1989), suggesting the presence of a sequence(s) 
capable of initiating the differentiation programme. This activity was found to 
reside in two non-identical sequences of 1.2 and 2.0kb (Colon-Teicher et al, 1993). 
However, the mechanism by which they exert their effect, or the identity of any 
putative gene products, remains unclear.
Postulating that regulatory genes should be expressed early in the differentiation 
programme, Sadowski and co-workers (1992) isolated five cDNAs that were 
expressed in the correct temporal pattern during induced differentiation of 3T3-L1
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cells. However, these still require further characterisation in order to establish a 
role, if any, in the commitment process. Other candidates for the “master 
regulator” of adipogenesis include a number of previously described transcription 
factors. Under appropriate conditions both C/EBPa and PPARy2 can convert 
fibroblastic cell lines with no overt adipogenic capacity (e.g. NIH-3T3) to the 
adipocyte phenotype (Freytag et al, 1994; Tontonoz et al, 1994b). In addition, the 
adipocyte determination and differentiation factor, ADD1, cloned by Spiegelman’s 
laboratory (Tontonoz et al, 1993) and the HNF/forkhead-\ike factor involved in the 
early expression of lipoprotein lipase (Enerback et al, 1992) are also proposed to be 
involved in adipocyte commitment. The role of each of these factors during 
adipogenesis is described fully in Chapter 2.
1.5.2 Growth Arrest at Confluence: Cell-Cell and Cell-Extracellular Matrix 
Communication.
Once determined, preadipocytes in culture proliferate until cell-cell contact at 
confluence inhibits further mitosis and the cells enter the Go phase of the cell cycle. 
This appears to be a prerequisite for subsequent differentiation and is associated 
with the expression of several “early” marker genes: lipoprotein lipase (Cornelius et 
al, 1988), FAAR (Amri et al, 1995) and the a2 chain of Type VI collagen (Dani et 
al, 1989). It is likely that these effects are mediated by cell-cell or cell-extracellular 
matrix (ECM) interactions, as described in other model systems. Thus, muscle cell 
precursors in Xenopus laevis require to interact in groups of at least 100 in order to 
induce the expression of MyoD (Holt et al, 1994)-the so-called “community 
effect”-whilst PI9 embryonal carcinoma cells are induced to differentiate by 
cellular aggregation (Skeijanc et al, 1994). However, with respect to adipogenesis, 
it is of interest to note that gap-junctional communication between cells is lost as 
differentiation progresses, and that down-regulation of Connexin-43 is observed 
prior to the expression of certain fat-specific genes (Smas and Sul, 1995).
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The influence of ECM components on differentiation and development is well 
documented (Adams and Watt, 1993). Laminin mediates the tissue-specific 
expression of P-casein in mammary epithelia (Streuli et al, 1995) and this occurs in 
the absence of cell-cell interaction (Streuli et al, 1991). In contrast, fibronectin 
inhibits the differentiation of both keratinocytes (Adams and Watt, 1989) and 3T3- 
F442A preadipocytes (Spiegelman and Ginty, 1983). In the case of adipogenesis, it 
was found that this block could be relieved by cytochalasin D, an agent which 
disrupts actin filaments (Spiegelman and Ginty, 1983). During the early stages of 
adipocyte differentiation, there are alterations in the expression of various ECM 
components and in the ultrastructure of the actin cytoskeleton (Smas and Sul,
1995). It is therefore likely that such alterations are involved in initiating or 
transducing signals for adipose differentiation, for example via integrin signalling 
pathways (Hynes, 1994).
Preadipocyte factor 1 (Pref-1) is a recently cloned transmembrane protein that may 
be involved in maintaining the preadipocyte phenotype (Smas and Sul, 1993). This 
protein is expressed exclusively in preadipocytes and is down-regulated as 
differentiation progresses. Interestingly, its expression is elevated in the 3T3-C2 
differentiation defective clone, and enforced expression in 3T3-L1 preadipocytes 
inhibited differentiation (Smas and Sul, 1993). This protein is characterised by 
large amounts of N-linked glycosylation and the presence of six tandem EGF-like 
repeats in the extracellular domain. This motif is found in a number of molecules 
involved in protein-protein interactions, including ECM components (Thieiy and 
Boyer, 1992) and the Drosophila proteins, Notch and Delta, which govern cell fate 
decisions (Fehon et al, 1990). It is therefore possible that Pref-1 may inhibit 
adipogenesis via ECM interactions, which are disrupted as differentiation 
commences due to alterations in the overall composition of the matrix.
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1.5.3 Mitotic Clonal Expansion.
Treatment of the determined preadipocyte culture with external modulators of 
adipogenesis results in the initiation of one or more rounds of mitosis, which 
appear to be required for subsequent differentiation (Bemlohr et al, 1985). Clonal 
expansion is also observed in the L6E9 myoblast line following treatment with 
IGF-1 (Engert et al, 1996), suggesting that in general proliferation precedes 
differentiation. However, certain mitogens may stimulate post-confluent mitosis 
without inducing differentiation. This suggests that DNA replication is necessary, 
but not sufficient, for adipogenesis. The function of this clonal expansion is not 
clear, but it is possible that replication and accompanying changes in chromatin 
structure may make cis-acting elements accessible to transcription factors, which 
either activate or derepress genes involved in the acquisition of the adipocyte 
phenotype.
1.5.4 The Differentiation-Specific Growth Arrest (Go).
Following clonal expansion, preadipocytes enter a unique growth arrested state, 
designated Go, which is thought to be permissive for terminal differentiation (Scott 
et al, 1982). Go can be distinguished from other forms of growth arrest by a 
number of criteria (Wille and Scott, 1982). Cells arrested at confluence (Gs) or due 
to nutrient (e.g. amino acid) deprivation (G n )  retain the ability to respond to serum 
mitogens and are unable to undergo adipogenesis, whilst cells arrested in Go have 
the ability to differentiate in the absence of further DNA synthesis and are 
unresponsive to serum stimulation. However, Go cells are responsive to the 
mitogenic effects of MIX, whilst cells arrested in the Gs or Gn state remain 
unaffected by this treatment. It has been proposed that each of these arrest states 
represents a distinct topographical stage in what is more typically referred to as the 
Go phase of the cell cycle, since they can be readily interconverted in the absence of 
further genome replication (Wille and Scott, 1982).
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The relationship between growth arrest and differentiation has been extensively 
studied in the A31T6 preadipocyte model (Wang et al, 1994). A31T6 cells that 
have attained the Go arrest state, but do not yet display the adipocyte phenotype, 
can be induced to re-enter the cell cycle by treatment with MIX (Scott et al, 1983). 
However, as differentiation proceeds this proliferative potential is progressively 
lost and the growth arrest becomes irreversible. This suggests that Go may initially 
be a relatively plastic state and that cells lodged in this phase of the cell cycle may 
either progress to terminal differentiation or else remain in a “non-terminally” 
differentiated state, depending on the external cues (Yun and Scott, 1983). The 
molecular basis for the differentiation-specific growth arrest is not fully understood. 
However, as described in Chapter 2, the larger isoform of C/EBPa is reported to 
possess anti-mitotic activity (Umek et al, 1991) and so may therefore function in a 
manner analogous to MyoD during myogenesis (Crescenzi et al, 1990).
1.5.5 Morphological Changes.
As differentiation progresses, alterations in cellular morphology become apparent: 
the spindle-shaped preadipocyte converting to a rounded cell type that rapidly 
enlarges as a consequence of cytoplasmic triglyceride accumulation. Changes in 
the actin cytoskeleton are involved in this phenomenon. In preadipocytes, actin 
filaments are present in a well defined stress fibre pattern which becomes highly 
disorganised as the adipocyte morphology is attained. Indeed, treatment with 
cytochalasin D is sufficient to rescue adipogenesis in cells blocked by growth on 
fibronectin (Spiegelman and Ginty, 1983). Expression of actin and tubulin 
decrease during differentiation (Spiegelman and Farmer, 1982) and this precedes 
both morphological changes and the expression of adipocyte-specific genes.
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1.5.6 Co-ordinate Changes in Gene Expression.
The terminal stages of adipocyte differentiation are initiated by the induction of 
C/EBPa and PPARy2, both of which are implicated in directing the co-ordinate 
expression of many fat-specific genes (see Chapter 2). Acquisition of the adipocyte 
phenotype involves changes in expression of a large number of genes (Sidhu, 
1979). These encode proteins involved in lipid and carbohydrate metabolism, 
hormone signalling, secretory molecules and components of the ECM and 
cytoskeleton. A comprehensive list of these proteins has been compiled by 
Cornelius et al (1994).
1.5.7 Triglyceride accumulation.
A classical feature of fully differentiated adipocytes is the accumulation of 
cytoplasmic triglyceride droplets. A key intermediate of triglyceride biosynthesis is 
glycerol-3-phosphate (Stryer, 1988). However, adipocytes lack the kinase required 
to phosphorylate endogenous glycerol and so utilise glucose in order to initiate the 
biosynthetic pathway. Glucose is taken up by the adipocyte where it enters the 
glycolytic pathway. At the branch point of glycolysis, where fructose 1,6- 
bisphosphate is cleaved to form dihydroxyacetone phosphate and glyceraldehyde-3- 
phosphate, an isomerase reaction occurs which favours the formation of 
glyceraldehyde-3-phosphate. However, during de novo triglyceride biosynthesis, 
the dihydroxyacetone phosphate is instead converted to glycerol-3-phosphate by the 
action of the enzyme, glycerophosphate dehydrogenase (GPD). Glycerol-3- 
phosphate then undergoes a number of acylation reactions to form phosphatidate, 
which is hydrolysed then re-acylated to form triacylglycerol, the major form of lipid 
stored by the adipocyte.
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1.5.8 Terminal Differentiation.
Maintenance of the terminally differentiated state is thought to be a consequence of 
continued expression of C/EBPa and is likely to result from combined functional 
effects: namely, the capacity to inhibit mitosis and transactivation of fat-specific 
genes. Sustained expression of C/EBPa results from autoactivation due to a C/EBP 
binding site in the proximal promoter (Lin and Lane, 1992). Agents such as TNFa 
cause dedifferentiation and this is associated with the loss of C/EBPa expression 
(see Section 1.4.4). Additionally, treatment of fully differentiated 3T3-L1 cells 
with either insulin or glucocorticoid results in both reduced expression and activity 
of the C/EBPa protein (MacDougald et al, 1994; MacDougald et al, 1995a). 
However, the physiological relevance of this observation remains unclear.
1.6 Obesity.
Adipocytes represent the major energy reserve of higher species and as such 
presumably evolved to aid survival during periods of nutrient deprivation. 
However, the lifestyle now prevalent in most western societies has rendered the 
requirement for such an energy reserve physiologically obsolete. In consequence, 
the availability of high-fat foodstuffs and a sedentary lifestyle are reflected in an 
increased incidence of obesity and its attendant syndromes, most notably cardio­
vascular disease and non-insulin dependent diabetes.
Whilst the aetiology of obesity is complex and likely to be multi-factorial, it is 
becoming increasingly apparent that in some cases a genetic component potentiates 
individuals towards this disease. Recent advances in our understanding of the 
molecular biology of obesity have arisen from the cloning and characterisation of a 
number of genes associated with murine models of obesity. These include the 
genetic lesions associated with the obese (Zhang et al, 1994), diabetes (Tartaglia et 
al, 1995), tubby (Kleyn et al, 1996; Noben-Trauth et al, 1996) and fat (Naggert et
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al, 1995) mice. At least one of these genes, obese (leptin), is a target of C/EBPa in 
mature adipocytes (MacDougald et al, 1995b; Hwang et al, 1996). Whilst the 
precise biological function of the obesity genes requires further investigation, a 
picture is emerging whereby the adipose secretes peptides, such as leptin, in 
response to feeding. These are targeted to specific receptors, including the product 
of the diabetes gene, within the hypothalamus which has been proposed to function 
as the “satiety” centre of higher organisms (Flier, 1995). In this manner, adipose is 
therefore functioning as an endocrine tissue, initiating a feedback loop in order to 
regulate food intake. Hence, the molecular biology of obesity has, in recent 
months, become an area of intense activity. Assuming that the observations made 
with murine models can be extrapolated to the human disease, the ultimate goal 
will be the introduction of therapeutics designed to specifically combat what is fast 
becoming one of the major health problems of the late twentieth century.
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CHAPTER 2: Transcriptional Regulation of Adipogenesis.
2.1 Introduction.
As described in Chapter 1, acquisition of the adipocyte phenotype is associated 
with dramatic changes in gene expression. This phenomenon is largely mediated 
by the activity of trans-acting factors which either activate or derepress the 
transcription of adipocyte-specific genes. Several transcription factors implicated 
in adipogenesis have been cloned and characterised and these are discussed in 
detail below.
2.2 The CCAAT/Enhancer Binding Protein (C/EBP) Family.
The C/EBP proteins are members of the basic leucine zipper (bLZ) family of 
transcription factors (Hurst, 1994), which are characterised by a C-terminal DNA 
binding domain rich in basic amino acids, positioned immediately upstream of a 
protein dimerisation motif. The prototypic family member, C/EBPa, was originally 
characterised as a protein with the ability to bind both the CCAAT pentanucleotide 
present in the proximal promoter of many genes (Graves et al, 1986) and the 
enhancer core homology region of certain animal viruses (Johnson et al, 1987). 
Whilst the consensus DNA binding site is reported to be ATTGCGCAAT, a broad 
range of substitutions is tolerated (Osada et al, 1996). Protein dimerisation is 
mediated by the leucine zipper, which comprises five heptad repeats with a leucine 
residue at every seventh position, that forms an amphipathic a-helical array 
(Johnson and McKnight, 1989). Protein-protein interactions occur via the 
association of these a-helices to form a parallel, double stranded, coiled-coil 
structure, stabilised primarily by hydrophobic interactions. Following dimerisation, 
DNA binding is proposed to occur by the “scissors-grip” model (Vinson et al,
1989). In addition to forming homodimers, C/EBP proteins are also able to 
heterodimerise with other family members and with unrelated bLZ proteins,
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including those of the ATF/CREB class (Vallejo et al, 1993). This creates 
functional diversity, as does the presence of highly divergent transactivation 
domains located in the N-terminus of the molecule (Friedman and McKnight,
1990). C/EBP proteins are expressed in a variety of cell types, where they function 
as mediators of both differentiation and stress responses. The role of individual 
C/EBP proteins during adipogenesis is discussed in Sections 2.2.1-2.2.4.
2.2.1 C/EBPa.
C/EBPa was originally characterised as a heat-stable protein present in rat liver 
(Landschulz et al, 1988), capable of binding two cz's-regulatory elements (Section 
2.2). A single 2.7kb mRNA gives rise to multiple isoforms (Ossipow et al, 1993), 
the 42-kDa and 30-kDa proteins being the most abundant. These differ at the N- 
terminus and are generated as alternative translation products by leaky ribosomal 
scanning (Calkhoven et al, 1994), initiation of the 30-kDa form occurring at an 
internal methionine codon located in a more favourable context than that for the 43- 
kDa form (Kozak, 1991). Expression of C/EBPa is limited to tissues displaying a 
high lipogenic capacity (Birkenmeier et al, 1989), including WAT, BAT, liver, lung 
and intestine, and whilst not strictly adipocyte-specific is probably the best 
characterised of all the adipogenic transcription factors.
Evidence for a role in adipogenesis comes from several sources. Expression of 
C/EBPa was seen to increase during induced differentiation of the 3T3-L1 cell line 
(Christy et al, 1989), due to transactivation of the c/ebpa gene (Christy et al, 1991). 
Subsequently, C/EBP binding sites were identified in the promoters of certain 
adipocyte-specific genes that are expressed in a temporal pattern suggestive of co­
ordinate regulation by C/EBPa during differentiation. Indeed, co-transfection 
studies confirmed the ability of C/EBPa to both bind and transactivate the 
promoters of several of these genes, including the fatty acid binding protein,
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aP2/422 (Herrera et al, 1989), stearoyl-CoA desaturase 1 [SCD1] (Christy et al,
1989) and GLUT 4 (Kaestner et al, 1990). Mutation of the C/EBP binding site in 
these promoter constructs specifically abolished this effect. However, whilst 
persuasive, such experiments do not in themselves provide direct evidence for a 
role for C/EBPa during adipogenesis. Thus, an alternative strategy was pursued.
Adopting an antisense approach, two separate groups were able to demonstrate that 
specific inhibition of C/EBPa was associated with a concomitant block to 
differentiation in 3T3-F442A and 3T3-L1 cells (Samuelsson et al, 1991; Lin and 
Lane, 1992). Expression of an antisense C/EBPa vector in these cell lines was 
associated with the loss of aP2/422, SCD1 and GLUT4 expression and an inability 
to accumulate cytoplasmic triglyceride. Interestingly, early markers such as 
lipoprotein lipase were unaffected, suggesting that C/EBPa is required for the 
terminal stages of differentiation. Expression of a sense C/EBPa construct in cell 
lines already harbouring the antisense vector was able to rescue the adipocyte 
phenotype.
Other workers sought to establish a role for C/EBPa in the differentiation process 
by transfection into preadipocytes. Assuming that the protein was necessary for 
adipogenesis, it was proposed that ectopic over-expression of C/EBPa in the 
undifferentiated cell type would result in adipogenic conversion. However, such 
studies were hampered by the anti-mitotic activity of C/EBPa, and stable cell lines 
expressing the protein could not be propagated. This was partially overcome by the 
use of a C/EBPa/oestrogen receptor fusion protein which was only active in the 
presence of P-oestradiol (Umek et al, 1991). However, contrary to expectation, 
activation of the fusion protein blocked mitosis but did not result in differentiation. 
Adipogenesis could only be achieved in the presence of external modulators. In 
contrast, Freytag and Geddes (1992) demonstrated that enforced expression of
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C/EBPa in 3T3-L1 cells generated small foci that could not be propagated but 
underwent spontaneous adipogenic conversion. The conversion rate was extremely 
low (-12%) but provided the first indication that C/EBPa is sufficient for 3T3-L1 
adipogenesis. Further studies employing an isopropyl p-D-thiogalactoside (IPTG) 
inducible C/EBPa vector in 3T3-L1 cells confirmed this finding (Lin and Lane,
1994). However, the most conclusive evidence that C/EBPa is a key factor in 
adipocyte differentiation comes from studies in cell lines that usually display no 
adipogenic capacity. Ectopic retroviral expression of C/EBPa was shown to 
promote the differentiation programme in a variety of murine fibroblastic cell lines, 
(Freytag et al, 1994), and this also occurred in the absence of inducing agents.
As described in Section 1.5.8, C/EBPa appears to have multiple roles in 
adipogenesis. Possibly the most intriguing of these is the ability to inhibit mitosis. 
This anti-mitotic function has been mapped to the N-terminal 12-kDa portion of the 
molecule, since over-expression of the 30-kDa isoform, which lacks this domain, in 
3T3-L1 cells does not inhibit proliferation (Lin et al, 1993). Since C/EBPa is 
induced at the cessation of clonal mitotic expansion, it has been proposed that it 
may be required for cells to enter the differentiation-specific growth arrest, Gd (see 
Section 1.5.4). Whilst the mechanism by which C/EBPa exerts this effect remains 
unclear, various possibilities exist, with analogies being drawn from the myogenic 
lineage. Both MyoD (Halevy et al, 1995) and Myogenin (Andres and Walsh, 1996) 
are proposed to mediate cell cycle withdrawal during myogenesis via the induction 
of the cyclin-dependent kinase inhibitor (CKI), p21. It is therefore of interest to 
note that expression of p21 was induced during growth arrest of a human 
fibrosarcoma cell line conditionally over-expressing C/EBPa (Timchenko et al,
1996). Whether C/EBPa employs such a mechanism during adipogenesis remains 
unclear. However, in 3T3-L1 cells, C/EBPa was found to induce the expression of 
the growth arrest and DNA damage gene, gaddAS, with similar kinetics to aP2/422
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and SCD1 (Constance et al, 1996), suggesting a way in which mitotic arrest and 
fat-specific gene expression could be coupled. Another candidate is the product of 
the retinoblastoma susceptibility gene, pRb. This protein is both induced and 
bound by MyoD (Martelli et al, 1994) and its growth suppressive activity is thought 
to be required for myogenesis (Gu et al, 1994). Myocytes lacking pRb accumulate 
in the S and G2 phases of the cell cycle and display defective muscle-specific gene 
expression (Novitch et al, 1996). Similarly, lung fibroblasts derived from rb null 
mice are unable to undergo adipogenesis (Chen et al, 1996a). In this system, pRb 
was found to influence terminal differentiation of wild type cells through direct 
interaction with C/EBP family members. However, work by Hendricks-Taylor and 
Darlington (1995) suggests that C/EBPa inhibits proliferation in many cell types in 
the absence of pRb.
Conclusions drawn regarding the role of C/EBPa during in vitro adipogenesis have 
been substantiated in vivo using nullizygous mouse models. Mice homozygous for 
a targeted deletion of the c/ebpa gene display abnormalities in both WAT and BAT 
(Wang et al, 1995), and have a reduced capacity to accumulate lipids. In addition, 
hyperproliferation is observed in the lung and liver, supporting a role for C/EBPa 
in cell cycle withdrawal (Flodby et al, 1996). However, the major feature of these 
mice is their inability to synthesise and store liver glycogen and, in concert with a 
number of other metabolic defects, they rapidly become hypoglycaemic and die 
within 8 hours post-partum. Since C/EBPa is known to transactivate a number of 
liver-specific genes in addition to those expressed during the terminal stages of 
adipogenesis, it has therefore been proposed that this transcription factor acts to co­
ordinate the expression of genes essential for integrative metabolic processes 
(Darlington et al, 1995) and hence is a critical regulator of global energy 
homeostasis (Yeh and McKnight, 1995).
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2.2.2 C/EBPp.
C/EBP P was cloned by Cao and co-workers (1991) in an attempt to identify factors 
that may be involved in adipogenesis, but was later found to be identical to a 
number of previously characterised proteins, including liver activatory protein 
[LAP] (Descombes et al, 1990), NF-IL6 (Akira et al, 1990) and IL-6DBP (Poli et 
al, 1990). As described above for C/EBPa, two isoforms of C/EBPP are derived 
from a single mRNA species by leaky ribosomal scanning, LAP (32-kDa) and a 20- 
kDa form referred to as the liver inhibitory protein [LIP] (Descombes and Schibler, 
1991). Whilst LAP and LIP possess identical bLZ domains, LIP lacks the N- 
terminal transactivation domain. As such, LIP is incapable of transactivating target 
genes harbouring C/EBP sites and so may be regarded as a dominant negative 
inhibitor of other C/EBP family members. It is proposed that LIP functions either 
as an inactive homodimer that competitively occupies the binding site, or else 
heterodimerisation generates complexes with impaired transactivation potential. 
Interestingly, the LAP:LIP ratio increases during adipogenesis, suggesting that LIP 
may be required to modulate the effects of LAP in the earlier stages of the 
differentiation programme.
C/EBPp is expressed in a number of cell types with high lipogenic or metabolic 
capacity, and functions in a variety of biological processes including haemopoiesis 
(Muller et al, 1995; Wall et al, 1996) and the acute phase response (An et al, 1996; 
Estes et al, 1995). In the 3T3-L1 cell line, C/EBPp is induced by MIX during 
clonal expansion, the levels declining thereafter (Yeh et al, 1995a). This temporal 
expression pattern and the presence of a specific binding site in the C/EBPa 
promoter suggested that C/EBPp may induce the expression of C/EBPa, possibly 
in combination with C/EBP6 (Figure 3). Hence, C/EBPp is implicated in a cascade 
of regulation during adipogenesis, relaying the effects of external modulators to the 
terminal phases of the differentiation programme (Yeh et al, 1995a).
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Figure 3. Interaction of C/EBP and PPAR Families 
During Adipogenesis.
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A role for C/EBPp in adipogenesis has also been demonstrated by transfection 
experiments. Retroviral expression of LAP in 3T3-L1 cells resulted in 
differentiation in the absence of inducers (Yeh et al, 1995a), whilst over-expression 
of LIP inhibited adipocyte conversion. Previously, work by Freytag and co-workers 
(1994) had suggested that retroviral expression of C/EBPp in a range of fibroblastic 
cell lines did not result in spontaneous differentiation. However, Yeh et al (1995) 
were able to demonstrate that ectopic over-expression of C/EBPp in the NIH-3T3 
cell line was adipogenic, but only in the presence of hormones. This finding was 
confirmed by the conditional expression of C/EBPp in NIH-3T3 cells (Wu et al, 
1995). Interestingly, in this system, C/EBPp did not induce the expression of 
C/EBPa, despite acquisition of the adipocyte phenotype, and a similar finding was 
reported by Yeh et al (1995). This suggests that C/EBPp may transactivate 
additional genes required to confer tissue specificity. Indeed, Wu et al (1995) 
demonstrated that conditional over-expression of C/EBPp in NIH-3T3 cells 
specifically induced the expression of the adipocyte specific transcription factor, 
PPARy2.
Since C/EBPp is highly expressed during the clonal expansion phase which 
precedes terminal differentiation, it is possible that this protein could also play a 
role in proliferation. Growth hormone treatment of the 3T3-F442A cell line 
induces the expression of the immediate early response genes, c-fos and c-jun, and 
this appears to be a consequence of increased C/EBPp DNA binding activity 
(Clarkson et al, 1995). However, the C/EBPP nullizygous mouse is characterised 
by increased proliferation, particularly within the myeloid and lymphoid 
compartments (Screpanti et al, 1995). Finally, C/EBPp has been found to interact 
directly with the cell cycle regulator pRb, both in myeloid cells (Chen et al, 1996b) 
and lung fibroblasts (Chen et al, 1996a-see Section 2.2.1), and this is associated 
with increased DNA binding and transactivation potential. Whether this represents
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a growth suppressive activity or is unrelated to the ability of pRb to mediate cell 
cycle withdrawal remains to be determined.
2.2.3 C/EBPS.
C/EBP8 was originally isolated as a protein expressed transiently during the early 
stages of adipogenesis (Cao et al, 1991) and was later found to be specifically 
induced by dexamethasone (Yeh et al, 1995a). The protein is present as a single 
species of 29-kDa and is implicated in the transactivation of C/EBPa. Like other 
family members, C/EBP8 is expressed in a variety of tissues and is involved in the 
acute phase response (Ramji et al, 1993). However, the precise role of C/EBP8 in 
adipogenesis is not well characterised. Retroviral expression in 3T3-L1 cells 
results in a modest differentiation potential (Yeh et al, 1995a), whilst over­
expression in NIH-3T3 cells is not adipogenic. However, co-expression of C/EBPp 
and 8 in this cell line has a synergistic effect, both on adipocyte conversion and 
expression of PPARy2 (Wu et al, 1996). Since PPARy2 is known to possess two 
C/EBP binding sites (Zhu et al, 1995), it is likely that C/EBPp and 8 act in concert 
to induce the expression of this transcription factor during adipogenesis (Figure 3).
2.2.4 CHOP-10/GADD153.
The C/EBP homologous protein, CHOP-10, was cloned from a 3T3-L1 cDNA 
library by its ability to bind C/EBPp (Ron and Habener, 1992) and was later found 
to be the murine homologue of the growth arrest and DNA damage gene, gadd 153 
(Fomace et al, 1989). As such, the activity of CHOP-10 is well documented in the 
stress response (Wang et al, 1996; Guyton et al, 1996). Additionally, chromosomal 
translocations of CHOP-10 are observed in a number of malignancies (Sanchez- 
Garcia and Rabbitts, 1994), most notably myxoid liposarcoma (Crozat et al, 1993).
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Whilst considered a member of the C/EBP family by virtue of sequence similarity, 
CHOP-10 is unique in that the basic DNA binding region contains helix-breaking 
amino acid substitutions (Ron and Habener, 1992), rendering it incapable of site- 
specific DNA binding. However, the protein retains the capacity to heterodimerise 
with other C/EBPs and so acts as a dominant negative inhibitor. In certain cases 
CHOP/C/EBP dimers may be directed to non-canonical binding sites (Barone et al,
1994), although the biological relevance of this finding remains unclear. CHOP-10 
has been shown to inhibit differentiation of the 3T3-L1 cell line, and this phenotype 
may be reversed by over-expressing C/EBPa (Batchvarova et al, 1995). However, 
it now seems likely that the key role of CHOP-10 during adipogenesis is as a 
glucose sensor. CHOP-10 is induced by low concentrations of glucose (Carlson et 
al, 1993), whilst maintaining glucose at high levels throughout the differentiation 
programme abrogates this effect. This suggests that CHOP-10 may only operate 
when cells are stressed, for example by nutrient deprivation, and that under normal 
conditions it is not a physiological regulator of adipogenesis.
2.3 The Peroxisome Proliferator-Activated Receptor (PPAR) Family.
The PPAR proteins are members of the nuclear hormone receptor superfamily 
(Calkhoven and Ab, 1996), which link lipophilic extracellular signals to gene 
expression. These transcription factors are characterised by a conserved DNA 
binding domain, containing two zinc finger motifs, and a divergent ligand binding 
and dimerisation domain. Increased transactivation of target genes is mediated by 
specific binding of endogenous ligand. PPARs were first isolated by virtue of their 
activation by peroxisome proliferators (Isseman and Green, 1990), a diverse range 
of compounds, classically associated with hepatic peroxisomal proliferation and 
induction of the p-oxidation pathway in rodent models. Three family members 
have since been cloned from Xenopus (Dreyer et al, 1992), which differ in their 
pharmacological responses to the various activators, suggesting distinct biological
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functions. PPARs bind to a specific response element, the PPRE, comprising direct 
repeats of the sequence AGGTCA, separated by a single nucleotide, the so-called 
DR-1 motif (Dreyer et al, 1992). DNA binding requires heterodimerisation with 
members of the retinoid X receptor (RXR) family (Kliewer et al, 1992) and is 
associated with the transactivation of several enzymes involved in lipid metabolism 
(Tugwood et al, 1992; Castelein et al, 1994).
2.3.1 PPARy2.
Whilst C/EBPa is enriched in adipose, it is also expressed in a variety of other cell 
types, suggesting that it is unlikely to be the sole determinant of adipocyte-specific 
gene expression during terminal differentiation. Indeed, the portion of the aP2/422 
gene which confers tissue specificity in transgenic mice lacks a consensus C/EBP 
binding site (Ross et al, 1990). The active region was mapped to a 518bp enhancer 
element, located approximately 5kb upstream of the transcriptional initiation site 
(Graves et al, 1991) and was found to comprise five protein recognition sites, 
designated adipose regulatory elements (AREs). Two of these domains, ARE6 and 
7, were bound by an adipocyte-specific factor, ARF6 (Graves et al, 1992). Binding 
of ARF6 was both necessary and sufficient for adipocyte-specific gene expression 
and transactivation of ARE6/7 reporter constructs occurred in adipocytes but not 
preadipocytes (Graves et al, 1992). Mutation of the ARE6 site abolished this 
effect.
The ARF6 target sequence was found to share sequence homology with the DR-1 
site bound preferentially by RXR/PPAR heterodimers. Subsequently, Tontonoz 
and co-workers (1994a) cloned the murine homologue of Xenopus PPARy from an 
adipocyte cDNA library, adopting a polymerase chain reaction (PCR) approach to 
identify clones with sequence similarity to RXR and PPAR family members. This 
adipocyte-specific form was referred to as PPARy2. Simultaneously, other
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laboratories cloned a second isoform, PPARyl (Kliewer et al, 1994; Zhu et al,
1993). These isoforms were found to arise from a single gene (Zhu et al, 1995), 
containing two promoters that generate two alternatively spliced gene products, 
differing at the N-termini. PPARyl is expressed at low levels in many tissues, 
whilst PPARy2 is present predominantly in adipose and is expressed with similar 
kinetics to C/EBPa during differentiation. Subsequently, characterisation of ARF6 
purified from the HIB-IB cell line demonstrated that it was a heterodimer, 
composed of PPARy2 and RXRa (Tontonoz et al, 1994c).
PPARy2 was originally classified as an “orphan” receptor since the natural ligand 
was unknown. As described above, synthetic activation of the PPARs could be 
achieved by a number of structurally unrelated chemicals, including fatty acid 
analogues. Indeed, treatment of U20S osteosarcoma cells conditionally over- 
expressing PPARy2 with eicosanoids resulted in increased transactivation potential 
(Yu et al, 1995). This effect was blocked by indomethacin, which inhibits 
prostaglandin biosynthesis. Subsequently, the endogenous ligand was shown to be 
a prostaglandin J2 metabolite (Forman et al, 1995; Kliewer et al, 1995), thus 
linking fatty acid stimulation to adipocyte differentiation.
As described for C/EBP family members, a role for PPARy2 in directing adipocyte 
differentiation was demonstrated by retroviral expression in NIH-3T3 cells 
(Tontonoz et al, 1994b). In this case, the differentiation potential of PPARy2- 
expressing cells was stimulated by treatment with various PPAR activators. 
However, co-expression of PPARy2 with C/EBPa resulted in differentiation in the 
absence of external stimulants. This synergy suggests that PPARy2 and C/EBPa 
may co-operate to orchestrate the events associated with terminal differentiation. 
Indeed, co-expression of these transcription factors in myoblasts is sufficient to 
cause transdifferentiation to the adipocyte phenotype (Hu et al, 1995). As
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described in Section 2.2.1, expression of both PPARy2 and C/EBPa during the 
differentiation programme appears to be under the control of C/EBP (3 and 5, and 
there is currently some speculation that PPARy2 and C/EBPa may also cross- 
regulate one another. In addition, PPARy2 and C/EBPa share a common set of 
target genes, including aP2/422 and phosphoenolpyruvate carboxykinase (Tontonoz 
et al, 1995b). Hence, a picture emerges (Figure 3) whereby a cascade of regulatory 
signals is channelled towards the activation of C/EBPa and PPARy2, thereby 
culminating in the co-ordinate expression of genes required to execute the final 
stages of the adipogenic programme.
2.3.2 Fatty Acid Activated Receptor (FAAR).
It is well established that fatty acids influence the early stages of adipogenesis 
(Abumrad et al, 1991; Abumrad et al, 1993). In an attempt to understand this 
phenomenon, Amri and co-workers (1995) cloned a protein from an obi771 library 
that appeared to mediate the transcriptional effects of fatty acids. This protein was 
referred to as the fatty acid activated receptor (FAAR), but was later found to be 
identical to human Nucl and PPAR8 (Kliewer et al, 1994). Like other PPAR 
family members, FAAR binds to DR-1 elements as a heterodimer with RXR 
proteins. FAAR is expressed in a wide range of tissues, including adipose, and 
whilst undetectable in growing obi771 cells, is strongly induced at confluence. 
This expression is augmented by treatment with palmitate. Ectopic expression of 
FAAR in the differentiation defective cell line, 3T3-C2, conferred fatty-acid 
responsiveness on both a lipid binding protein, ALBP, and the lipid transporter, 
FAT (Amri et al, 1995), and there is some evidence to suggest that FAAR may also 
regulate the expression of lipoprotein lipase in response to lipids (Amri et al, 1996). 
However, Schoonjans et al (1996) have recently demonstrated that upregulation of 
lipoprotein lipase in adipose is mediated by PPARy2, whilst in liver, tissue-specific 
expression is directed by PPARa. Since the gold standard of adipogenic potential
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appears to be the ability to convert fibroblastic cell lines to the adipocyte 
phenotype, it is therefore of interest to note that in a recent study both PPARa and 
y2 were able to induce differentiation of NIH-3T3 cells in response to various 
PPAR activators, whilst ectopic expression of FAAR was without effect (Brun et 
al, 1996). In contrast, FAAR had been previously reported to mediate the 
conversion of myoblasts to adipocytes following fatty acid treatment (Teboul et al,
1995). Clearly, the role of FAAR in adipocyte differentiation requires further 
investigation.
2.4 Adipocyte Determination and Differentiation Factor 1 (ADD1).
Transcription factors of the basic region-helix-loop-helix (bHLH) class have been 
implicated in cell fate determination in a number of lineages, including MyoD in 
myogenesis, SCL in haemopoiesis and the achaete-scute complex in neurogenesis 
(Jan and Jan, 1993). In addition to the basic DNA binding domain, these proteins 
are characterised by a protein dimerisation motif (HLH), typified by two 
amphipathic a  helices joined by an intervening theta form loop, and the ability to 
bind the canonical E-box sequence, CANNTG. Reasoning that adipocyte 
determination may also be mediated by such a factor, a protein was cloned from a 
rat adipocyte library via interaction with the E-box motif of the fatty acid synthase 
gene (FAS). This protein was found to be a novel member of the bHLH-leucine 
zipper (bHLH-LZ) family and was designated adipocyte determination and 
differentiation factor 1 [ADD1] (Tontonoz et al, 1993). ADD1 is expressed at low 
levels in several tissues, including WAT, but is found predominantly in BAT. Both 
3T3-F442A preadipocytes and 10T1/2 cells express low levels of the protein, which 
is seen to increase dramatically following hormonal induction of adipogenesis, 
suggesting that ADD1 may function in a manner analogous to MyoD, which is also 
present in the undifferentiated cell type. ADD1 is able to transactivate the 
promoters of two adipocyte-specific genes, FAS (Tontonoz et al, 1993) and
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lipoprotein lipase (Kim and Spiegelman, 1996). Retroviral expression of ADD1 in 
NIH-3T3 cells had a modest adipogenic effect, which could be augmented by co­
expression with PPARy2 (Kim and Spiegelman, 1996), whilst expression of a 
dominant negative form of ADD1 in the 3T3-L1 cell line repressed adipogenesis. 
The human homologue of ADD1 was independently identified as the sterol 
response element binding protein [SREBP1] (Wang et al, 1993), that binds the 
motif ATCACCCCAC (Yokoyama et al, 1993), and is implicated in the 
transcriptional regulation of cholesterol homeostasis. This suggests that ADD1 
may play multiple roles in lipid metabolism.
2.5 HNF-3/Forkltead.
Lipoprotein lipase is one of the earliest genes to be induced during adipogenesis. 
Differentiation-linked expression was found to be conferred by two cw-regulatory 
elements, LP-a and LP-p, (Enerback et al, 1992), which share sequence homology 
to the binding site for members of the HNF-3Iforkhead family of transcription 
factors, which are implicated in tissue-specific gene expression and developmental 
processes (Clevidence et al, 1993; Kaestner et al, 1993). Indeed, a HNF- 
3/forkhead-\ike binding activity was detected in 3T3-F442A cells and this was 
found to increase during differentiation. Lipoprotein lipase is induced in 
preadipocytes as they reach confluence and appears to be independent of the action 
of the adipogenic hormones. At this time, the ct2 chain of Type IV collagen is also 
being expressed and a dense extracellular matrix (ECM) is deposited. During liver 
differentiation, HNF-3 expression and subsequent transactivation of the albumin 
gene promoter requires stimulation by ECM-associated collagen (Liu et al, 1991). 
By analogy, it is therefore proposed that the early phases of adipocyte 
differentiation are mediated by similar interactions and this explains why growth 
arrest at confluence is an absolute requirement for the differentiation programme to 
proceed efficiently.
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CHAPTER 3: c-Myc: a Multifunctional Transcriptional Regulator.
3.1 Introduction.
The c-myc proto-oncogene is the prototypic member of a highly related gene 
family, which is strongly implicated in the genesis of a wide range of human 
malignancies. The gene itself encodes an unstable nuclear phosphoprotein 
comprising several domains consistent with a role in transcriptional regulation and 
is thought to function in a variety of biological processes, including the inhibition 
of cellular differentiation.
3.2 Myc Family Proteins.
c-myc was originally identified as the cellular homologue of a gene transduced by 
the transforming avian retrovirus, MC29 (Vennstrom et al, 1982). Subsequently, 
two further myc family members were isolated from amplified regions detected in 
naturally occurring tumours. These were designated N- and L-myc and were 
associated with neuroblastoma (Schwab et al, 1983) and small cell lung carcinoma 
(Nau et al, 1985) respectively. All myc family members share a characteristic three 
exon structure, whereby exons two and three constitute a single open reading 
frame, whilst exon one is essentially non-coding (Kelly and Siebenlist, 1986). This 
first exon is thought to regulate gene expression. The protein itself comprises 
several distinct domains and is a member of the basic helix-loop-helix leucine 
zipper (bHLH-LZ) family of transcription factors (Torres et al, 1992), which also 
includes ADD1 (Tontonoz et al, 1993) and USF (Gregor et al, 1990).
As described in Chapter 2, the basic region mediates sequence-specific DNA 
binding, whilst the HLH and LZ motifs provide a dimerisation interface. Like 
ADD1 (Section 2.4), Myc family members bind to the sequence CACGTG 
(Blackwell et al, 1990; Prendergast and Ziff, 1991) and protein dimerisation is a
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pre-requisite for this activity. Whilst Myc is able to bind DNA as a homodimer in 
vitro, this is not thought to occur in vivo where the physiologically relevant form is 
a heterodimer with a second, but unrelated, bHLH-LZ protein, Max (Blackwood 
and Eisenman, 1991). Max is a stable nuclear phosphoprotein, constitutively 
expressed in a wide range of cell types and during diverse cellular conditions. Two 
major forms are generated by alternative splicing, p21 and p22, which differ only 
by a nine amino acid insertion N-terminal to the basic region in p22. These are able 
to form both homo and heterodimers with intrinsic DNA binding capacity but the 
physiological relevance of the two isoforms is not yet known.
In addition to the C-terminal bHLH-LZ motif, Myc proteins also contain an N- 
terminal domain with transactivating potential. This region is characteristically 
proline and glutamine-rich, interspersed with acidic regions, and when fused to the 
DNA binding domain of the yeast protein GAL4 is able to stimulate expression of a 
reporter gene construct (Kato et al, 1990).
3.3 Myc Functions as a Transcription Factor.
3.3.1 Myc as an Activator.
Transactivation is a property of the Myc/Max heterodimer, and requires the Max 
bHLH-LZ domain but both the Myc bHLH-LZ and N-terminal regions (Amati and 
Land, 1994), suggesting that Max may be required solely for DNA binding. 
Indeed, Max contains no obvious transactivation domain and so is likely to be 
transcriptionally inert (Kato et al, 1992). Since these regions of Myc are essential 
for its growth regulatory properties (Stone et al, 1987), it appears that dimerisation, 
DNA binding and transactivation are fundamental to Myc activity. That the 
Myc/Max complex is the biologically active form has been verified by genetic 
complementation studies (Amati et al, 1993). In addition, using synthetic promoter 
constructs containing the CACGTG binding site, it has been demonstrated that the
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Myc/Max complex can activate transcription in both mammalian and yeast cells 
(Kretzner et al, 1992; Amati et al, 1992; Crouch et al, 1993). However, Max 
homodimers repress this activity, suggesting that the relative Myc:Max ratio may 
also influence the ability of Myc to promote gene expression.
Whilst c-Myc is known to function in a variety of biological phenomena (Section 
3.6), the identification of Myc target genes has thus far proven somewhat limited. 
Candidates include ornithine decarboxylase [ODC] (Bello-Femandez et al, 1993; 
Wagner et al, 1993), a-prothymosin (Eilers et al, 1991), p53 (Roy et al, 1994) and 
EC A3 9 (Benvenisty et al, 1992), all of which contain one or more CACGTG 
motifs downstream of the transcription initiation site (Vastrik et al, 1994). Target 
genes most recently identified include an RNA helicase (Grandori et al, 1996), the 
eukaryotic initiation factor 4E (Jones et al, 1996) and the cell cycle phosphatase, 
cdc25 (Galaktionov et al, 1996). However, the physiological relevance of many of 
these genes for Myc function is not entirely clear.
3.3.2 Myc as a Repressor.
The search for direct targets of c-Myc transcriptional activity led investigators to 
conclude that Myc may also repress gene expression (Kaddurah-Daouk et al, 1987). 
Genes repressed by c-Myc include C/EBPa (Li et al, 1994), collagen (Yang et al,
1991), Cyclin D1 (Philipp et al, 1994), CHOP-10 (Chen et al, 1996), LFA-1 
(Inghirami et al, 1990) and c-Myc itself (Grignani et al, 1990; Crouch et al, 1990). 
Additionally, N-Myc has been shown to down-regulate neural cell adhesion 
molecule (N-CAM) expression in neuroblastoma cells (Akeson and Bernards,
1990). In some cases, repression apparently occurs via an alternative binding site 
within the promoter of susceptible genes, known as the initiator element [Inr] 
(Smale and Baltimore, 1989) and may involve interaction with proteins other than 
Max.
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3.4 Alternative Myc Binding Proteins.
Several alternative Myc binding partners have recently been described. A number 
of these are factors involved in transcriptional initiation and include the TATA box 
binding protein [TBP] (Maheswaran et al, 1994), TFII-I (Roy et al, 1993) and YY1 
(Shrivastava et al, 1993; Shrivastava et al, 1996). TFII-I is thought to be involved 
in the Myc-mediated repression of gene expression via the Inr (Roy et al, 1993; 
Phillip et al, 1994). Additionally, the Myc transactivation domain contains a region 
capable of binding in vitro to the cell cycle regulator, pRb (Rustgi et al, 1991). 
However, work by Gu et al (1994) suggests that in vivo Myc may associate with the 
pRb family member, p i07, and that this results in suppression of Myc-associated 
transactivation (Beijersbergen et al, 1994). Interaction of Myc with TBP overlaps 
this p i07 binding site (Hateboer et al, 1993). Other proteins found to associate 
with c-Myc include AP-2 (Gaubatz et al, 1995), a-tubulin (Alexandrova et al,
1995), and the novel proteins Nmi (Bao and Zervos, 1996) and BIN1 (Sakamuro et 
al, 1996).
3.5 Alternative Max Binding Proteins.
Like Myc, Max also has the ability to associate with other proteins, most notably a 
family of novel bHLH-LZ factors, designated Madl (Ayer et al, 1993), Mxil/Mad2 
(Zervos et al, 1993), Mad3 and Mad4 (Hurlin et al, 1995a). These proteins 
dimerise specifically with Max and as such compete with equal affinity to Myc for 
Max association and recognition of the consensus binding site. As reported for 
Max/Max homodimers, Mad/Max complexes also repress gene expression (Wu et 
al, 1996). This activity appears to be dependent on the co-repressor, mSin3, which 
binds to the paired a-helical (PAH) region located at the N-terminus of the various 
Mad proteins (Ayer et al, 1995; Schreiber-Agus et al, 1995). Since expression of 
the Mad proteins is reciprocal to that of c-Myc during a number of cellular 
processes, it has been proposed that Mad family function may be to antagonise Myc
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activity. Hence, whilst Myc positively regulates proliferation and apoptosis, Madl- 
4 may be required to promote differentiation and cell survival (Amati and Land,
1994).
3.6 Biological Functions of Myc.
3.6.1 Proliferation.
Whilst present at low or undetectable levels in quiescent and differentiated cells, 
expression of c-myc correlates strongly with cellular proliferation. Myc expression 
is induced upon mitogenic stimulation in a manner that is independent of de novo 
protein synthesis (Kelly et al, 1983). Hence, c-myc is classified as an immediate 
early response gene. The rapid induction of Myc is a critical event in the Go-Gi 
transition and it has been demonstrated that conditional activation of a c-Myc- 
oestrogen receptor fusion protein is sufficient to mediate cell cycle entry in the 
absence of exogenous growth factors (Eilers et al, 1991). However, in contrast to 
other genes of this class (e.g. c-fos; cfun) which are only expressed transiently 
during this phase, Myc is required at a basal level throughout the cell cycle (Harm 
et al, 1985), suggesting a role in the maintenance of proliferation. In contrast, Mad 
proteins are detected in quiescent cells whilst Max is constitutively expressed 
regardless of the cell cycle status. Myc presumably exerts its effects on 
proliferation by modulating genes required during the cell cycle. For example, 
ODC, the rate limiting enzyme of polyamine biosynthesis, and a-prothymosin are 
both required for S phase. Additionally, Myc may activate the expression of 
Cyclins A and E (Jansen-Durr et al, 1993) and more recently has been shown to 
positively regulate the expression of cdc25 (Galaktionov et al, 1996).
3.6.2 Transformation.
As described in Section 3.2, c-myc was originally characterised as the cellular 
homologue of the transforming component of MC29. The viral gene is composed
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predominantly of sequences derived from the coding regions of chicken c-myc, 
suggesting that loss of the first exon correlates with deregulated expression. 
Indeed, this appears to be the case in Myc-associated malignancies where 
inappropriate expression of an essentially normal protein results in oncogenesis. 
Hence, DNA rearrangements generally lead to quantitative rather than qualitative 
differences (Cole, 1986). The transforming potential of Myc in vitro requires the 
co-operation of a second activated oncogene, such as Ha-ras (Land et al, 1983), 
consistent with the multi-step model of carcinogenesis (Vogelstein and Kinzler,
1993). Thus, in most primary cell lines Myc requires another oncogene for 
transformation, whilst in established cell lines Myc can act alone. In contrast, high 
levels of Max (Prendergast et al, 1992) or the Mad family proteins (Lahoz et al,
1994) can suppress Myc-mediated transformation.
3.6.3 Apoptosis.
Apoptosis (programmed cell death) is a physiologically relevant cell suicide 
mechanism, distinct from necrosis, whereby cells are triggered to die by a range of 
stimuli that induce the expression of a novel set of “death genes” (White, 1996). 
Paradoxically, whilst Myc is intimately associated with proliferation, it is also able 
to induce apoptosis under sub-optimal growth conditions (Evan et al, 1992). This 
activity is blocked by a discrete class of cytokine (Harrington et al, 1994). Since 
Myc-induced apoptosis has the same requirements as gene activation (Section 
3.3.1) it is likely that Myc is modulating the expression of apoptotic genes. A 
possible candidate is ODC (Packham and Cleveland, 1994), the activity of which 
ultimately results in the generation of reactive oxygen species, thought to be key 
modulators of apoptosis.
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3.7 The Role of Myc in Development and Cellular Differentiation.
3.7.1 Development.
The expression pattern of myc family genes during development is well 
documented (Downs et al, 1989; Schmid et al, 1989) and correlates with the types 
of tumour induced by deregulated expression of each Myc protein. Whilst c-myc is 
expressed at all stages and in many tissues during development, expression of bl­
and L-myc is restricted to specific stages and cell types. Surprisingly, the 
correlation between proliferation and expression of c-myc is not strong in the early 
stages of embryogenesis, whilst during organogenesis c-myc is readily detected in 
tissues with a high proliferative capacity. There are exceptions to this general rule, 
however. Expression of c-myc is maximal in cells of mesodermal origin but low in 
endoderm and ectoderm, even though all three tissues are actively proliferating. 
Additionally, c-myc has been detected in both proliferating and post-mitotic lens 
cells (Harris et al, 1992) and lens development is unaffected by enforced expression 
of a myc transgene (Morgenbesser et al, 1995). In contrast, expression of N- and L- 
myc is often associated with the onset of differentiation and appears not to correlate 
that well with proliferative potential.
The role of Myc family members in development has been investigated using 
nullizygous mouse technology. Mice homozygous for a targeted deletion of c-myc 
die between day 9.5 and 10.5 of gestation (Davis et al, 1993) and display retarded 
development. Abnormalities included defects of the heart, pericardium and neural 
tube. This suggests that c-myc may not be required for the early stages of 
development, including embryonic stem cell proliferation, but is essential for 
survival after day 10.5. Work by three separate groups showed that 'N-myc null 
mice are also embryonic lethal (Stanton et al, 1992; Charron et al, 1992; Sawai et 
al, 1993). These mice die between day 11.5 and 12.5 of development and display 
deficiencies in normal organogenesis. In contrast, L-myc null mouse are viable,
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surviving well into adulthood with no obvious abnormalities (Hatton et al, 1996). 
Thus it seems likely that Myc proteins have some overlapping functions during 
normal development, and so may be able to substitute for one another at a given 
stage. However, individual proteins also seem to possess discrete functions which 
cannot be fulfilled in their absence by other family members. In contrast, Max is 
essential for survival at an early stage, null mutations being embryonic lethal at day
3.5 to 6.5 (Henriksson and Luscher, 1996). This suggests that Max function is 
unique and cannot be compensated for by another protein. Whilst the effects of 
targeted deletions within mad family genes have yet to be reported, the expression 
pattern during development is well established, with mad mRNAs being detected 
almost exclusively in differentiating cell types (Vastrik et al, 1995; Chin et al, 
1995; Hurlin et al, 1995a)
The expression pattern of myc genes in adult tissues has also been determined 
(Zimmerman et al, 1986). Expression of c-myc is relatively generalised and 
corresponds to tissues that are actively proliferating, for example during liver 
(Makino et al, 1984) and muscle (Izumo et al, 1988) regeneration. In addition, c- 
myc is also highly expressed in cells that are undergoing apoptosis, such as 
mammary tissue during involution (Strange et al, 1992). In contrast, expression of 
N- and L-myc is restricted to a subset of differentiated tissues, as are the mad genes.
3.7.2 Differentiation.
Rapid down-regulation of c-myc expression is observed in many cell lines 
following exposure to differentiation inducers. These include murine 
erythroleukaemia (MEL) cells (Lachman and Skoultchi, 1984), HL60 
promyelocytic cells (Westin et al, 1982; Reitsma et al, 1983), U937 monoblastic 
cells (Einat et al, 1985) and primary keratinocytes (Dotto et al, 1986). This 
generally occurs prior to growth arrest and initiation of terminal differentiation.
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However, in some lines, such as MEL (Lachman and Skoultchi, 1984) and L6E9 
myoblasts (Endo and Nadal-Ginard, 1986), myc down-regulation is biphasic, with a 
transient decrease being followed by a second peak of activity which declines later. 
In contrast, in the F9 teratocarcinoma cell line down-regulation of c-myc is delayed 
until the terminal stages of differentiation (Campisi et al, 1984). That myc down- 
regulation is necessary for differentiation has been confirmed by a number of anti­
sense experiments. Expression of a myc anti-sense construct in MEL cells resulted 
in accelerated differentiation (Prochownik et al, 1988), whilst a similar approach in 
the HL60 cell line suppressed expression of the endogenous c-myc gene, reduced 
proliferation and potentiated monocytic differentiation (Yokoyama and Imamoto, 
1987; Holt et al, 1988). In F9 cells expression of anti-sense myc resulted in 
differentiation indistinguishable from that induced by retinoic acid (Griep and 
Westphal, 1988). However, over-expression of a sense construct generated F9 cell 
lines that were resistant to induced differentiation. Indeed, over-expression of Myc 
proteins has been shown to inhibit differentiation in a number of cell types, 
including MEL (Coppola and Cole, 1986), U937 (Larsson et al, 1988), primary 
quail myoblasts (Falcone et al, 1985) and preadipocytes (Freytag, 1988).
In contrast to c-myc, there appears to be little regulation of max expression during 
differentiation. However, in erythroid (Dunn et al, 1994; Delgado et al, 1995) and 
epithelial cells (Martel et al, 1995) there is some evidence for fluctuations in the 
levels of Max. Additionally, differentiation in many haematopoietic cell lines is 
associated with a switch from Myc/Max to Mad/Max complexes (Zervos et al, 
1993; Ayer and Eisenman, 1993; Larsson et al, 1994), suggesting that Mad function 
may be required for differentiation. Indeed, increased expression of Mad proteins 
also accompanies epidermal cell differentiation (Gandarillas and Watt, 1995; 
Hurlin etal, 1995b).
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3.8 c-Myc is a Negative Regulator of Adipogenesis.
Constitutive over-expression of a murine c-myc cDNA in the 3T3-L1 cell line was 
found to be sufficient to inhibit adipogenesis, as judged by an inability to 
accumulate cytoplasmic triglyceride and repression of the adipocyte-specific gene, 
pyruvate carboxylase (Freytag, 1988). The ability of c-myc to inhibit 3T3-L1 
differentiation correlated with the level of transgene expression and the phenotype 
could be rescued by the expression of a c-myc anti-sense construct in lines already 
harbouring the myc transgene. This suggests that inhibition of adipogenesis was 
specifically due to enforced expression of Myc. A series of transfection studies 
using the human c-myc mutants previously described by Stone et al (1987) 
demonstrated that inhibition of 3T3-L1 differentiation required those domains of 
the protein already deemed necessary for Myc-mediated transactivation (Freytag et 
al, 1990). It was therefore proposed that the ability of Myc to inhibit adipogenesis 
arose as a direct consequence of its activity as a transcription factor. To investigate 
whether Myc controls the expression of cellular genes in the 3T3-L1 system, Yang 
and co-workers (1991) screened Myc-expressing cell lines to identify genes that 
were differentially expressed. As a result, they found that four clones were 
repressed in lines expressing high levels of Myc. DNA sequence analysis revealed 
that these were the genes for pro-a 1 (I), pro-a 2 (I) and pro-a 3(VI) collagen and a 
gene of unknown identity. Interestingly, expression of pro-a 2 (I) collagen mRNA 
was restored in c-myc anti-sense cell lines. The effect of Myc on these genes was 
shown to require cfs-elements in the collagen promoter, suggesting that Myc- 
mediated repression occurs at the level of transcription. Later, it was shown that 
enforced expression of Myc in 3T3-L1 cells was also associated with inhibition of 
C/EBPa (Freytag and Geddes, 1992). It was therefore proposed that loss of 
C/EBPa expression was a critical determinant of the ability of Myc to inhibit 
differentiation. Indeed, expression of a c/ebpa construct in lines already over­
expressing c-myc was sufficient to rescue adipogenesis. This did not involve
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suppression of the myc gene, suggesting that the decision to differentiate may be 
dependent on the relative levels of the two proteins.
TNFa is well known to block adipogenesis and it appears that the inhibitory effects 
of this cytokine are mediated at the level of C/EBPa (see Section 1.4.4). 
Additionally, TNFa has been shown to induce the expression of c-myc in both 
preadipocytes and adipocytes (Ninomiya-Tsuji et al, 1993) and this correlates with 
the TNF-mediated reduction in adipocyte-specific gene expression. Conditional 
expression of c-myc in TA1 cells mimicked the effects of TNFa, whilst myc 
antisense constructs impaired TNF activity. Hence, a pathway may be envisaged 
whereby inhibition of adipogenesis by TNFa is mediated by the activity of the Myc 
oncoprotein. Whilst there is no evidence to support a role for c-myc in adipose 
development in vivo, it is of interest to note that in certain pathological conditions 
increased expression of TNFa is associated with WAT wastage (Torti et al, 1985). 
It is therefore tempting to speculate that this may involve c-Myc. However, up- 
regulation of TNFa is also a classical feature of obesity, where it is associated with 
the development of insulin resistance and diabetes (Hotamisligil et al, 1996).
3.9 Models for the Myc-Mediated Block to Adipogenesis.
A number of models designed to clarify the role of c-Myc in differentiation control 
are outlined below:
3.9.1 Myc Mediates Continued Proliferation.
Proliferation and differentiation are generally considered to be alternative and 
mutually exclusive pathways. Thus, Myc may inhibit differentiation by fostering 
continued cell cycle progression. Indeed, many Myc-associated malignancies 
manifest as immature cell types with increased proliferative potential. Transgenic 
mice in which expression of c-myc is directed to the lymphoid compartment display
deregulated cell cycle control in the pre-B cell population and impaired B cell 
maturation (Langdon et al, 1986). Additionally, lymphoid tumours were apparent 
in many of the animals (Adams et al, 1985). Hence, it is possible that inhibition of 
differentiation may be a direct consequence of abnormal proliferation.
3.9.2 Myc Prevents Cells from Arresting in Go-
As described in Section 1.5.4, arrest in the Go state following mitotic clonal 
expansion is a pre-requisite for adipogenesis. It has therefore been proposed that 
Myc may inhibit 3T3-L1 differentiation by preventing cells from entering the Go 
state (Freytag, 1988). Whilst 3T3-L1 cells over-expressing c-myc retained the 
ability to arrest at confluence and undergo DNA replication in response to the 
adipogenic hormones, they differed from the parental line in that they did not lose 
responsiveness to serum mitogens following the hormone treatment. Thus, cells 
expressing high levels of Myc entered S phase in response to 30% serum whilst 
untransfected 3T3-L1 cells were refractory to this treatment. Interestingly, 
confluent monolayers of 3T3-L1 cells that had not been exposed to the 
differentiation inducers were also responsive to the mitogenic effects of 30% 
serum. This suggests that hormone treatment is necessary for the 3T3-L1 cell line 
to achieve the Go arrest state and that the presence of high levels of Myc somehow 
interferes with this process.
3.9.3 Myc Modulates the Activity o f Key Regulators o f Adipogenesis.
Myc has been shown to inhibit the expression of a number of key factors involved 
in differentiation, including MyoD and myogenin in myogenesis (Miner and Wold, 
1991) and C/EBPa in adipogenesis (Freytag and Geddes, 1992). The precise 
mechanism by which Myc exerts these effects is not clear, but studies of the 
C/EBPa promoter have shed some light on this phenomenon. The 5’ proximal 
promoter region is found to contain a consensus Myc/Max binding site (Vasseur-
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Cognet and Lane, 1993a). Interestingly, this is located in a 30bp segment 
characterised by a high density of negative elements, including that for the novel 
factor, C/EBPa undifferentiated protein (CUP), which is thought to repress 
expression of the c/ebpa gene in inappropriate cell types (Vasseur-Cognet and 
Lane, 1993b). Thus, Myc/Max complexes may repress C/EBPa via the CACGTG 
site, possibly in association with other factors such as CUP. However, recent work 
by Li and co-workers (1994) suggests that Myc-mediated repression requires the Inr 
element of the C/EBPa promoter. Examination of deletion mutants suggested that 
this activity also required the presence of a distinct region of the Myc protein, 
designated Myc box II. It is therefore of interest to note that a previous study had 
concluded that Myc Box II mutants were incapable of inhibiting adipogenesis 
(Freytag et al, 1990). Finally, a somewhat controversial study suggests that Myc 
may also affect gene expression via the C/EBP binding site (Hann et al, 1994). An 
interesting feature of the c-myc gene is that it encodes two alternatively translated 
isoforms (Hann and Eisenman, 1984), designated Mycl and 2. Hann and co­
workers demonstrated that Mycl was able to bind and transactivate via the C/EBP 
site of the Rous sarcoma virus EFII enhancer, whilst Myc2 bound without effect. 
Since Myc2 is the predominant form of the protein it is possible that repression of 
C/EBPa arises as a consequence of competitive binding for the C/EBP site by 
Myc/Max and other C/EBP family members. Whilst the physiological relevance of 
Mycl-mediated transactivation is not clear it should be noted that this form is 
preferentially translated as cultures attain high cell densities and growth arrest. It is 
therefore possible that Mycl may be involved in the positive modulation of 
C/EBPa driven adipogenesis. However, this remains to be formally proven.
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Initial Aims of the Project.
The primary objective of this project was to study the process of cellular 
differentiation. The c-myc proto-oncogene has been shown to block differentiation 
in a variety of cell types. Since the 3T3-L1 preadipocyte cell line has proven a 
valid in vitro model of adipogenesis, it was therefore proposed to exploit the ability 
of c-myc to inhibit differentiation in this system in order to gain further insight into 
the processes that might regulate induced adipogenesis, with particular emphasis 
being placed on the role of adipogenic transcription factors. Additionally, it was 
anticipated that such studies might also increase our understanding of the 
mechanism/s by which c-myc inhibits differentiation in vitro.
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MATERIALS AND METHODS.
MATERIALS AND METHODS.
CHAPTER 4: Materials.
4.1 Tissue Culture.
Supplier: European Collection o f Animal Cell Cultures, Salisbury, Wiltshire, 
England.
3T3-L1 preadipocyte cell line.
Supplier: Gibco Europe Life Technologies Ltd., Paisley, Scotland.
10X Dulbeccos MEM.
200mM glutamine. 
lOOmM sodium pyruvate.
7.5% (w/v) sodium bicarbonate.
2.5% (w/v) trypsin.
Geneticin sulphate (G418).
Supplier: Beatson Institute Central Services.
Sterile dH20.
Penicillin (7.5 mg/ml).
Streptomycin (10 mg/ml).
Amphotericin B (250pg/ml).
Sterile PBS-EDTA.
Sterile PBS.
Sterile glycerol.
Sterile INNaOH.
Sterile glassware and pipettes.
Supplier: Advanced Protein Products, Brierley Hill, West Midlands, England.
Foetal calf serum.
Supplier: ICN Biomedicals, Thame, Oxon, England.
Donor calf serum.
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Supplier: A/S Nunc, Roskilde, Denmark 
Tissue culture flasks.
Nunc cryotubes.
Chamber slides.
Supplier: Becton Dickinson Labware, Plymouth, Devon, England.
Tissue culture dishes.
Supplier: Costar Corporation, Cambridge, Massachusetts, USA.
Tissue culture plates.
Supplier: Fisher Scientific International, Loughborough, Leicestershire, England. 
Dimethyl sulphoxide (DMSO).
4.2 Plasticware.
Supplier: Becton Dickinson Labware, Plymouth, Devon, England.
Falcon tubes.
Supplier: Bibby-Sterilin Ltd., Stone, Staffordshire, England.
20ml universal and 5ml bijou tubes.
Supplier: Du Pont Co., Wilmington, Delaware, USA.
Sorvall ultracentrifuge tubes.
Microfuge tubes, pipette tips and other plasticware were obtained from the Beatson 
Institute Store.
4.3 Bacterial Culture.
Supplier: Beatson Institute Central Services.
L-broth, prepared as outlined in Sambrook et al (1989).
Sterile glassware.
Supplier: Difco, Detroit, Michigan, USA.
Bacto-agar.
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Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England. 
Ampicillin.
Kanamycin.
Supplier: Bibby-Sterilin Ltd., Stone, Staffordshire, England.
Petri dishes.
4.4 Nucleotides, Polynucleotides and DNA.
Supplier: Amersham International pic, Amersham, Buckinghamshire, England.
[a-32P] dCTP ~ 3000 Ci/mmol.
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Salmon sperm DNA.
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
Random hexanucleotide mix.
Unlabelled nucleotides.
4.5 Chemicals.
All chemicals (AnalaR grade) not individually listed were obtained from either 
BDH Chemicals Ltd., Poole, Dorset, England or Fisher Scientific International, 
Loughborough, Leicestershire, England.
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Bromophenol blue. 
Dithiothreitol (DTT). 
Polyvinylpyrrolidone 
Bromodeoxyuridine (BrdU). 
Oil red O. Nitroblue tetrazolium (NBT).
Ethidium bromide.
Tween 20.
Propidium iodide.
Ficoll.
1-Methyl-3-isobutylxanthine (MIX). Paraformaldehyde.
Insulin. Diaminobenzidine (DAB).
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Dexamethasone (DEX). Ponceau S.
Bovine serum albumin Fraction V. (3-mercaptoethanol. 
3-(N-morpholino) propane sulphonic acid (MOPS). 
5-bromo-4-chloro-3-indolyl phosphate (BCIP). 
Tetramethylethylene diamine (TEMED).
Supplier: ICN Biomedicals, Thame, Oxori, England.
Bovine pituitary growth hormone.
Supplier: Premier Beverages, Adbaston, Staffordshire, England.
“Marvel” non-fat dried milk powder.
Supplier: James Burrough Ltd., Witham, Essex, England.
Ethanol.
Supplier: Cinna/Biotecx Laboratories Inc., Houston, Texas, USA. 
RNAzol B.
Supplier: New Bruswick Scientific, Haverhill, Suffolk, England.
3-methyl-1 -butanol.
Supplier: Fluka Chemika-Biochemika AG, Buchs, Switzerland. 
Formamide.
Supplier: Boehringer Mannheim UK Ltd., Lewes, East Sussex, England. 
Caesium chloride.
Supplier: Bethesda Research Laboratories, Life Technologies, Inc., USA. 
Agarose, ultrapure electrophoresis grade.
4.6 Antisera.
Supplier: Santa Cruz Biotechnology Inc., Santa Cruz, California, USA. 
C/EBPa antisera: Rabbit IgG polyclonal (14AA).
C/EBP p antisera: Rabbit IgG polyclonal (C-19).
Madl antisera: Rabbit IgG polyclonal (C-19). 
p21 antisera: Rabbit IgG polyclonal (C-19).
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Supplier: Promega Ltd., Southampton, Hampshire, England.
Goat anti-rabbit IgG (Fc) alkaline phosphatase conjugate.
Supplier: Amersham International pic, Amersham, Buckinghamshire, England.
Donkey anti-rabbit IgG (whole molecule) horseradish peroxidase 
conjugate.
Supplier: DAKO Ltd., High Wycombe, Buckinghamshire, England.
BrdU antisera: Mouse IgG monoclonal (Bu20a).
The sources of antisera obtained as gifts are listed where quoted.
4.7 Enzymes and Enzyme Inhibitors.
All DNA modifying enzymes and their buffers, except those listed below, were 
obtained from: Bethesda Research Laboratories, Gibco Ltd. Paisley, Scotland.
Supplier: Boehringer Mannheim UK, Lewes, East Sussex, England.
RNAse A.
Supplier: NBL Gene Sciences Ltd., Cramlington, Northumberland, England.
Calf intestinal alkaline phosphatase.
Klenow Polymerase.
Supplier: Sigma Chemical Co. Ltd., Poole, Dorset, England.
Diethylpyrocarbonate (DEPC).
4.8 Gels and Columns.
Supplier: Severn Biotech Ltd., Kidderminster, Worcestershire, England.
Design-a-Gel 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide 
solution.
Supplier: Pharmacia Ltd., Milton Keynes, Buckinghamshire, England.
NICK columns.
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4.9 Kits.
Supplier: Amersham International pic, Amersham, Buckinghamshire, England.
ECL western blotting detection kit.
Supplier: Vector Laboratories Ltd., Peterborough, Cambridgeshire, England.
VectaStain ABC mouse IgG peroxidase immunostaining kit. 
Supplier: QIAGENLtd., Dorking, Surrey, England.
RNeasy total RNA kit.
QLAshredder cell lysate homogeniser.
4.10 Membranes, Paper and X-ray Film.
Supplier: Amersham International pic, Amersham, Buckinghamshire, England.
Hybond N+ nylon membranes.
Supplier: Sartorius AG, Gottingen, Germany.
Nitrocellulose Extra blotting membrane.
Collodion dialysis bags.
Supplier: Vernon-Carus Ltd., Preston, Lancashire, England.
Gauze swabs.
Supplier: Whatman International Ltd., Maidstone, Kent, England.
3 MM filter paper.
Supplier: Eastman Kodak Co., Rochester, New York, USA.
X-ray film (X-OMAT AR).
Kodak Gold print film ISO 100.
Supplier: Fuji Photo Film Co., Tokyo, Japan.
X-ray film (RX).
4.11 Markers.
Supplier: Bethesda Research Laboratories, Gibco Ltd., Paisley, Scotland.
Pre-stained protein markers: range 3-46 kDa and 14-200 kDa. 
<()X174 RF DNA / Hae III fragments.
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X DNA / Hind III fragments. 
RNA ladder.
4.12 Water.
De-ionised water (dH20) for general use and for the preparation of solutions and 
buffers was obtained from a Millipore MilliRO 15 system. Water for enzymatic 
reactions and recombinant DNA work (RQH2O) was further purified by reverse 
osmosis on a Millipore MilliQ system to 18Qcm.
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CHAPTER 5: Methods.
5.1 Cell Culture and Induction of Differentiation.
5.1.1 Serial Passage o f the 3T3-L1 Cell Line.
The 3T3-L1 preadipocyte cell line was maintained in culture as an adherent 
monolayer, according to the protocol of Dr. E.K. Parkinson (Beatson Institute). 
After dissociation with 0.25% trypsin in PBS-EDTA, cultures were seeded at a 
density of 104 cells per 90mm tissue culture dish in lOmls IX Dulbeccos MEM 
supplemented with 10% donor calf serum, 0.3% sodium bicarbonate, ImM sodium 
pyruvate, 2mM glutamine and 6.5mM NaOH in an atmosphere of 5% CO2 in air at 
37°C. Sub-confluent monolayers were passaged every 7 days, with fresh cultures 
being established every 2 months from frozen stocks.
5.1.2 Culture o f Rat-1 Cells.
Rat-1 cells for control transfections were obtained from Dr. D.H. Crouch (Beatson 
Institute) and grown in IX Dulbeccos MEM, supplemented with 10% foetal calf 
serum, 0.37% sodium bicarbonate, ImM sodium pyruvate and 2mM glutamine. 
After trypsinisation, cultures were seeded at a density of 2xl05 cells per 25cm2 
tissue culture flask one day prior to transfection and maintained in an atmosphere of 
5% CO2 in air at 37°C.
5.1.3 Cell Storage and Recovery.
The cell lines described in this study were stored frozen in liquid nitrogen. 
Cultures of growing cells were harvested by trypsinisation and centrifugation at 
lOOOrpm for 5 minutes in a MSE benchtop centrifuge. Cell pellets were 
resuspended to a final concentration of 106 cells/ml in the appropriate growth 
medium containing 10% (v/v) DMSO and 20% serum and aliquotted into 2ml 
cryotubes. These were placed in a polystyrene container at -70°C for 24 hours, after
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which time they were deposited in liquid nitrogen for long-term storage. Cultures 
were recovered by transferring cryotubes directly from liquid nitrogen into water at 
37°C. Once thawed, the cells were diluted in 5ml of pre-warmed growth medium, 
and centrifuged for 5 minutes at lOOOrpm in a MSE benchtop centrifuge. Cells 
from one vial were resuspended in 5ml of fresh growth medium and seeded into a 
25cm tissue culture flask.
5 A A Mycoplasma Testing.
Cell lines were regularly tested for the presence of Mycoplasma contamination 
using the method of Chen (1977). This was performed in house by Mary Freshney 
and Marion Lacey.
5.1.5 Induction o f Differentiation.
Cultures of 3T3-L1 preadipocytes were grown to confluence, and maintained in this 
state for 4 days prior to induction of differentiation. At induction (day 0), the 
growth medium was aspirated and replaced with fresh medium supplemented with 
0.5mM methyl isobutylxanthine (MIX), 0.25 pM dexamethasone (DEX) and 
lOpg/ml bovine pancreatic insulin. After 48 hours (day 2) cultures were changed to 
growth medium containing lOpg/ml insulin, and subsequently fed every 2 days 
until day 10, at which time maximal differentiation was judged to have occurred.
5.1.6 Markers o f Differentiation.
A. Morphology. Throughout the differentiation process, cultures were viewed by 
phase contrast microscopy to assess the number of cells that had attained the 
rounded and enlarged morphology typical of mature adipocytes. Preadipocytes 
were characteristically fibroblastic in appearance.
B. Oil red O Staining. Cultures were washed with PBS prior to fixation with 
0.66% (w/v) paraformaldehyde in PBS for 10 minutes at room temperature. Fixed
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cells were washed twice with PBS, followed by a brief rinse in 60% isopropanol. A 
0.25% stock solution of oil red O in isopropanol, prepared as described by Bancroft 
and Cook (1984), was diluted appropriately prior to use and monolayers stained for 
10 minutes at room temperature. Excess stain was removed by several washes with 
PBS, and the stained monolayers viewed by phase contrast microscopy. Where 
appropriate, stained cultures were photographed using an Olympus OM-21 camera 
mounted onto the microscope. Processing of all print film was performed by Boots 
the Chemist, Sauchiehall Street, Glasgow.
5.1.7 Calcium Phosphate Transfection.
Cell lines stably expressing the avian myc gene constructs were generated by 
calcium phosphate precipitation (Graham and van der Eb, 1973). One day prior to
^  *7 •transfection, cells were seeded at a density of 2x10 per 25cm flask and incubated 
in a humid atmosphere of 5% CO2 in air at 37°C. On the following day, lOpg 
CsCl-purified plasmid DNA was mixed with 240pl 0.2X SSC (20X is 3M NaCl, 
0.3M sodium citrate, pH 7), 35pl 2M calcium chloride and 275pl 2X HEPES- 
buffered saline [HeBS](280mM NaCl, lOmM KC1, 1.5mM disodium hydrogen 
orthophosphate dihydrate, 12mM glucose, pH 7.05 +/- 0.05), and incubated at room 
temperature for 15 minutes. After this time, the resultant precipitate was 
transferred to the exponentially growing cultures seeded on day 1 and incubated in 
a humid atmosphere of 5% CO2 in air at 37°C for 3-4 hours. To increase the 
efficiency of transfection the cells were then subjected to a glycerol shock. After 
aspirating the medium and washing the monolayer with fresh growth medium, 
cultures were incubated with 1ml IX HeBS/15% glycerol for 4 minutes at room 
temperature. This solution was removed by aspiration and, after rinsing with 
growth medium, the cultures were fed with 5 ml fresh growth medium and 
reincubated under the standard culture conditions until the monolayers had attained 
approximately 80% confluence. At this point the cells were trypsinised and
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reseeded into 90mm tissue culture dishes in 10ml growth medium, supplemented 
with 1 mg/ml geneticin (G418). The antibiotic-containing medium was replaced 
every 2 days and after approximately 2 weeks G418 resistant colonies were 
apparent. Single colonies were picked for further investigation.
5.1.8 Picking Colonies after Selection.
A solution of sterile 2.5 % low melting point agarose in serum free growth medium 
was briefly microwaved at full power, cooled to 37°C, and 7mls carefully pipetted 
into the tissue culture dish. Once set, pre-marked colonies were picked through the 
agarose using a Pasteur pipette and each seeded into a single well of a 24 well 
tissue culture plate by gentle aspiration. Once 80% confluent, clones were 
subcultured in the usual manner.
5.1.9 Single Cell Cloning.
Single cell cloning was undertaken by plating cells at a dilution of 10 cells/ml in a 
90mm tissue culture dish and the resultant colonies picked as described in 5.1.8. 
Plating at low dilution in this manner ensures that colonies will have arisen from a 
single cell and so represent a homogeneous population.
5.1.10 Growth Curves.
Cultures were initially seeded at a density of 5xl04 cells per 35mm dish and 
incubated under standard growth conditions. At various time points (generally days 
1-6), cells were trypsinised and resuspended in 1ml of growth medium. Cell counts 
were then performed manually using a haemocytometer and the time point plotted 
against the log number of cells in each culture.
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5.1.11 Geimsa Staining.
To assess plating or transfection efficiency cultures were stained using Geimsa. 
Following fixation in methanol for 10 minutes at room temperature, cells were 
stained with Geimsa (diluted 1:10 with dFfeO) for 1 hour. Excess stain was 
removed by washing in tap water and the number of colonies in each culture 
counted manually.
5.1.12 Growth in Soft Agar.
• l  ,Following trypsinisation, cells were resuspended at a final density of 5x10 in 
growth medium supplemented with 50pg/ml streptomycin, 37pg/ml penicillin, 
1.25ng/ml amphotericin B and 0.35% bacto-agar, in a total volume of 3ml. This 
suspension was carefully pipetted onto a pre-prepared baseplate, comprising 5mls 
0.7% bacto-agar in growth medium set in a 60mm bacteriological Petri dish. Once 
set, dishes were incubated in a sealed box for 2 weeks in an atmosphere of 5% CO2 
in air at 37°C, being refed twice weekly with 2mls growth medium/0.35% bacto- 
agar.
5.2 Recombinant DNA Techniques.
5.2.1 Restriction Digests and Agarose Gel Electrophoresis.
Generally, lpg of DNA for plasmid analysis and 10pg for fragment isolation were 
digested in a volume sufficiently large enough to dilute the restriction endonuclease 
10-fold. Digests were carried out using 5 units of enzyme per pg plasmid DNA, 
except when partial digestion was required, in which case the enzyme was diluted 
10-fold in IX reaction buffer (supplied as a 1 OX stock with the enzyme) prior to 
use. All digests were incubated according to the recommendations of the supplier, 
generally 1 hour at 37°C, the reaction being stopped by the addition of l/6th. 
volume of gel-loading buffer (0.25% bromophenol blue, 40% sucrose). After 
digestion, the resultant fragments were separated in non-denaturing agarose gels
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and visualised by UV transillumination. Gels were prepared by dissolving 1-1.5% 
(w/v) electrophoresis grade agarose in IX TAE buffer (40mM Tris-acetate, 20mM 
sodium acetate, 2mM EDTA, pH 7.4), containing 5pg/ml ethidium bromide. After 
microwaving to dissolve the agarose, molten gels were cooled to 50°C, and poured 
into an appropriate gel former. Gels were run in IX TAE at 100V for 5 minutes to 
run the samples into the gel, then subsequently at 40-50V. To estimate the size of 
fragments resolved by electrophoresis, molecular weight markers derived from 
restriction digests of viral genomes were included for comparison. For large 
fragments, a Hind III digest of bacteriophage X was used, whilst for smaller 
fragments a Hae III digest of the phage <|>X174 was the marker of choice.
5.2.2 Purification o f DNA Fragments from Agarose Gels.
After electrophoresis, the band of interest was excised from the gel and purified by 
passing through siliconised glasswool. This was achieved by placing a plug of 
glasswool into the bottom of a 0.5ml microfuge tube, which had previously been 
pierced at the base with a sterile needle. This tube was then inserted into a 1.5ml 
screw top microfuge tube, the gel slice macerated and placed within the smaller 
tube and the entire assembly spun at full speed in a microfuge for 2-3 minutes. 
This forces the liquid from the gel, which collects in the larger tube. The small 
tube was then discarded and the DNA precipitated from the flow-through with 
1/10th. volume 3M sodium acetate and 2 volumes ice cold ethanol. Following 
incubation on dry ice for 15 minutes, the DNA was pelleted by spinning in a 
microfuge at full speed for 5 minutes, and resuspended in 10-20 pi TE (lOmM Tris- 
HC1 pH 7.4, ImM EDTA pH 8). The purified DNA was quantified by agarose gel 
electrophoresis and comparison with known quantities of <|)X174 Hae ID marker.
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5.2.3 Phosphatase Treatment o f Vector DNA.
To prevent religation, digested vector DNA was treated with phosphatase to 
remove the 5’ phosphate group, lpg vector DNA was digested to completion in a 
total reaction volume of 50pl and treated with 1 unit calf intestinal phosphatase for 
1 hour at 37°C. This reaction was stopped by the addition of 6pi 10% SDS and 6pl 
10X STE (lOOmM Tris-HCl pH 8, 1M NaCl, lOmM EDTA) and subsequent 
incubation at 68°C for 15 minutes. Following extraction with 1 volume TE- 
saturated phenol, the DNA was precipitated with 3M sodium acetate and ethanol, in 
the presence of 2pg carrier tRNA. The phosphatase treated vector was resuspended 
in TE to a final concentration of lOng/pl.
5.2.4 Ligation o f DNA Fragments into Vector DNA.
Phosphatase treated vector DNA was mixed with a 3-fold excess of purified 
fragment DNA, in the presence of 1 unit T4 DNA ligase. The reaction was 
incubated at 4°C overnight.
5.2.5 Preparation o f Competent Bacterial Cells.
The TGI strain of Escherichia coli was obtained from Beatson Institute glycerol 
stocks. A growing culture was established by inoculating 5ml L-broth with a 
loopful of TGI and incubating overnight at 37°C in an orbital shaker at 225 rpm. 
The following day 2.5ml of this culture was used to inoculate 250ml L-broth and 
incubated under the above conditions until the culture was judged to be in 
exponential growth (OD6oo~0.3). At this point the cells were harvested by 
centrifugation in a DuPont Sorvall RC-5B centrifuge at 5000rpm for 10 minutes. 
The bacterial pellet was resuspended in 100ml 0.1M NaCl/5mM magnesium 
chloride and spun for 10 minutes at 5000rpm. The resultant pellet was resuspended 
in 50ml 0.1M calcium chloride/5mM magnesium chloride and incubated on ice for 
20 minutes, with occasional gentle mixing. Following centrifugation at 5000rpm
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for 10 minutes, the bacterial cells were resuspended in 15ml 0.1M calcium 
chloride/5mM magnesium chloride and used immediately for transformation. 
Alternatively, long term stocks were established by the addition of 5ml 60% 
glycerol/0.1M calcium chloride/5mM magnesium chloride. This solution was 
aliquoted into snap-top microfuge tubes and stored at -70°C.
5.2.6 Transformation o f Bacterial Cells with Plasmid DNA.
TGI competent cells were slowly thawed on ice and 100pi aliquots placed into pre­
chilled 2058 tubes (Falcon). Approximately lng of plasmid DNA or lOpl ligation 
mix were added to the cells and gently mixed by stirring with a pipette tip. After 
incubation on ice for 45 minutes, the cells were heat-shocked at 42°C for 90 
seconds and placed on ice for a further 2 minutes. 400pl of L-broth was then added 
to the cells and this mixture incubated at 37°C for 1 hour in an orbital shaker at 
225rpm, to allow time for the cells to express the appropriate antibiotic resistance 
gene. After this time, lOOpl of the cell suspension was spread onto L-broth plates 
containing 1.5%(w/v) bacto-agar and supplemented with the appropriate antibiotic 
at a concentration recommended by Sambrook et al (1989). Plates were air-dried 
for 5 minutes and incubated in an inverted position overnight at 37°C.
5.2.7 Small Scale Preparation o f Plasmid DNA.
A single bacterial colony from an agar plate was picked using a sterile toothpick 
and transferred to 5ml of L-broth containing the appropriate antibiotic. This culture 
was incubated overnight at 37°C with shaking at 225rpm, and 1.5ml transferred to a 
microfuge tube and centrifuged at full speed for 5 minutes. After aspirating the 
supernatant, the bacterial pellet was resuspended in 100fil of solution I (50mM 
glucose, 25mM Tris-HCl pH 8, lOmM EDTA). The cells were then lysed by the 
addition of 200pl of freshly prepared solution II (0.2M NaOH, 1% SDS), followed 
by gentle inversion of the tube. To precipitate the chromosomal DNA, 150pi of
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solution III (3M sodium acetate, pH 4.8) was added, the solution mixed thoroughly 
by inversion and placed on ice for 5 minutes. The precipitated chromosomal DNA 
and protein was removed by centrifugation for 5 minutes at full speed and the 
supernatant transferred to a fresh tube. Nucleic acid was precipitated from the 
supernatant by the addition of an equal volume of isopropanol and incubation at 
room temperature for 10-30 minutes. Following centrifugation for 5 minutes at full 
speed, the pellet was resuspended in lOOpl TE/3M sodium acetate and the nucleic 
acids reprecipitated by the addition of 2 volumes of ethanol and incubation on dry 
ice for 10 minutes. The DNA was recovered by centrifugation at full speed for 5 
minutes and the resulting pellet dissolved in 75pi TE. Typically 5pi of this mixture 
was then used for analysis by restriction digest, in the presence of DNAse-free 
RNAse at a final concentration of 1 pg/pl.
5.2.8 Large Scale Preparation o f Plasmid DNA.
A 5ml culture of bacteria, prepared as described above, was used to inoculate 
500ml of L-broth containing the appropriate antibiotic and incubated overnight at 
37°C with shaking. The cells were harvested by centrifugation in a DuPont Sorvall 
RC-5B centrifuge at 5000rpm at 4°C for 10 minutes and the pellet thoroughly 
resuspended in 20ml solution I (see above). Following the addition of 40ml of 
freshly prepared solution II (see above), the cell lysate was placed on ice for 5 
minutes. After this time, 30ml solution III (see above) was added, the solution 
mixed thoroughly and placed on ice for a further 10 minutes to precipitate the 
protein and genomic DNA. Following centrifugation at 5000rpm at 4°C for 10 
minutes to pellet the flocculant, the supernatant was transferred to a fresh tube by 
filtration through a double layer of gauze and the nucleic acids precipitated with a 
equal volume of isopropanol for 15 minutes at room temperature. The nucleic acid 
was recovered by centrifugation as described above. After being air-dried for 5 
minutes, the pellet was re-dissolved in 7.7ml TE containing 8.47g CsCl and 0.35ml
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of lOmg/ml ethidium bromide solution. Samples were transferred to screw-cap 
ultracentrifuge tubes and spun at 40,000rpm for greater than 40 hours in a Du Pont 
Sorvall OTD Combi ultracentrifuge. Bands corresponding to closed circular 
plasmid DNA were removed from the tubes using a syringe and serially extracted 
with 3-methyl-1-butanol to remove the ethidium bromide. Purified DNA was 
precipitated with 3M sodium acetate and ethanol as previously described, air dried 
and resuspended in 500pl of TE. If the plasmid DNA was to be used to transfect 
mammalian cell lines, it was further purified by dialysis overnight against 1 litre TE 
in a collodion bag.
5.2.9 Storage o f Bacterial Glycerol Stocks.
Stationary bacterial cultures in liquid medium were mixed with an equal volume of 
glycerol, chilled on ice, then stored at -70°C in plastic cryotubes. Cultures were re­
established by inoculation of 5ml of L-broth medium, containing the appropriate 
antibiotic, with a sterile loopful of the glycerol stock.
5.2.10 Quantitation o f Nucleic Acid Concentrations.
Nucleic acids were quantified with respect to their absorbance of UV light. 5(il of 
sample was added to 500pl of de-ionised water and the absorbance of the solution 
measured at 260nm and 280nm in a quartz cuvette, using de-ionised water as a 
blank. The concentration of the solution was calculated on the basis that an optical 
density of 1 corresponds to a concentration of 50pg/ml for plasmid or genomic 
DNA and 40pg/ml for RNA. The ratio of the readings OD26o/OD28o was used as an 
estimate of the purity of the nucleic acid. Samples with ratios between 1.8 and 2.0 
were taken as being sufficiently pure for all the techniques undertaken in this study.
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5.3 Northern Blot Analysis.
5.3.1 Preparation o f Total Cellular RNA.
Total cellular RNA was isolated using RNAzol B. Monolayers were cultured in 
150cm2 flasks, then lysed with 10ml RNAzol solution, before being transferred to a 
2059 Falcon tube. Following the addition of 1ml chloroform and incubation on ice 
for 5 minutes, the suspension was centrifuged for 15 minutes at 10,000rpm in a pre­
chilled Sorvall RC-5B centrifuge. Exactly 5ml of the upper phase was removed 
and an equal volume of isopropanol added. Tubes were incubated on ice for 30 
minutes, then centrifuged as described above. The resultant pellet was resuspended 
in 5ml 75% ethanol and spun at 7500rpm for 8 minutes. Residual ethanol was 
removed with a pulled Pasteur pipette, the pellet air dried for 5 minutes and 
resuspended in 25-50pl DEPC-treated Milli-Q water. The RNA concentration was 
determined as described in Section 5.2.10. For the growth hormone experiments, 
total RNA was prepared using the QLAGEN RNeasy kit, as advised by the 
manufacturers.
5.3.2 Electrophoresis and Transfer o f RNA.
RNA was denatured by suspension in 5 volumes of fresh sample buffer (750pl 
formamide, 240pl 37% formaldehyde, 150pl 10X MOPS [0.2M 3-(N-morpholino) 
propane sulphonic acid, 50mM sodium acetate, 5mM EDTA, pH 7], 200pl 50% 
glycerol and 7pi 2.5% bromophenol blue) and heating at 65°C for 15 minutes. 
Following the addition of l/25th. volume lmg/ml ethidium bromide, lOpg RNA 
per lane was size fractionated by electrophoresis through 1.25% (w/v) agarose gels 
in IX MOPS, containing 2.2M formaldehyde, using IX MOPS as the gel running 
buffer. lOpg RNA ladder, treated as described above, was included for size 
comparison. Gels were generally run overnight at 30V and the buffer circulated by 
a peristaltic pump (Pharmacia). After electrophoresis, gels were washed in water (2 
x 30 minutes), then transferred overnight to Hybond N+ membranes by capillary
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blotting using 20X SSC (3M NaCl, 0.3M sodium citrate, pH 7). The RNA was 
fixed to the membrane by exposure to UV light in a Stratagene 1800 crosslinker, 
after which the filters were washed in 2X SSC, sealed in polythene bags and stored 
at 4°C until required.
5.3.3 Preparation o f Random-Primed Radio-Labelled Probes.
The probes used in this study for Northern blot analysis were as follows:
The avian c-myc probe was the 500bp Clal fragment of fpGV-WT, described in 
Section 6.4, which corresponds to the C-terminus of the protein.
The FAAR probe was the 1.5kb Bam HI fragment of pSGFAAR, (kindly provided 
by Dr. Ez-Zoubir Amri, University of Nice, France), corresponding to the murine 
FAAR cDNA (Amri et al, 1995).
CHOP-10 corresponded to the 710bp Bam YWAccl fragment of Chop-10 pBS (a 
gift from Dr. David Ron, Skirball Institute of Biomolecular Medicine, New York, 
USA). This probe encompassed almost the entire murine CHOP-10 coding 
sequence (Ron and Habener, 1992).
Probes for C/EBPa, p and 8 were kindly provided by Dr. Steve McKnight, Tularik 
Inc., South San Francisco, California, USA. C/EBPa corresponded to the 900bp 
Ncol fragment of MSV/EBPa, whilst C/EBP p and 8 were the 1.5kb Bam HIlEco 
RI fragment of MSV/EBPp and the lkb Bam HIlEco RI fragment of MSV/EBP8 
respectively. All three represent cDNA clones, C/EBPa being of rat origin 
(Landschulz et al, 1988), whilst C/EBPp and 8 were isolated from a 3T3-L1 cDNA 
library (Cao et al, 1991).
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The PPARy2 probe was the 520bp Stul fragment of PPARy2/SPORT, 
corresponding to a portion of the murine cDNA (Tontonoz et al, 1994a) and was 
the gift of Dr. Peter Tontonoz, Dana-Farber Cancer Institute, Boston, 
Massachusetts, USA.
The aP2 probe was the 700bp Pstl fragment of aP2/pGEM and corresponded to the 
murine cDNA. This was kindly provided by Dr. M. Daniel Lane, Johns Hopkins 
University School of Medicine, Baltimore, Maryland, USA.
The SCD1 probe was the 800bp PstVEco RI fragment of PC4 (Ntambi et al, 1988), 
corresponding to a murine cDNA clone. This was also the gift of M. Daniel Lane.
All probes were radio-labelled with [a -32P] dCTP by random priming (Sambrook 
et al, 1989). Typically, 50-75ng purified fragment DNA in a total volume of 8pl 
were denatured by boiling for 10 minutes. Following incubation on ice for 5 
minutes, the DNA was mixed with 5 pi random hexanucleotide/cold dNTP mix 
(prepared according to the manufacturers instructions), 1.85 MBq [a -  P] dCTP, 2 
units of Klenow polymerase and incubated at 37°C for 30 minutes. Labelled probes 
were separated from unincorporated nucleotides by purification on NICK columns 
as described in the manufacturers instructions. Prior to use in hybridisation 
reactions, all double-stranded probes were denatured by heating to 100°C for 10 
minutes and placed on ice for a further 5 minutes.
5.3.4 Hybridisation.
Nylon membranes were pre-hybridised in a solution of 50% formamide, 5X SSPE 
(20X SSPE is 3.6 M NaCl, 0.2 M sodium phosphate, 20 mM EDTA, pH 7.4), 5X 
Denhardt's reagent (prepared as described in Sambrook et al, 1989), 0.5 % (w/v) 
SDS and 200pg/ml sonicated salmon sperm DNA at 42°C for at least 4 hours.
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Radio-labelled probe was added at a concentration of 1 x 10 cpm/ml and the 
incubation continued for a further 16 to 24 hours. The blots were then washed 
thoroughly (2 x 20 minutes in 2X SSC/0.1% SDS at room temperature, followed by 
30 minutes in 0.1 X SSC/0.1% SDS at 65°C), and exposed to Kodak X-OMAT film 
with intensifying screens at -70°C.
5.3.5 Removal o f Radio-Labelled Probe from Nylon Membranes.
In order that nylon membranes could be re-hybridised with a series of different 
probes, bound probe was removed by washing in boiling 0.1% (w/v) SDS for 30 
minutes at room temperature, with shaking. Filters were then re-sealed into 
polythene bags and stored at 4°C until required. At no point during this procedure 
were the blots allowed to dry out as this causes the probe to become irreversibly 
bound to the nylon membranes.
5.4 Western Blot Analysis.
5.4.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE). 
The separation of proteins for immuno-blot analysis were undertaken using the 
discontinuous buffer system (described in Sambrook et al, 1989). A solution of 
30% (w/v) acrylamide/0.8% (w/v) bisacrylamide was diluted to the desired 
concentration of acrylamide (generally 7.5-12.5%) in 4X gel buffer (1.5M Tris-HCl 
pH 8.8, 0 .4% (w/v) SDS) and water to give a final volume of 50ml. This solution 
was polymerised by the addition of 250p,l 10% (w/v) ammonium persulphate and 
lOOpl TEMED and cast to within 3cm of the top of two glass plates separated by 
2mm spacers within an ATTO gel forming apparatus (ATTO Corp., Japan). To aid 
polymerisation and to prevent the formation of bubbles, the gel was overlaid with 
water-saturated butanol, which was rinsed away with dH20 once the gel had set. A 
stacking gel was then prepared, containing 0.125M Tris-HCl pH 6.8, 0.1% (w/v) 
SDS, 0.005% (w/v) ammonium persulphate and 0.002% TEMED. This was poured
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on top of the resolving gel, a comb inserted and the stack allowed to polymerise. 
Protein samples were prepared by lysing cell monolayers in SDS-PAGE sample 
buffer (0.08M Tris-HCl pH6.8, 10% glycerol, 5% SDS and 40pl/ml (3- 
mercaptoethanol), followed by sonication, and equivalent amounts of protein 
loaded in each lane. Pre-stained molecular weight markers were included for size 
comparison. SDS-PAGE gels were run at 200V for 2 hours in IX TG running 
buffer (50mM Tris-HCl, 1% (w/v) glycine and 0.25% (w/v) SDS). Once 
electrophoresis was complete, the separated proteins were transferred to 
nitrocellulose filters by semi-dry electro-blotting for 1 hour at 200mA using layers 
of Whatman 3MM paper pre-soaked in transfer buffer (60mM Tris.HCl, 50mM 
glycine, 1.7mM (w/v) SDS and 20% (v/v) methanol), in a blotter made to our 
specifications by Don McBean (Beatson Institute). To assess the efficiency of 
transfer and the relative loading per lane, filters were stained with Ponceau S 
solution for 2-3 minutes, and destained with dH20 prior to Western blot analysis.
5.4.2 Western Blot Analysis.
Filters were probed by either of the following methods:
A. Enhanced Chemi-Luminescence (ECL). Blots were first blocked overnight at 
4°C with shaking in TBST (lOmM Tris-HCl, 150mM NaCl, 0.1% (v/v) Tween 20), 
containing 5% (w/v) non-fat milk powder, and subsequently incubated in this 
solution with an appropriate dilution of the primary antibody, raised against the 
protein of interest, for 1 hour at room temperature with shaking. The filters were 
thoroughly washed in TBST ( 1x15  minutes, followed by 4 x 5 minutes), before 
incubation with a horseradish peroxidase conjugated secondary antibody, diluted 
1:5000 in TBST/5% (w/v) milk, for 1 hour at room temperature. Following 
washing (as described above), the extent of reactivity against the protein of interest 
was determined using the ECL Western blotting detection system (Amersham) and 
exposure to Fuji RX film.
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B. Alkaline Phosphatase Detection. This method is essentially as described for the 
ECL detection, but with some minor modifications. Blocking, antibody incubation 
and washes were all performed in TBST containing 2.5% (w/v) milk, and filters 
were subjected to 4 x 5 minute washes only. After the final wash, filters were 
rinsed in TBST, and subjected to several 2 minute washes in AP buffer (0.1M Tris- 
HCl, 0.1M NaCl, 5mM magnesium chloride, pH 9.5). Reactivity was then 
determined by the addition of a solution containing 16mg NBT and 8mg BCIP in 
50ml AP buffer. A positive reaction was indicated by the formation of an insoluble 
purple deposit. The reaction was stopped by rinsing in and stained filters 
stored in the dark at room temperature to prevent fading.
5.5 Cell Cycle Analysis.
5.5.1 Propidium Iodide Staining and Flow Cytometry.
Monolayers were washed with 7.5ml pre-warmed PBS-EDTA, then treated with 
5ml trypsin for 1 minute. After this time, the trypsin was transferred to a 15ml 
conical tube and the monolayer reincubated for a further 2-3 minutes. The cells 
were resuspended in 10ml growth medium, added to the conical tube and 
thoroughly dispersed by pipetting. Following centrifugation at lOOOrpm for 5 
minutes in an MSE benchtop centrifuge, the cell pellet was resuspended in 10ml ice 
cold PBS, and recentrifuged as described above. The resultant pellet was 
resuspended in 1ml cold PBS, then 9ml ice cold 70% ethanol added whilst 
vortexing. At this point the fixed cells could be stored at 4°C until required. To 
stain the cells, the ethanol was removed by centrifugation as before and the pellet 
resuspended in 0.5-2ml PBS, containing 250pg/ml RNAse A and 10p,g/ml 
propidium iodide, and left for 30 minutes at room temperature. Samples were 
analysed using a fluorescence-activated flow cytometer (Becton Dickinson 
FACScan). Equal numbers of events were examined for each population of cells 
and the cell cycle distribution estimated using the MODFIT-LT programme.
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5.52 In Situ BrdUStaining.
Monolayers cultured in chamber slides were treated with BrdU to a final 
concentration of lOpM for the required length of time, then stained using the 
VectaStain immunocytochemistry kit. Following incubation with BrdU, the cells 
were fixed with methanol:acetone (1:1 ratio) for 10 minutes at room temperature 
and air-dried. After fixation, the slides were washed in PBS/0.25% Tween 20 for 5 
minutes, followed by a 10 minute wash in PBS. The DNA was denatured by 
treating with 1M HC1 for 15 minutes at 60°C, after which time the slides were 
washed 3 times in PBS for a total time of 10 minutes. The slides were next 
incubated with anti-BrdU antiserum, diluted 1:30 in PBS/0.5%BSA, for 1-3 hours 
at room temperature. Following washing in PBS/0.05% Tween 20 (3 x 10 
minutes), the slides were incubated with the biotinylated secondary antibody 
(supplied in the kit) for 1 hour at room temperature. The slides were washed as 
described above, and incubated with the avidin-biotin complex (ABC-supplied in 
kit). Following this incubation, the slides were washed as previously described, 
and stained with DAB solution (lOmg DAB and 1 0 j j .1 hydrogen peroxide in 16.7ml 
PBS) for precisely 7.5 minutes, after which time the reaction was stopped by 
washing with PBS. A positive reaction was indicated by brown nuclear staining.
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RESULTS.
RESULTS.
CHAPTER 6: Generation and Preliminary Characterisation of 3T3-L1 Cell 
Lines Constitutively Expressing Avian c-myc.
6.1 Introduction.
The primary objective of this project was to investigate the ability of the c-myc 
proto-oncogene to inhibit cellular differentiation. We therefore adopted the 
strategy of generating stable cell lines constitutively expressing c-myc and 
examined the consequence of this enforced expression on the ability of cells to 
undergo a well-defined differentiation programme. For this purpose the murine 
3T3-L1 preadipocyte cell line was selected since an earlier study had demonstrated 
that this line was susceptible to a Myc-mediated differentiation block (Freytag, 
1988).
6.2 The 3T3-L1 Preadipocyte Cell Line has the Ability to Differentiate into 
Cells Resembling Mature Adipocytes.
The 3T3-L1 preadipocyte cell line is probably one of the best characterised in vitro 
models of adipogenesis. In the undifferentiated state, 3T3-L1 cells are typically 
fibroblastic (Figure 4A), with a bipolar appearance and little lipogenic capacity. 
However, as adipogenesis proceeds the cells adopt an enlarged, rounded appearance 
and triglyceride droplets are seen to accumulate within the cytoplasm. These 
eventually coalesce and displace the nucleus to one side, giving rise to the 
characteristic “signet ring” morphology. This stored lipid may be visualised 
histologically with oil red O which specifically stains triglycerides a deep red 
colour (Figure 4B). Oil red O staining therefore provides a quick and reliable 
method by which to assess the ability of a culture to undergo terminal 
differentiation.
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Figure 4.
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Figure 4. Morphological Features of the 3T3-L1 Cell Line.
Panel A. Sub-confluent culture of 3T3-L1 preadipocytes viewed by phase contrast 
light microscopy (xlOO magnification).
Panel B. 3T3-L1 adipocytes following staining with oil red O viewed by phase 
contrast light microscopy (xlOO magnification).

6.3 Requirements for the Efficient Differentiation of the 3T3-L1 Cell Line.
The key premise of our investigation was that enforced expression of c-myc in the 
3T3-L1 cell line would inhibit adipogenesis. We therefore felt that it would be 
prudent to optimise the differentiation conditions for our cells prior to transfection. 
In this way, we could be confident that any effects observed following gene transfer 
arose from constitutive expression of the c-myc transgene and did not reflect an 
inherent deficit in the ability of the 3T3-L1 cells to undergo adipogenesis.
6.3.1 Spontaneous Differentiation o f the 3T3-L1 Cell Line is an Inefficient Process 
Which is Enhanced by Hormone Treatment.
Once a culture of 3T3-L1 cells had attained confluence, it could be maintained in 
this state for long periods without differentiating. When viewed microscopically, 
occasional mature adipocytes were observed and it was assumed that these had 
arisen spontaneously. However, these cells represented less than 5% of the total 
population, suggesting that spontaneous differentiation is an inefficient process. In 
contrast, treatment of the same culture with a cocktail of adipogenic hormones 
rapidly induced differentiation. Examination of the monolayer at regular intervals 
by phase contrast microscopy indicated that morphological changes started to occur 
approximately three days post-induction, with cells assuming a more rounded 
appearance. Cytoplasmic triglyceride accumulation was first observed at day 4 and 
increased thereafter, reaching a maximum at day 10. Following induced 
differentiation, cells resembling mature adipocytes represented approximately 80- 
90% of the total cell population. Thus, hormonal treatment greatly enhanced the 
ability of the 3T3-L1 cell line to undergo adipogenesis.
The induction protocol used was essentially that described by Freytag (1988). On 
day 0 of the differentiation programme, 3T3-L1 monolayers were treated with 
growth medium supplemented with 0.25pM dexamethasone, 0.5mM MIX and
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lOpg/ml bovine pancreatic insulin for 48 hours. After this time (day 2), the 
hormone cocktail was removed and replaced with fresh growth medium 
containing 10pg/ml insulin. This medium was changed every two days until day 
10, at which point differentiation was judged to be complete. The contribution 
made by each hormone to the adipogenic process was also assessed. Replicate 
3T3-L1 cultures were treated with the hormones, either alone or in combination, 
and the ability of each culture to undergo adipogenesis assayed by oil red O 
staining at day 10. As expected, induction with the full complement of hormones 
resulted in maximal differentiation, whilst cultures treated with unsupplemented 
growth medium were essentially devoid of mature adipocytes (Figure 5). 
Treatment with MIX alone resulted in impaired differentiation (-50%) when 
compared to cultures induced by the hormone cocktail. In contrast, cells exposed 
to dexamethasone or insulin alone did not differentiate and were indistinguishable 
from the uninduced cultures. However, supplementing MIX with either insulin or 
dexamethasone had a synergistic effect and restored the differentiation capacity to 
that observed with all three hormones. Surprisingly, treatment with 
dexamethasone and insulin in combination was still without effect. Thus, induced 
differentiation of the 3T3-L1 cell line required MIX and at least one other 
hormone for optimal conversion.
6.3.2 Cellular Density at Induction is a Critical Determinant o f Differentiation in 
the 3T3-L1 Cell Line.
In the course of this work it became apparent that the state of the 3T3-L1 culture 
prior to induction was also critical. Hence, pre-confluent monolayers or cultures 
that had just attained confluency did not differentiate as readily as those which 
had been maintained at confluence for several days before hormone treatment. 
This requirement for sustained confluency is demonstrated in Figure 6. Cells 
were seeded at a range of densities and differentiation induced once the culture
76
Figure 5.
77
Figure 5. Assessment of the Adipogenic Potential of Dexamethasone, Methyl 
Isobutylxanthine and Insulin.
Differentiation was induced in replicate 3T3-L1 cultures by the following 
treatments:
Growth medium (Uninduced).
Growth medium supplemented with 0.25pM dexamethasone, 0.5mM MIX and 
10|ig/ml insulin (DEX+MIX+Insulin).
Growth medium supplemented with 0.25|liM  dexamethasone (DEX).
Growth medium supplemented with 0.5mM MIX (MIX).
Growth medium supplemented with 1 Opg/ml insulin (Insulin).
Growth medium supplemented with 0.25pM dexamethasone and 0.5mM MIX 
(DEX+MEX).
Growth medium supplemented with 0.25 pM dexamethasone and lOpg/ml insulin 
(DEX+Insulin)
Growth medium supplemented with 0.5mM MIX and 1 Opg/ml insulin 
(MIX+Insulin).
Following differentiation, cultures were stained with oil red O at day 10 and the 
ability to differentiate determined relative to that of DEX+MIX+Insulin.
Hormone Treatment. Ability to 
Differentiate.
Uninduced —
Dex + MIX + Insulin +
Dex —
MIX +/-
Insulin —
Dex + MIX +
Dex + Insulin —
MIX + Insulin +
Figure 6.
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Figure 6. Effect of Cellular Density on 3T3-L1 Differentiation.
3T3-L1 cells were trypsinised and seeded into 60mm tissue culture dishes at the 
following densities:
A. lxlO3
B. 5xl03
C. lxlO4
D. 5xl04
E. 1x10s
F. 5x10s
Once the cells in culture F had been at confluence for 2 days, all cultures were 
subjected to the standard differentiation protocol. At day 10 monolayers were 
stained with oil red O and viewed by phase contrast light microscopy (xlOO 
magnification) in order to assess the degree to which each culture had 
differentiated.
Vc. D.
E. F.
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seeded at the highest density had been confluent for two days. Following staining 
with oil red O at day 10, it was apparent that cultures which had been sub­
confluent at induction contained few mature adipocytes (Figure 6A and B), whilst 
those which had attained confluence at day 0 were able to differentiate to a greater 
extent (Figure 6C and D). However, maximal differentiation was observed where 
monolayers had been maintained at confluence prior to induction (Figure 6E and
F).
A similar conclusion was drawn from a second experiment in which a post­
confluent 3T3-L1 monolayer was wounded by scraping a strip of cells from the 
centre of the dish. The cells were allowed to recover for 24 hours, during which 
time the preadipocytes at the edge of the wound migrated into the space 
generating a culture composed of three distinct populations: pre-confluent, 
confluent and post-confluent fibroblasts. The ability of each of these sub­
populations to undergo adipogenesis was then assessed by subjecting the culture 
to the standard differentiation protocol. Oil red O staining was performed at day 
10, the striking feature of which was the presence of a macroscopic band of 
unstained cells running across the dish. Figure 7 shows the boundary between the 
stained and unstained cells, as viewed under low power light microscopy. Using a 
higher magnification it was apparent that the culture at the centre of the dish was 
composed almost entirely of fibroblasts, and that these presumably represented 
the cells that had migrated into the wound. In contrast, the culture on either side 
of the wound was fully differentiated. Taken together, these findings suggest that 
the efficiency of induced differentiation in the 3T3-L1 system is greatly enhanced 
in post-confluent monolayers. In order to ensure optimal conditions, it was 
therefore proposed that all cultures should be maintained in a post-confluent state 
for a period of four days prior to induction of differentiation.
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Figure 7. Effect of Wounding the Monolayer Prior to Differentiation.
A post-confluent 3T3-L1 monolayer was treated as described in the text, subjected 
to the differentiation protocol and stained with oil red 0  at day 10. The figure 
shows the border between the stained and unstained cells by light microscopy (x40 
magnification).
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The molecular basis for this phenomenon is not entirely clear but may reflect the 
need to establish cell-cell or cell-ECM interactions (see Section 1.5.2). However, 
cell-cell communication may not be paramount since the 3T3-F442A cell line can 
be induced to differentiate in suspension culture (Pairault and Green, 1979). 
Indeed, it has been suggested that gap-junctional communication is lost as 
adipogenesis commences (Smas and Sul, 1995). At present the issue of ECM 
interactions remains unresolved since attempts to induce premature differentiation 
of pre-confluent cells on reconstituted ECM were unsuccessful (data not shown). 
A second possibility is that post-confluent cells produce a secreted factor which 
conditions the medium, resulting in competence to differentiate once a certain 
threshold level is attained. However, conditioned medium harvested from 3T3-L1 
preadipocytes was unable to stimulate differentiation of pre-confluent monolayers 
(data not shown). Finally, there appears to be a requirement for growth arrest 
prior to induction. Pre-confluent cultures were found to be impaired in their 
ability to undergo the differentiation programme and it is possible that this arose 
as a consequence of continued proliferation. Thus, maintenance at confluence 
may be required for full cell cycle withdrawal.
6.3.3 The 3T3-L1 Cell Line does not Harbour a Differentiation-Defective Sub- 
Population.
It was noted that induced differentiation of the 3T3-L1 line generally resulted in 
approximately 80-90% of the total cell population acquiring the characteristic 
adipocyte morphology. Two possibilities were proposed to account for this 
observation. Firstly, the ability of individual cells within a culture to undergo the 
differentiation programme may be stochastic, dependent upon chance rather than 
adipogenic potential per se. Alternatively, the residual fibroblastic fraction could 
represent a sub-population that had lost the ability to undergo adipogenesis. To 
test these hypotheses, 3T3-L1 cells were differentiated as usual then trypsinised
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and reseeded at low density. Since adipocytes are post-mitotic they could not be 
propagated and were rapidly lost from the culture. In contrast, the fibroblastic 
cells proliferated readily generating a culture composed almost entirely of the 
progeny of those cells that originally failed to differentiate. Once post-confluent, 
this culture was then subjected to the standard differentiation protocol. Oil red O 
staining at day 10 revealed that as before 80-90% of the population had undergone 
adipogenesis. Since this procedure could be repeated several times, with the same
result, we therefore concluded that the 3T3-L1 line used in our study did not
harbour a sub-population of cells that were refractory to induced differentiation. 
Hence, adipogenesis is likely to be a stochastic process.
6.4 Construction of Avian c-myc Expression Vectors.
Avian wild type c-myc, and the c-mycAl and c-mycAlQ LZ deletion mutants were 
the kind gift of Dr. D.H. Crouch (Beatson Institute) and have been described in 
detail elsewhere (Crouch et al, 1990). The wild type c-myc was essentially an 
artificial cDNA composed of exons 2 and 3 of the genomic sequence, fused via a 
66bp fragment derived from v-myc in order to eliminate intron 2. However, the 
construct retains the exon 2 splice acceptor site. The LZ mutants were generated 
by oligonucleotide directed mutagenesis of the wild type cDNA, which introduced 
premature stop codons into the sequence (Figure 8A). The positions of these 
termination codons were selected to progressively truncate the protein from the 
extreme C-terminus. Hence, c-MycA7 has a deletion of seven amino acids 
including leucine 4 of the LZ motif, whilst c-MycAlO lacks ten residues including 
leucines 4 and 3A (Figure 8A). Unlike leucine 4, leucine 3A is not part of the 
canonical heptad repeat. However, it is conserved in Myc proteins from all 
species and occurs in the 3 position of a potential 3,4 hydrophobic repeat where it 
is likely to perform an essential function in the formation and stabilisation of the 
coiled-coil structure.
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Figure 8. Generation of Avian c-myc Expression Vectors.
Panel A depicts the extreme C-terminus of avian c-Myc, with the position of the 
leucine residues highlighted (L). The relative position of the premature stop 
codons introduced into the c-myc A1 and c-myc A10 sequences are also indicated (*) 
and the resultant truncated proteins represented by open blocks (reproduced from 
Crouch etal, 1990).
Panel B outlines the strategy for sub-cloning the avian c-myc sequences from 
RCAN into fpGV-1.
Abbreviations: SA splice acceptor site; ATG translation start site; LTR long 
terminal repeat; SD splice donor site; neor neomycin phosphotransferase gene; 
PolyA polyadenylation signal.
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When originally constructed by Crouch and co-workers, these artificial c-myc 
cDNAs were cloned into the replication competent avian retrovirus, RCAN 
(Hughes et al, 1987). However, this vector was felt to be unsuitable for high-level 
expression in mammalian cells since it is composed of elements designed for 
optimal activity in cells of avian origin. In addition, it lacks a selectable marker. 
Thus, for the purposes of the present study the c-myc sequences were sub-cloned 
into an alternative vector, fpGV-1 (DeClue and Martin, 1989), a linear map of 
which is shown in Figure 8B. Inserted sequences were placed under the control of 
the Moloney murine leukaemia virus long terminal repeat (LTR) and transfected 
cells selected by virtue of a co-linear neo resistance marker, which confers 
kanamycin resistance in E. coli and G418 resistance in eukaryotic cells. fpGV-1 
is approximately 5kb in size and contains both the Col El and SV40 origins of 
replication, a splice donor site and polyadenylation signal. In addition, the 
polylinker harbours unique Bam HI (3658), Eco RI (3676) and Cla I (4332) 
restriction sites. The sub-cloning strategy is outlined in Figure 8B. In brief, the c- 
myc sequences were excised from RCAN as a 1.5kb partial Cla I fragment and 
ligated into the Cla I site of fpGV-1. The orientation of the insert was then 
mapped by restriction digest and the region across the LZ sequenced to confirm 
the identity of each cloned fragment (data not shown).
6.5 Generation of 3T3-L1 Cell Lines Constitutively Expressing Avian c-myc.
Wild type c-myc (fpGV-WT) or empty vector (fpGV-1) were introduced into the 
3T3-L1 preadipocytes by calcium phosphate precipitation and stable transfectants 
selected with G418. Following antibiotic selection, resistant colonies were pooled 
and assessed for their ability to undergo induced differentiation. As judged by oil 
red O staining at day 10, both the parental 3T3-L1 and vector control cell lines 
differentiated fully, indicating that fpGV-1 did not interfere with the ability of 
3T3-L1 cells to differentiate. In contrast, the cell line harbouring the c-myc
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transgene displayed a modest impairment in differentiation capacity (-60%, data 
not shown), suggesting that the transfected gene was exerting an inhibitory effect. 
In order to enhance this effect, we therefore subjected both the fpGV-WT and 
fpGV-1 pooled lines to single cell cloning procedures. This resulted in the 
generation of six fpGV-WT clones designated WT2-8 and seven fpGV-1 cell 
lines, a representative clone (fpGV5) being used as a control for subsequent 
experiments. Preadipocyte cell lines harbouring c-myc A l and c-myc A10 were 
also generated essentially as described above. However, they differ from the WT 
lines in that they each represent a single colony picked after antibiotic selection. 
Six cell lines were established per construct.
6.6 3T3-L1-WT Clones Fail to Undergo Induced Differentiation.
Following cloning, the 3T3-L1-WT cell lines were assayed for their ability to 
differentiate under the standard conditions. As judged by morphology and oil red 
O staining at day 10, both the parental 3T3-L1 and fpGV5 cell lines differentiated 
fully. However, hormone treatment failed to induce any of the morphological 
features of adipogenesis in the WT clones (Figure 9), which retained the 
fibroblastic appearance of the 3T3-L1 preadipocyte. Hence, the presence of an 
avian c-myc transgene was sufficient to inhibit cellular differentiation in the 3T3- 
L1 system.
Whilst cytoplasmic triglyceride accumulation provides an excellent visual index 
of adipocyte differentiation, we decided to confirm our observations by examining 
a molecular marker of terminal differentiation. For this purpose we selected 
C/EBPa, since expression of this protein correlates well with the adipocyte 
phenotype. In addition, earlier work in this field had suggested that c-Myc and 
C/EBPa were reciprocally regulated during adipogenesis (Freytag and Geddes, 
1992) and that C/EBPa is a putative target for Myc-mediated transcriptional
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Figure 9. Morphology of the WT Cell Lines at Day 10 of the Differentiation 
Programme.
To investigate the ability of the WT clones to undergo adipogenesis, cultures were 
subjected to the standard differentiation protocol and stained with oil red O at day 
10. Morphology and accumulation of cytoplasmic triglyceride were assessed by 
phase contrast light microscopy (xlOO magnification).
A. 3T3-L1
B. fpGV5
C. WT2
D. WT5
E. WT6
F. WT7
G. WT8

repression (Li et al, 1994). Following induced differentiation, lysates were 
prepared at day 10 and expression of C/EBPa assessed by Western blot analysis 
using the 14AA polyclonal antibody (Santa Cruz). This antibody was raised 
against a peptide corresponding to amino acids 253-265 of the rat sequence and 
was known to cross-react with both the 43-kDa and 30-kDa isoforms of C/EBPa. 
As expected, C/EBPa was not present in fpGV5 protein extracts at day 0 of the 
differentiation programme (Figure 10). However, at day 10 both the 43-kDa and 
30-kDa isoforms were apparent. In contrast, neither isoform was detected in day 
10 lysates prepared from the WT clones, indicating that cell lines harbouring 
fpGV-WT were indeed impaired in their ability to undergo terminal 
differentiation.
6.7 3T3-L1-WT Clones Express Low Levels of Avian c-Myc.
In order to verify that the transfected c-myc gene was expressed in the WT clones, 
Northern blot analysis of total cellular RNA was performed. We predicted that 
transcription of fpGV-WT would generate two major mRNA species, one of 
approximately 6.5kb corresponding to virtually the entire sequence of the 
construct and a second of approximately 2.1 kb, representing the spliced avian c- 
myc mRNA. Whilst preliminary analysis of a Rat-1 cell line transfected with 
fpGV-WT confirmed this expectation, a number of splice variants or 
intermediates were also detected (Figure 11). This observation may reflect 
rearrangements of the construct which frequently occur when transfected DNA is 
integrated into the cellular genome. The c-myc probe employed in this study 
represented the 500bp Cla I fragment of fpGV-WT (Figure 8B) which 
corresponds to the C-terminal portion of the avian protein, a region which is 
highly conserved between species. However, this probe did not hybridise to any 
transcripts within the 3T3-L1 and fpGV5 samples. It is thought that this finding 
reflects the fact that the RNA was prepared once the cultures had attained
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Figure 10. Western Blot Analysis of C/EBPa Expression in the WT Cell 
Lines at Day 10 of the Differentiation Programme.
Protein samples were prepared at day 10 of the differentiation programme and 
equivalent amounts subjected to SDS-PAGE and Western blotting. Expression of 
C/EBPa was assessed using the 14AA polyclonal antibody (1:1000) and the 
alkaline phosphatase detection method. The position of the 43-kDa and 30-kDa 
isoforms of C/EBPa are indicated.
Negative Control: fpGV5 (day 0)
Positive Control: fpGV5 (day 10)
+  WT2 WT5 WT6 WT7 WT8
43-kDa.
30-kDa.
Figure 11.
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Figure 11. Northern Blot Analysis of c-myc mRNA in the WT Cell Lines.
Panel A. Equivalent amounts of total cellular RNA were resolved by gel 
electrophoresis and subjected to Northern blot analysis, using the 500bp Cla I 
fragment of fpGV-WT as a probe. The position of the 6.5kb and 2.1 kb transcripts 
are indicated.
Lane 1: 3T3-L1 
Lane 2: fpGV5 
Lane 3: Rat-l-WT 
Lane 4: WT2 
Lane 5: WT5 
Lane 6: WT6 
Lane 7: WT7 
Lane 8: WT8
Panel B. Equivalence of loading and integrity of the RNA are demonstrated by 
ethidium bromide staining of the gel prior to transfer.
1 2 3 4 5 6 7 8
A.
6 .5  kb « Mi**
m
2.1 kb.
confluence, at which time expression of the endogenous c-myc gene would 
probably be beneath the limits of detection for Northern blotting. Alternatively, 
poor cross-species hybridisation could also account for this observation. In 
contrast, analysis of the WT clones suggested that all of these lines expressed a 
number of mRNA species that specifically hybridised to the c-myc probe (Figure 
11). However, only WT2, WT6 and WT8 were found to express the subgenomic 
2.1 kb avian c-myc mRNA.
In contrast, endeavours to detect the avian c-Myc protein within the WT cell lines 
proved somewhat disappointing. Immunoprecipitation following metabolic 
labelling and immunocytochemisty were both negative (data not shown), whilst 
Western blot analysis was generally inconclusive, despite employing a range of 
primary antibodies and detection methods. To ensure that the fpGV-myc 
constructs were indeed functional, control transfections were performed using the 
Rat-1 cell line. Stable lines were generated by calcium phosphate precipitation 
and selection with G418 as described in the Materials and Methods. Antibiotic 
resistant colonies were then pooled and expression of the transgene assessed by 
Western blot analysis using the polyclonal antibody, 237-6 (the generous gift of
D.A.F. Gillespie, Beatson Institute) This antibody was raised against the full 
length human c-Myc protein but had previously been shown by our laboratory to 
cross-react with avian c-Myc. Wild type c- Myc, c-MycA7 and c-MycAlO were 
all readily detected in the Rat-1 lysates and could be distinguished from one 
another on the basis of size (Figure 12A). In contrast, a representative Myc 
Western blot using lysates prepared from the WT cell lines is shown in Figure 
12B, extremely low levels of the protein being detected in the WT2, WT6 and 
WT8 samples. That the WT clones apparently expressed such low amounts of the 
exogenous protein was somewhat surprising, since in other systems inhibition of 
differentiation generally correlates with over-expression of c-Myc. Thus, in the
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Figure 12. Western Blot Analysis of c-Myc Expression in the Transfected Cell 
Lines.
Panel A. Protein samples were prepared from Rat-1 lines harbouring the fpGV- 
myc constructs and equal amounts subjected to SDS-PAGE and Western blot 
analysis using the 237-6 polyclonal antibody (1:1000) and the ECL detection 
method.
WT: Rat-l-WT 
A7: Rat-1-A7.
A10: Rat-1-A10 
fpGV: Rat-l-fpGV
Panel B. Protein samples were prepared from 3T3-L1 cell lines harbouring the 
fpGV-WT construct and equivalent amounts subjected to SDS-PAGE and 
Western blot analysis using the 237-6 polyclonal antibody (1:1000) and the ECL 
detection method.
Lane 1: Rat-l-WT 
Lane 2: WT2 
Lane 3: WT5 
Lane 4: WT6 
Lane 5: WT7 
Lane 6: WT8
W T  A7 A10 fpGV
A.
B.
c-Myc — ►
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HL60 cell line the endogenous c-myc gene is greatly amplified and myelopoiesis 
can only occur if expression of c-Myc is down-regulated at induction of the 
differentiation programme (Westin et al, 1982). However, previous studies also 
failed to detect expression of exogenous c-Myc in the 3T3-L1 cell line by a 
variety of methods (Freytag, 1988; Freytag and Geddes, 1992), but were able to 
demonstrate the presence of the mRNA and a specific biological effect. It 
therefore appears likely that in contrast to other well-documented systems, 
inhibition of 3T3-L1 adipogenesis requires relatively low levels of Myc protein. 
This is supported by additional experiments in which we exploited the LacSwitch 
IPTG inducible vector system (Stratagene) in order to conditionally express avian 
c-myc in 3T3-L1 cells. The promoter of this vector was found to be sufficiently 
leaky that low levels of c-myc mRNA were expressed even in the absence of the 
inducer and this correlated with an impaired ability of transfected cells to undergo 
the differentiation programme (data not shown).
6.8 High Level Expression of Avian c-Myc in the 3T3-L1 Cell Line May be 
Cytotoxic.
Whilst expression of exogenous c-Myc was low or undetectable in the majority of 
the WT clones, a single cell line (WT3) expressed large amounts of the protein 
(Figure 13A). This clone was characterised by an abnormal morphology (Figure 
13B), in which the cells were enlarged and displayed an irregular cytoplasm. 
Additionally, the line had a reduced growth rate when compared to 3T3-L1 and 
fpGV5 controls (Figure 14) suggesting that high level expression of avian c-Myc 
in the 3T3-L1 system could be cytostatic or even cytotoxic. Myc “toxicity” has 
previously been described in a number of immortalised cell lines (Facchini et al, 
1994; Wurm et al, 1986). Additionally, NIH-3T3 cell lines transfected with 
human c-myc were characterised by high level expression of the c-myc mRNA but 
low levels of the protein (Ray et al, 1989), suggesting that expression of the
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Figure 13. Western Blot Analysis of c-Myc Expression in the WT3 Cell Line.
Panel A. Equivalent amounts of protein were subjected to SDS-PAGE and 
Western blot analysis using the 237-6 polyclonal antibody (1:1000) and the 
alkaline phosphatase detection method.
Lane 1: fpGV5 
Lane 2: WT3 
Lane 3: Rat-l-WT
Panel B. Morphology of WT3 cell line. Phase contrast light microscopy (xlOO 
magnification).
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Figure 14. Growth Rate of the WT3 Cell Line.
The growth rates of the individual cell lines were determined as described
Materials and Methods and a representative plot shown.
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transgene may be subject to post-transcriptional control. If high level expression 
of c-Myc in cell lines such as 3T3-L1 is indeed toxic then a situation may be 
envisaged in which selection pressure favours clones expressing low levels of the 
protein. This could explain the low abundance of avian c-Myc within the 
majority of the 3T3-L1-WT clones.
6.9 Enforced Expression of Avian c-Myc Does Not Transform the 3T3-L1 
Cell Line.
The Myc-mediated block to differentiation is often associated with cellular 
transformation (Gonos and Spandidos, 1993). In order to determine whether 
enforced expression of the avian c-myc transgene also caused transformation in 
the 3T3-L1 line we examined a number of well-defined parameters of this 
phenomenon. With the exception of WT3, the Myc-expressing clones were 
morphologically indistinguishable from the parental 3T3-L1 cell line and fpGV5. 
They retained the property of contact inhibition, since they were able to arrest at 
confluence (Figures 42 and 43, Chapter 9) and did not form foci. None of the 
clones were found to proliferate in soft agar (data not shown), suggesting that 
growth was dependent upon attachment to a substrate and could not occur 
independently of such anchorage. Finally, when compared to 3T3-L1 and fpGV5, 
the WT clones did not display an increased growth rate (Figure 15). These 
observations are in agreement with those of Freytag (1988), who demonstrated 
that constitutive expression of murine c-myc in the 3T3-L1 cell line was not 
associated with cellular transformation.
6.10 The WT Cell Lines Do Not Undergo Apoptosis in Low Serum 
Conditions.
Since over-expression of avian c-myc in the 3T3-L1 system did not result in 
transformation we decided to examine an additional biological function of c-Myc,
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Figure 15. Growth Characteristics of the WT Cell lines.
The growth rates of the individual cell lines were determined as described
Materials and Methods and a representative plot shown.
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namely the ability to mediate programmed cell death in unfavourable growth 
conditions. Exponentially growing cultures were changed to medium containing 
0.2% donor calf serum and the appearance of the cells monitored by light 
microscopy over a period of several hours. Cultures that are actively undergoing 
apoptosis are characterised by a number of morphological features (Martin et al, 
1994). Upon receipt of the apoptotic signal, adherent cells round up and detach 
from the substrate. The nuclear DNA becomes condensed, possibly as a result of 
fragmentation by specific nucleases, and the nucleus rapidly disintegrates. In 
addition, the plasma membrane undergoes “Webbing” resulting in the formation 
of the characteristic apoptotic bodies. However, examination of the WT clones 
failed to reveal any of these features even after 24 hours incubation indicating that 
they were resistant to apoptosis during serum depletion. Thus, it was concluded 
that constitutive expression of avian c-myc does not potentiate apoptosis in the 
3T3-L1 cell line under sub-optimal growth conditions. However, a recent study 
using dominant negative mutants of c-myc demonstrated that over-expression of 
the Myc HLH-LZ domain in 3T3-L1 cells readily induced apoptosis in a manner 
that appeared to be independent of Max (Kohlhuber et al, 1995). It should be 
noted, however, that these workers did not address the ability of the wild type 
protein to induce apoptosis in this system.
6.11 Deletion of Ten Amino Acids from the LZ Domain Impairs the Ability 
of c-Myc to Inhibit Adipogenesis.
It was previously demonstrated by our laboratory that whilst both v-Myc and c- 
Myc were able to block differentiation in the primary quail myoblast system, a 
deletion mutant, c-MycA7, was not inhibitory (La Rocca et al, 1994). This 
mutation deletes seven residues from the extreme C-terminus of the protein, 
including one leucine of the heptad repeat. However, the protein retained the 
ability to bind Max and was able to transform the cells. Since these experiments
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had not been repeated in another model differentiation system, we therefore felt 
that it would be of interest to examine the ability of c-MycA7 to inhibit 3T3-L1 
adipogenesis. Clones harbouring the mutant were generated as described in 
Section 6.5 and subjected to the standard differentiation protocol. Surprisingly, in 
contrast to the results obtained in the quail myoblasts, c-MycA7 was able to fully 
inhibit adipocyte differentiation as judged by oil red O staining at day 10. A 
representative clone, A7B, is shown in Figure 16. However, 3T3-L1 cell lines 
constitutively expressing c-MycAlO, which differs from c-MycA7 by the deletion 
of a further three amino acids, were not impaired in their ability to undergo 
induced differentiation (Figure 16). As expected, attempts to detect the mutant 
proteins in 3T3-L1 lysates by Western blot analysis were equivocal but the c- 
mycAl and c-mycAlO mRNAs were demonstrated in representative clones by 
Northern blotting (Figure 17). We therefore concluded that whilst the ability of c- 
Myc to inhibit adipogenesis could tolerate the loss of seven amino acids from the 
LZ domain of the molecule, larger deletions rendered the protein inactive.
6.12 The 3T3-L1 Cell Line Predominantly Expresses p21 Max.
It is widely accepted that the biologically active form of c-Myc constitutes a 
heterodimer with a second bHLH-LZ factor designated Max (Amati and Land, 
1994). However, it was recently reported that functional Max is not expressed in 
the PC 12 pheochromocytoma cell line, due to synthesis of a mutant max transcript 
(Hopewell and Ziff, 1995). In this respect, it is of interest to note that ectopic 
expression of c-myc in PC 12 cells had previously been shown to cause cellular 
transformation and inhibit nerve growth factor induced differentiation (Maruyama 
et al, 1987). Taken together, these results suggest that Myc may be able to 
function independently of Max in the PC 12 system. Since the status of Max in a 
variety of cell lines, including 3T3-L1, was not known we decided to analyse the 
expression of this protein by Western blotting. As depicted in Figure 18A (data
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Figure 16. Morphology of the c-MycA7 and c-MycAlO Cell Lines at Day 10 of 
the Differentiation Programme.
Cell lines were subjected to the standard differentiation protocol and the ability to 
accumulate cytoplasmic triglyceride assessed by oil red O staining at day 10. 
Phase contrast light microscopy (xlOO magnification).
A. 3T3-L1
B. fpGV5
C. WT6
D. A7B
E. A10C
w&tim
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Figure 17. Northern Blot Analysis of c-myc mRNA in the c-MycA7 and c-
MycAlO Cell Lines.
Panel A. Equivalent amounts of total cellular RNA were resolved by gel 
electrophoresis and subjected to Northern blot analysis using the 500bp Cla I 
fragment of fpGV-WT as a probe. The position of the 6.5kb and 2.1 kb transcripts 
are indicated.
Lane 1: 3T3-L1 
Lane 2: fpGV5 
Lane 3: Rat-l-WT 
Lane 4: WT6 
Lane 5: A7B 
Lane 6: A IOC
Panel B. Equivalence of loading and integrity of the RNA are demonstrated by 
ethidium bromide staining of the gel prior to transfer.
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Figure 18. Western Blot Analysis of Max Expression in the 3T3-L1 Cell Line.
Panel A. Equivalent amounts of protein were subjected to SDS-PAGE and 
Western blot analysis using the 1.2FB polyclonal antibody (1:1000) and the ECL 
detection method. The positions of the p21 and p22 isoforms of Max are 
indicated.
Lane 1: 3T3-L1 
Lane 2: QT35 
Lane 3: Q8 
Lane 4: MH2 
Lane 5: Rat-1 
Lane 6: U937 
Lane 7: HL60 
Lane 8: CHO 
Lane 9: HeLa
Panel B. Protein samples were prepared from the 3T3-L1 cell line on the days 
indicated and equivalent amounts subjected to SDS-PAGE and Western blot 
analysis using the 1.2FB polyclonal antibody (1:1000) and the ECL detection 
method. The positions of the p21 and p22 Max isoforms are highlighted.

generously provided by W. Clark, Beatson Institute), protein samples were 
prepared from a number of cell lines and Max detected using the rabbit polyclonal 
antiserum, 1.2FB (the kind gift of Trevor Littlewood, Imperial Cancer Research 
Fund, London). Interestingly, the expression pattern of the two Max isoforms was 
found to vary widely between the cell lines studied. Hence, in avian cell lines 
(e.g. QT35; Q8; MH2) the p22 isoform predominated, whilst lines derived from 
human (HeLa; U937; HL60), hamster (CHO) and rodent (Rat-1) sources 
expressed both forms. In contrast, the 3T3-L1 cell line was characterised by the 
predominant expression of the p21 isoform, and this pattern was retained 
throughout the differentiation programme (Figure 18B).
6.13 Expression of Madl is Not Associated with 3T3-L1 Adipogenesis.
In a number of cell types, differentiation is associated with a switch from 
Myc/Max to Mad/Max complexes (Larsson et al, 1994; Hurlin et al, 1995b). 
Since expression of the Mad family during induced differentiation of the 3T3-L1 
cell line has not previously been studied, we felt that it would be of interest to 
analyse the expression patterns of these proteins during adipogenesis. Protein 
lysates were prepared at various time points and subjected to Western blot 
analysis using a commercially available polyclonal Madl antiserum, C-19 (Santa 
Cruz). This antibody was raised against a synthetic peptide corresponding to 
residues 203-221 of human Madl but cross-reacts with Madl of murine origin. In 
the 3T3-L1 cells, Madl was found to be expressed in uninduced (day 0) samples 
(Figure 19). However, treatment with the hormone cocktail resulted in a rapid 
down-regulation of the protein (days 1 and 2). Following removal of the inducing 
hormones, high levels of Madl were detected in day 3, 4 and 6 lysates, whilst in 
the day 10 sample the protein appeared to be down-regulated. This expression 
pattern is highly suggestive of a role in growth arrest, since the protein was absent 
in lysates derived from the clonal expansion phase but was detected at time points
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Figure 19. Western Blot Analysis of Madl Expression During the 
Differentiation Programme.
Equivalent amounts of protein prepared from the 3T3-L1, WT6 and WT8 cell 
lines on the days indicated were subjected to SDS-PAGE and Western blot 
analysis using the C-19 polyclonal antibody (1:250) and the alkaline phosphatase 
detection method.
Positive control (+): 3T3-L1 (day 4)
Day 0 1 2 3 4 6 10
3T3-L1
Day 0 1 2 3 4 6 10 +
in which the cells were no longer proliferating. This proposal is strengthened by 
analysis of Madl expression in two representative Myc-expressing clones, WT6 
and WT8. Whilst these cell lines were unable to differentiate, the pattern of Madl 
expression was very similar to that observed in the 3T3-L1 cells (Figure 19). 
Thus, in the 3T3-L1 cell line Madl is unlikely to be associated with terminal 
differentiation but may play a role in cell cycle exit. Unfortunately, the 
commercial antibodies currently available for detection of Mxil, Mad3 and Mad4 
were extremely unreliable and, in the absence of appropriate positive controls, 
Western blot analyses were equivocal. Thus, determination of the expression 
patterns of these proteins during 3T3-L1 differentiation will require further 
investigation.
6.14 The WT Cell Lines Provide a Model System in Which to Study the 
Effects of Enforced Expression of c-Myc on Cellular Differentiation.
In summary, we have generated a number of 3T3-L1 preadipocyte cell lines 
constitutively expressing avian c-Myc. Whilst the protein is present at extremely 
low levels, this appears to be sufficient to block induced differentiation as judged 
by loss of expression of the key regulator of adipogenesis, C/EBPa, and an 
inability to accumulate cytoplasmic triglyceride. This function requires regions at 
the extreme C-terminus of the molecule, since the deletion mutant c-MycAlO had 
lost the capacity to inhibit differentiation. Enforced expression of c-Myc in the 
3T3-L1 cell line was not associated with cellular transformation or the ability to 
undergo apoptosis in low serum. Thus, it appears that the WT cell lines represent 
a model system in which to examine a single biological function of c-Myc, viz the 
capacity to block differentiation.
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CHAPTER 7: Enforced Expression of c-myc in the 3T3-L1 System Inhibits the 
Terminal Stages of the Differentiation Programme.
7.1 Introduction.
Whilst constitutive expression of c-myc in the 3T3-L1 cell line had previously been 
shown to inhibit differentiation (Freytag, 1988; Freytag and Geddes, 1992), the 
precise point at which Myc exerted this effect had not been determined. In order to 
address this issue, we decided to examine the expression patterns of a number of 
molecular markers representative of the various stages of the differentiation 
programme. By identifying genes that were differentially expressed, it was 
anticipated that we should be able to define a point where the Myc-mediated block 
to adipogenesis was likely to occur.
7.2 The 3T3-L1 Cell Line May Spontaneously Lose the Ability to Differentiate.
It has previously been demonstrated that the 3T3-L1 cell line may spontaneously 
lose the ability to differentiate following serial passage at high density or single cell 
cloning procedures and that this trait is stably inherited by the clonal progeny 
(Green and Kehinde, 1975). Since our aim was to define key regulatory points in 
the adipogenic programme, we felt that in addition to studying the Myc-mediated 
block it would also be of interest to investigate the properties of a cell line that had 
spontaneously lost the ability to differentiate. The line chosen for this purpose was 
derived by single cell cloning from the same batch of 3T3-L1 cells as fpGV5 and 
the WT cell lines and was designated Def (differentiation defective).
7.3 Strategy for the Molecular Analysis of Adipogenesis.
As shown in Figure 2, adipogenesis can be subdivided into a number of discrete 
phases each of which is associated with the expression of a particular set of genes. 
In order to carry out a detailed analysis of gene expression during induced
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differentiation, we obtained Northern probes for a number of these markers from 
other workers in the field (described in Materials and Methods) and where 
appropriate Western blot analyses were also performed. To simplify the analysis of 
the Myc-expressing cell lines two representative clones, WT6 and WT8, were 
chosen. These had previously been used to examine the expression of Madl 
(Figure 19). In addition, since the differentiation profiles of the control cell lines, 
3T3-L1 and fpGV5, were found to be highly similar, only data relating to the 3T3- 
L1 cell line is presented.
7.4 Expression of the C/EBP Family During Induced Differentiation.
As described in Chapter 2, several members of the C/EBP family of bLZ 
transcription factors are implicated in adipocyte differentiation. These are thought 
to participate in a cascade of regulation culminating in the expression of C/EBPa, a 
key regulator of the terminal stages of adipogenesis.
7.4.1 C/EBP a
We had previously shown by Western blot analysis that in contrast to 3T3-L1 and 
fpGV5, neither isoform of C/EBPa could be detected in day 10 lysates derived 
from the WT cell lines (Figure 10). This was also found to be the case following 
induced differentiation of Def (data not shown). Since repression of gene 
expression may occur at a post-transcriptional level, we decided to examine the 
expression of the c/ebpa mRNA during adipogenesis. Total cellular RNA was 
prepared at various time points and subjected to Northern blot analysis using a 
c/ebpa specific probe. In the 3T3-L1 cell line, the 2.7kb c/ebpa mRNA was first 
detected at day 2 and increased thereafter (Figure 20). This pattern of expression 
was in agreement with previous observations and correlated well with expression of 
the protein during 3T3-L1 adipogenesis (Christy et al, 1989). In contrast, the 
c/ebpa transcript could not be detected at any time point in the Def cell line.
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Figure 20. Northern Blot Analysis of c/ebpa mRNA During the 
Differentiation Programme.
Total cellular RNA was prepared on the days indicated and equal amounts 
subjected to Northern blot analysis using the 900bp Nco I fragment of MSV/EBPa 
as a probe. Equivalence of loading is demonstrated by the 28S signal.
Day 0 1 2 3 4 6 10
Def
C /E B P a
28S
W T8
C /E B P a
28S
However, examination of WT6 and WT8 indicated that very low levels of c/ebpa 
mRNA were present and that this occurred in a temporal pattern similar to that 
observed in the 3T3-L1 line. Thus, it appears that repression of c/ebpa in the WT 
and Def cell lines may occur by different mechanisms. The data derived from the 
analyses of c/ebpa mRNA and protein expression in the WT cell lines may be 
explained in a number of ways. Firstly, if c-Myc represses the c/ebpa promoter, as 
has previously been suggested (Li et al, 1994), it is possible that the low level of c- 
Myc present in the WT clones was insufficient to fully inhibit transcription. 
However, reducing the c/ebpa mRNA below a certain threshold level may still be 
sufficient to block adipogenesis. Alternatively, c/ebpa may be subject to post- 
transcriptional control in the Myc-expressing cell lines, possibly at the level of 
translation or protein stability. Obviously, further investigation will be required to 
clarify this issue.
A major problem encountered when embarking on this analysis was the selection of 
an appropriate loading control, since genes traditionally employed are differentially 
expressed during adipogenesis. Hence, actin and tubulin are seen to decrease 
(Spiegelman and Farmer, 1982) whilst expression of GAPDH is upregulated as 
differentiation proceeds (Cornelius et al, 1994). It was therefore fortuitous that the 
c/ebpa probe was found to cross-hybridise to the 28S ribosomal RNA (Figure 20). 
Equivalence of loading and integrity of the RNA preparations were therefore 
assessed by examination of this 28S signal and ethidium bromide staining of the gel 
prior to transfer (not shown).
7.4.2 C/EBPp.
Northern blot analysis of c/ebpP expression during the differentiation programme is 
shown in Figure 21. In the 3T3-L1 cell line, the 1.5kb c/ebpP transcript was 
present throughout adipogenesis but was obviously up-regulated between days 1
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Figure 21. Northern Blot Analysis of c/ebpP mRNA During the 
Differentiation Programme.
Total cellular RNA was prepared at the time points indicated and equal amounts 
subjected to Northern blot analysis using the 1.5kb Bam HIlEco RI fragment of 
MSV/EBPp as a probe. Equivalence of loading is demonstrated by the 28S signal.
Day 0 1 2 3 4 6 10
3T3-L1
Def
W T 6
WT 8
C / E B P p
28S
C / E B P p
28S
C / E B P p
28S
C / E B P p
28S
and 4. Since expression of c/ebpP was previously shown to be induced by MIX 
(Yeh et al, 1995a), this observation probably represents a consequence of hormonal 
stimulation of the differentiation pathway. However, a similar pattern of 
expression was observed in the WT and Def cell lines, indicating that inhibition of 
adipogenesis was not associated with repression of the c/ebpP gene at the level of 
transcription.
Since we had previously demonstrated that repression of C/EBPa did not 
necessarily equate with inhibition of transcription in 3T3-L1 cells constitutively 
expressing c-myc (Section 7.4.1), we decided to examine the expression of C/EBPp 
by Western blot analysis. Protein samples were prepared at various time points and 
C/EBPp detected using the polyclonal antibody, C-19 (Santa Cruz), raised against 
amino acids 258-276 of the rat protein. This antiserum is able to recognise both the 
LAP (31-kDa) and LIP (20-kDa) isoforms of C/EBPp. In the 3T3-L1 cell line 
expression of LAP was first apparent at day 1 of the differentiation programme but 
was elevated in the day 2 lysate (Figure 22), the levels declining thereafter. The 
LIP isoform was found to exhibit a similar pattern of expression. As described 
above, it is likely that the increased expression of both isoforms during hormone 
treatment (days 1 and 2) was a consequence of MIX stimulation. LIP and LAP 
were also found to be upregulated in the WT cell lines during the first two days of 
the differentiation programme (Figure 22). However, expression during the later 
stages appeared to be reduced when compared to the 3T3-L1 cell line although this 
was not a consistent finding and may represent blot to blot variation. In contrast, 
LIP and LAP were barely detectable in the Def cell line. In order to make a direct 
comparison of the cell lines, expression of C/EBPp in day 2 lysates was therefore 
examined on the same filter (Figure 23). Whilst Def displayed reduced levels of 
LAP when compared to the other cell lines, the major deficit appeared to be in the 
expression of LIP, suggesting that c/ebpP may be subject to post-transcriptional
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Figure 22. Western Blot Analysis of C/EBPp Expression During the
Differentiation Programme.
Protein samples were prepared at the time points indicated and equivalent 
amounts subjected to SDS-PAGE and Western blot analysis using the C-19 
polyclonal antibody (1:500) and the ECL detection method. The positions of the 
LIP and LAP isoforms of C/EBPp are indicated.
Day 0 1 2 3 4 6 10
3T3-L1
Def
WT6
WT8
LAP
LIP
LAP
LIP
LAP
LIP
LAP
LIP
Figure 23.
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Figure 23. Western Blot Analysis of C/EBPp Expression at Day 2 of the
Differentiation Programme.
Protein samples were prepared at day 2 of the differentiation programme and 
equal amounts subjected to SDS-PAGE and Western blot analysis using the C-19 
polyclonal antibody (1:500) and the alkaline phosphatase detection method. The 
positions of the LIP and LAP isoforms of C/EBPp are indicated.
Lane 1: 3T3-L1 
Lane 2: Def 
Lane 3: WT6 
Lane 4: WT8
Equivalence of loading is indicated by the cross-reacting material (CRM).
C R M
LAP
control in this cell line. In contrast, there was little difference in the expression of 
either isoform between the Myc-expressing cell lines and 3T3-L1.
7.4.3 C/EBP5.
Since expression of C/EBP5 was previously shown to be induced by 
dexamethasone (Yeh et al, 1995a), it was not surprising that Northern hybridisation 
with a c/ebp8 specific probe gave a similar result to that observed with c/ebpp. 
Hence during induced differentiation of the 3T3-L1 cell line expression of the 
c/e bp 8 mRNA was low at day 0 but rapidly increased following hormone treatment, 
declining to basal levels by day 6 (Figure 24). A similar pattern of expression was 
observed in the WT6, WT8 and Def clones. Thus, it appears unlikely that the 
c/ebp8gene is a target for repression during 3T3-L1 adipogenesis.
7.4.4 CHOP-10/GADD153.
Northern blot analysis of chop-10 mRNA levels during induced differentiation of 
the 3T3-L1 line suggested that expression of this gene correlated with growth arrest 
(Figure 25). Hence, the 1.1 kb mRNA was strongly expressed at confluence and 
from day 3 onwards, but was reduced during the clonal expansion phase (days 1 
and 2). This pattern of expression was reminiscent of the Madl protein during the 
differentiation programme (Figure 19). In addition to a role in growth arrest, 
CHOP-10 has also been implicated as a dominant negative inhibitor of C/EBP 
family function (Ron and Habener, 1992) and constitutive expression in the 3T3-L1 
cell line was sufficient to inhibit differentiation (Batchvarova et al, 1995). CHOP- 
10 therefore represents an appealing target for up-regulation during the inhibition of 
adipogenesis. However, examination of chop-10 expression in the WT and Def 
cell lines did not support this proposal (Figure 25). Indeed, it has previously been 
demonstrated that enforced expression of c-myc in the Rat-1 cell line was
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Figure 24. Northern Blot Analysis of c/ebpS mRNA During the
Differentiation Programme.
Total cellular RNA was prepared on the days indicated and equal amounts 
subjected to Northern blot analysis using the 1.5kb Bam HI/Eco RI fragment of 
MSV/EBP5 as a probe. Equivalence of loading is demonstrated by the 28S signal.
Day 0 1 2 3 4 6 10
3T3-L1
Def
WT6
WT8
mmm
C/EBP5
28S
C/EBP8
28S
C/EBP5
28S
C/EBP5
28S
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Figure 25. Northern Blot Analysis of chop-10 mRNA During the
Differentiation Programme.
Total cellular RNA was prepared at the time points indicated and equal amounts 
subjected to Northern blot analysis using the 710bp Bam HI!Acc I fragment of 
Chop-10 pBS as a probe. Equivalence of loading is demonstrated by the 28S 
signal.
Da y  0 1 2 3 4 6 10
3T3-L1
Def
WT 6
W T 8
C H O P - 1 0 
28S
CH O P -10
28S
CH O P -1 0
28S
C H O P - 1 0 
28S
associated with the repression of CHOP-10 (Chen et al, 1996), although this was 
obviously not the case in the 3T3-L1 cell line.
7.5 Expression of the PPAR Family During Induced Differentiation.
As described in Chapter 2, the PPAR family of transcription factors are implicated 
in mediating the cellular response to fatty acids during adipogenesis. In addition, 
PPARy2 is thought to be a key regulator of the terminal stages of the differentiation 
programme.
7.5.1 FAAR.
Expression of the faar mRNA was examined in the 3T3-L1 cell line by Northern 
blot analysis. In agreement with a previous report (Amri et al, 1995), the 3.1 kb 
mRNA was present at confluence and increased following hormonal induction, 
remaining at a fairly invariant level throughout the differentiation programme 
(Figure 26). A similar pattern was observed in the WT and Def cell lines, 
suggesting that this gene was unaffected by the differentiation block.
7.5.2 PPAR/2.
In accordance with previous reports (Tontonoz et al, 1994a), expression of the 2kb 
ppary2 mRNA in the 3T3-L1 cell line was first detected at low levels in the day 1 
sample and increased thereafter, reaching a maximum at day 4 (Figure 27). High 
levels of expression were retained throughout the terminal stages of the 
differentiation programme. In contrast, ppary2 mRNA was not detected at any time 
point in the Myc-expressing or Def cell lines. Hence, ppary2 is a target for 
repression during inhibition of preadipocyte differentiation.
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Figure 26. Northern Blot Analysis of faar mRNA During the Differentiation
Programme.
Total cellular RNA was prepared at the time points indicated and equal amounts 
subjected to Northern blot analysis using the 1.5kb Bam HI fragment of 
pSGFAAR as a probe. Equivalence of loading is demonstrated by the 28S signal.
Day 0 1 2 3 4 6 10
3T3-L1
FAAR
Def
FAAR
WT6
FAAR
28S
WT8
FAAR
28S
Figure 27.
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Figure 27. Northern Blot Analysis of ppary2 mRNA During the
Differentiation Programme.
Total cellular RNA was prepared on the days indicated and equal amounts 
subjected to Northern blot analysis using the 520bp Stu I fragment of 
PPARy2/SPORT as a probe. Equivalence of loading is demonstrated by the 28S 
signal.
Day 0 1 2 3 4 6 10
3T3-L1
PPARy2
28S
Def
PP ARy2 
28S
WT6
PP ARy2 
28S
WT8
PP ARy2 
28S
7.6 Expression of Genes Required for Lipid Metabolism.
Acquisition of the adipocyte phenotype is associated with the co-ordinate 
expression of a number of genes involved in lipid metabolism (Cornelius et al, 
1994). We therefore elected to examine the expression patterns of two of these 
genes: ap2, which encodes a fatty acid binding protein and scdl, which encodes the 
enzyme stearoyl CoA desaturase 1. As determined by Northern blot analysis, 
expression of these genes was restricted to the terminal stages of the differentiation 
programme in the 3T3-L1 cell line (Figure 28), consistent with a role in 
lipogenesis. In contrast, neither gene could be detected in the WT and Def cell 
lines. This observation therefore provides a molecular basis for the inability of 
these cell lines to accumulate cytoplasmic triglyceride following induction of the 
differentiation programme.
7.7 The WT and Def Cell Lines are Unable to Participate in the Terminal 
Stages of the Differentiation Programme.
By conducting a detailed analysis of the expression patterns of a number of markers 
during induced differentiation, we have been able to define a point at which 
adipogenesis may be blocked. Our observations are summarised in Figure 29 and 
demonstrate that inhibition of differentiation is manifest at the terminal stages of 
the programme in both a cell line that had spontaneously lost the ability to 
differentiate and lines constitutively over-expressing the c-Myc oncoprotein. 
Hence, expression of the key adipogenic transcription factors, C/EBPa and 
PPARy2, is deregulated which results in an inability to express genes required for 
lipid metabolism. However, subtle differences detected in the expression patterns 
of C/EBPa and C/EBP p between these cell lines suggests that repression may not 
occur by a common mechanism.
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Figure 28. Northern Blot Analysis of ap2 and scdl mRNAs During the
Differentiation Programme.
Total cellular RNA was prepared at the time points indicated and equal amounts 
subjected to Northern blot analysis using either the 700bp Pst I fragment of 
aP2/pGem or the 800bp Pst l/Eco RI fragment of PC4. Equivalence of loading is 
demonstrated by the 28S signal.
Day 0 1 2 3 4 6 10
3T3-L1
Def
aP2
SCD1
28S
aP2
SCD1
28S
WT6 SC D 1
aP2
WT8 S C D 1
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Figure 29. Profiles of Gene Expression During the Differentiation 
Programme.
The molecular markers analysed in this study were sub-divided into early, 
intermediate and late gene classes and the expression patterns in the Def and WT 
clones compared with those observed in the 3T3-L1 cell line. Inverted arrows 
indicate reduced levels of expression, whilst the asterisk indicates where gene 
expression could not be detected. Where no difference was observed the box is 
left blank.
GENE CLASS Def WT6 WT8
EARLY:
CHOP-10 mRNA
FAAR mRNA
INTERMEDIATE:
C/EBPpmRNA
Protein 1
C/EBP5mRNA
LATE:
C/EBPa mRNA *
Protein * * *
PPAR ^ mRNA ★ * *
aP2 mRNA * * *
SCD1 mRNA * * *
CHAPTER 8: The Myc-Mediated Block to Adipogenesis Is Abrogated by 
Foetal Calf Serum.
8.1 Introduction.
The differentiation protocol employed in this study was routinely carried out in 
the presence of 10% donor calf serum (DCS). However, reference to the 
literature suggested that many workers used foetal calf serum [FCS] (Student et 
al, 1980; Smulson et al, 1995; Benjamin et al, 1994). We therefore felt it 
would be of value to assess whether the type of serum employed during the 
differentiation programme was a critical determinant of adipogenic capacity. 
Duplicate 3T3-L1 cultures were induced to differentiate in the presence of 
either 10% DCS or 10% FCS and the ability to accumulate triglyceride 
assessed by oil red O staining at day 10. In accordance with our previous 
observations (Section 6.3.1), induction in the presence of 10% DCS resulted in 
80-90% of the total population attaining the characteristic adipocyte 
morphology. However, differentiation in the presence of 10% FCS increased 
this number by an additional 5-10% (Figure 30A), indicating that FCS may be 
slightly more effective at promoting adipogenesis than DCS. In light of this 
finding, we therefore modified the standard differentiation protocol by 
substituting FCS for DCS at induction.
8.2 Induced Differentiation in the Presence of 10% FCS Rescues the Myc- 
Mediated Block to Adipogenesis.
Whilst induction in the presence of FCS led to a modest increase in the number 
of 3T3-L1 adipocytes, implementation of the revised differentiation protocol 
had a startling effect on the adipogenic capacity of the Myc-expressing cell 
lines, WT6 and WT8. As described in Section 6.6, induction in the presence of 
10% DCS was not associated with acquisition of the adipocyte phenotype in
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Figure 30. Morphology at Day 10 of the Differentiation Programme in the 
Presence of 10% FCS.
Cultures were induced to differentiate in the presence of either 10% DCS or 10% 
FCS and the ability to accumulate cytoplasmic triglyceride assessed at day 10 of 
the programme by oil red O staining. Phase contrast light microscopy (xlOO 
magnification).
A. 3T3-L1
B. Def
C. WT6
D. WT8
1 0 %  D C S 1 0 %  F C S
these clones, presumably as a consequence of the enforced expression of c-myc. 
However, treatment of WT6 and WT8 with the hormone cocktail in the 
presence of 10% FCS resulted in approximately 60-80% of the total cell 
population undergoing adipogenesis as judged by oil red O staining at day 10 
(Figure 30C and D). This phenomenon was not unique to WT6 and WT8, 
since the remaining WT clones could also be induced to differentiate by this 
treatment (data not shown). Additionally, the differentiation block described in 
the c-MycA7 cell lines (Section 6.11) was abrogated in the presence of FCS 
(data not shown). In contrast, the differentiation defective cell line, Def, was 
unresponsive to the adipogenic effects of FCS (Figure 30B), although this 
treatment was associated with an abnormal morphology. Thus, it was 
concluded that the Myc-mediated block to adipogenesis could be rescued by 
FCS, whilst a cell line that had spontaneously lost the ability to differentiate 
was refractory to this treatment. These findings therefore indicate that 
inhibition of 3T3-L1 adipogenesis may occur by more than one mechanism.
8.3 Differentiation is Not Associated with Down-Regulation of the Avian c- 
myc Transgene in the WT Cell Lines.
One possible explanation for the observed effect of FCS on the ability of Myc- 
expressing cell lines to differentiate is that expression of the avian c-myc 
transgene was down-regulated during this treatment. To address this issue, 
total cellular RNA was prepared from the WT6 and WT8 clones at several 
points following induction of differentiation in either 10% DCS or 10% FCS. 
Equal quantities were then subjected to Northern blot analysis using the c-myc 
specific hybridisation probe. As can be seen in Figure 31, expression of the 
avian c-myc 2.1kb mRNA was similar at all time points in both DCS and FCS, 
demonstrating that relief of the Myc-mediated block was not associated with 
down-regulation of the transgene. Conversely, up-regulation of c-myc was not
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Figure 31. Northern Blot Analysis of the Avian c-myc 2.1kb mRNA in the
WT6 and WT8 Cell Lines Following Differentiation in 10% FCS.
Total cellular RNA was prepared at the times indicated following induction of the 
differentiation programme in the presence of either 10% DCS or 10% FCS. Equal 
amounts of RNA were subjected to Northern blot analysis using the 500bp Cla I 
fragment of fpGV-WT as a probe. Equivalence of loading is demonstrated by the 
28S signal.
10% DCS 10% FCS
Day 0 2 4 10 0 2 4 10
W T 6
W T 8
c-Myc
28S
observed in the Def cell line (data not shown), reinforcing the proposal that 
spontaneous loss of differentiation capacity occurs independently of c-Myc.
8.4 FCS Restores the Expression of Late Stage Markers in the WT Cell 
Lines.
Since treatment of the WT cell lines with FCS restored the ability to 
accumulate cytoplasmic triglyceride, we speculated that this phenomenon 
would also be associated with re-expression of the late stage markers. We 
therefore examined profiles of gene expression during the differentiation 
programme in the presence of FCS and compared them to those obtained using 
DCS. For simplicity we limited the study to those time points felt to be most 
informative (days 0, 2, 4 and 10) and made a direct comparison by probing 
samples on the same filter. Northern blot analysis of the 3T3-L1 cell line under 
the two conditions indicated that expression of the late stage markers was 
accelerated in the presence of 10% FCS (Figure 32). However, it should be 
noted that our previous data clearly demonstrate that these genes are induced 
between days 2 and 4 in 10% DCS (Chapter 7) and that these findings were in 
agreement with previous observations. In contrast, treatment of the WT lines 
with 10% FCS resulted in the restoration of those genes found to be repressed 
in the presence of 10% DCS (Figures 33 and 34), namely c/ebpa, ppary2, ap2 
and scdl. Additionally, Western blot analysis of C/EBPa expression using the 
14AA polyclonal antibody demonstrated that this protein was present in lysates 
prepared from WT6 and WT8 at day 10 of the differentiation programme 
following treatment with 10% FCS (Figure 35). This was in stark contrast to 
our previous observations (Figure 10). This analysis therefore provides a 
molecular basis for the morphological changes detected in cell lines 
constitutively expressing c-myc following induced differentiation in the 
presence of 10% FCS.
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Figure 32. Northern Blot Analysis of Late Gene Expression in the 3T3-L1
Cell Line Following Induced Differentiation in the Presence of 10% FCS.
Total cellular RNA was prepared at the times indicated following induction of the 
differentiation programme in the presence of either 10% DCS or 10% FCS. Equal 
amounts of RNA were subjected to Northern blot analysis using the probes 
previously described. Equivalence of loading is demonstrated by the 28S signal.
10% DCS 10% FCS
Day 0 2 4 10 0 2 4 10
C/EBPoc
PPAR72
aP2
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28S
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Figure 33. Northern Blot Analysis of Late Gene Expression in the WT6 Cell
Line Following Induced Differentiation in the Presence of 10% FCS.
Total cellular RNA was prepared at the times indicated following induction of the 
differentiation programme in the presence of either 10% DCS or 10% FCS. Equal 
amounts of RNA were subjected to Northern blot analysis using the probes 
previously described. Equivalence of loading is demonstrated by the 28S signal.
10% DCS 
Day 0 2 4 10
10% F C S
0 2 4 10
C/EBPoc
PPAR72
aP2 
S C D 1 
28S
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Figure 34. Northern Blot Analysis of Late Gene Expression in the WT8 Cell
Line Following Induced Differentiation in the Presence of 10% FCS.
Total cellular RNA was prepared at the times indicated following induction of the 
differentiation programme in the presence of either 10% DCS or 10% FCS. Equal 
amounts of RNA were subjected to Northern blot analysis using the probes 
previously described. Equivalence of loading is demonstrated by the 28S signal.
10% DCS 10% FCS
C/EBPoc 
PP AR y2
aP2
S C D 1 
28S
Day 0 2 4 10 0 2 4 10
Figure 35.
130
Figure 35. Western Blot Analysis of C/EBPa Expression Following Induction
of the Differentiation Programme in the Presence of 10% FCS.
Protein samples were prepared at days 0 and 10 of the differentiation programme 
and equivalent amounts subjected to SDS-PAGE and Western blot analysis using 
the 14AA polyclonal antibody (1:500) and the alkaline phosphatase detection 
method. The positions of the 43-kDa and 30-kDa isoforms of C/EBPa are 
highlighted.
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8.5 Each Cell Line is Responsive to a Different Concentration of FCS.
It was clear from the data presented above that treatment with 10% FCS was 
sufficient to over-come the inhibition of 3T3-L1 adipogenesis imposed by 
constitutive expression of c-myc. Since the Myc-mediated differentiation block 
was manifest in 10% DCS, we wondered whether the FCS effect could be 
titrated out by dilution with DCS. Replicate cultures were induced to 
differentiate in 10% DCS, 10% FCS or a mixture of the two (see Figure 36 for 
details) and the adipogenic capacity determined by staining with oil red O at 
day 10. Stained cultures were then viewed macroscopically and the degree of 
differentiation compared with that observed in the presence of 10% FCS. This 
data is tabulated in Figure 36. The 3T3-L1 cell line was found to be maximally 
responsive to a mixture of 2% FCS:8% DCS, whilst WT8 required at least 4% 
FCS for optimal effect. In contrast, WT6 could only differentiate in the 
presence of high concentrations of FCS (8%). We therefore concluded that the 
three cell lines differ in their ability to respond to the adipogenic effects of 
FCS.
8.6 The FCS Effect May be Mediated by Growth Hormone.
A possible explanation for the FCS effect on 3T3-L1 differentiation is that a 
critical serum component(s) is either absent from DCS or enhanced in FCS. As 
described in Chapter 1, growth hormone is a well characterised positive 
modulator of adipogenesis and thus presents as a plausible candidate for this 
factor. Indeed, the concentration of this hormone is elevated in FCS (Figure 
37). We therefore postulated that supplementing DCS with growth hormone 
should mimic the effects of FCS in the WT cell lines. Replicate cultures were 
induced to differentiate in the presence of 10% DCS containing bovine 
pituitary growth hormone at a range of concentrations (50-500ng/ml) and the 
ability to differentiate compared with cultures induced in the presence of 10%
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Figure 36. Assessment of the Adipogenic Capacity of Serum Mixtures.
Replicate cultures were induced to differentiate in the presence of 10% DCS, 10% 
FCS or a mixture of the two types of sera and the ability to differentiate assessed 
by oil red O staining at day 10. A cross indicates where differentiation was 
equivalent to that observed in 10% FCS.
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Figure 37. Comparison of the Hormone Composition of FCS and DCS.
The table depicts the average concentrations of a number of hormones present 
FCS and DCS. Information kindly provided by Gibco Life Technologies Inc.
Hormone. Units.
Foetal
Calf
Serum
Donor
Calf
Serum
Growth Hormone ng/ml 131 26
Insulin ulU/ml 4.3 5.4
Oestradiol pg/ml 13.8 32.9
Progesterone ng/ml 0.03 1.65
Testosterone ng/ml 0.4 1.05
T4 pg/dl 14.8 9.2
T3 ng/ml 1.2 1.9
FCS. This data is summarised in Figure 38, which shows the morphology of 
the three cell lines at day 10 of the differentiation programme following 
treatment with 10% DCS supplemented with 150ng/ml growth hormone. In the 
3T3-L1 cell line the effect of growth hormone on adipogenic capacity was 
found to be concentration independent, since 50ng/ml was as effective as 
500ng/ml (data not shown), although the number of cells attaining the 
differentiated phenotype was slightly less than that observed with 10% FCS. A 
similar result was obtained with WT8 and this was also associated with 
restoration of expression of the late stage markers (Figure 39). However, 
unlike the parental 3T3-L1 cell line, the adipogenic capacity of WT8 appeared 
to be concentration dependent with maximal differentiation being observed at 
150ng/ml growth hormone. In contrast, WT6 could only be induced to 
differentiate in the presence of 10% FCS and was refractory to even high 
concentrations of growth hormone.
That the WT clones demonstrated opposing responses to this treatment was 
somewhat surprising since they had behaved in a similar manner when exposed 
to 10% FCS. However, the results of the serum mixing experiment (Figure 36) 
demonstrated that the two cell lines had different requirements regarding serum 
stimulation. Interestingly, treatment of the remaining WT cell lines with 10% 
DCS supplemented with 150ng/ml growth hormone uncovered a range of 
responses (data not shown), suggesting that more than one serum factor may be 
involved in abrogation of the Myc-mediated block to adipogenesis. As 
expected, the differentiation defective clone, Def, was unaffected by growth 
hormone (data not shown).
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Figure 38. Morphology at Day 10 of the Differentiation Programme 
Following Treatment with Growth Hormone.
Cells were induced to differentiate in the presence of 10% DCS supplemented 
with 150ng/ml bovine pituitary growth hormone and the ability to accumulate 
cytoplasmic triglyceride assessed by oil red O staining at day 10. Phase contrast 
light microscopy (xlOO magnification).
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Figure 39. Northern Blot Analysis of Late Stage Markers Following
Differentiation in the Presence of Growth Hormone
Cells were induced to differentiate in the presence of 10% DCS supplemented 
with 150ng/ml bovine pituitary growth hormone and total cellular RNA prepared 
at the times indicated. Equal amounts were then subjected to Northern blot 
analysis using the probes previously described. Equivalence of loading is 
demonstrated by the 28S signal.
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8.7 Summary.
The ability of c-Myc to inhibit 3T3-L1 differentiation appears to be dependent 
on external factors, since treatment with 10% FCS was able to relieve the Myc 
block. This phenomenon was associated with the restoration of a number of 
gene markers which were previously found to be repressed in cell lines 
constitutively over-expressing c-myc. However, FCS was unable to induce 
adipogenesis in a cell line that had spontaneously lost the ability to 
differentiate, suggesting that inhibition of adipocyte differentiation may occur 
via more than one mechanism. The way in which FCS abrogates the inhibitory 
effects of c-Myc has yet to be fully characterised but is likely to involve the 
activity of growth hormone.
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CHAPTER 9: Enforced Expression of c-myc in the 3T3-L1 Cell Line is Not 
Associated with Cell Cycle Alterations.
9.1 Introduction.
Proliferation and differentiation are generally thought to be mutually exclusive 
events. Hence, whilst expression of c-myc correlates positively with proliferative 
potential, it is also associated with inhibition of differentiation in a number of cell 
types. A simple explanation for this observation is that c-myc inhibits cellular 
differentiation by promoting continued cell cycle progression. With respect to the 
3T3-L1 preadipocyte system, it is well documented that a number of cell cycle 
events are required to occur prior to acquisition of the differentiated phenotype. 
These include growth arrest at confluence (Gs), mitotic clonal expansion in 
response to the inducing agents and a second arrest (Go) following hormone 
withdrawal. It is therefore possible that enforced expression of c-myc in the 3T3- 
L1 cell line inhibits adipogenesis by perturbing one or more of these critical 
events. In order to address this issue we therefore examined a number of cell 
cycle parameters following induction of the differentiation programme.
9.2 Enforced Expression of c-myc in the 3T3-L1 Cell Line is Not Associated 
With Cell Cycle Alterations Following Induction of the Differentiation 
Programme.
In order to gain an insight into cell cycle behaviour during adipogenesis, replicate 
cultures were induced to differentiate in the presence of 10% DCS, under which 
condition differentiation was blocked in the Myc-expressing clones, and samples 
taken at various time points. Cell cycle profiles for each cell line were then 
generated by flow cytometry following staining with propidium iodide. 
Surprisingly, analysis of the 3T3-L1 cell line clearly indicated that it was 
composed of two distinct sub-populations displaying different ploidy (Figure 40),
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Figure 40. Cell Cycle Analysis of the 3T3-L1 Cell Line Following Induction of
the Differentiation Programme.
Replicate cultures were induced to differentiate in the presence of 10% DCS and 
samples prepared at the times indicated (see Materials and Methods). Stained 
samples were then subjected to flow cytometry and equal numbers of events 
examined at each time point. The x axis of the profile represents the DNA content 
as determined by propidium iodide staining, the fluorescence activity of the dye 
being proportional to the amount of cellular DNA. The cell number is indicated 
on the y axis.
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one being diploid (2n) and the other tetraploid (4n). Whilst the mechanism by 
which this phenomenon arose is not entirely clear, it is well documented that the 
3T3-L1 cell line has an unstable karyotype (ATTC, Catalogue of Cell Lines and 
Hybridomas), although this is generally associated with aneuploidy resulting from 
chromosome loss. The 3T3-L1 cell cycle profile indicated that both the 2n and 4n 
sub-populations were arrested at confluence (0 hours, Figure 40). However, 
subsequent treatment with the adipogenic hormones resulted in both populations 
making a fairly synchronous entry into S phase following a lag period of 24 hours. 
After 48 hours the majority of these cells had re-entered Go despite the continued 
presence of the inducing agents suggesting that hormonal stimulation was 
associated with a single round of mitosis. In contrast, hormone withdrawal 
followed by refeeding did not result in further cell cycle progression and the cells 
remained in Go throughout the remaining time points. Hence, although the 3T3- 
L1 line was found to harbour cells of more than one ploidy, their cell cycle 
behaviour in response to external cues was indistinguishable.
The cell cycle profile of the differentiation defective clone, Def, indicated that this 
cell line was also composed of the two sub-populations (Figure 41). Like the 
parental 3T3-L1 cell line, these cells were growth arrested at confluence but 
responded to the inducing agents by entering S phase at 24 hours. However, in 
contrast to the 3T3-L1 cells, a slight increase in the G2/M tetraploid population at 
the 48 and 72 hour time points suggested that a small percentage of the cells 
continued to cycle following hormone withdrawal. It is therefore possible that the 
block to adipogenesis manifest in this cell line may arise as a consequence of 
continued proliferation following the clonal expansion phase of the differentiation 
programme, resulting in an inability to fully withdraw from the cell cycle. 
However, further experimental work will be required to confirm these 
observations.
140
Figure 41.
141
Figure 41. Cell Cycle Analysis of the Def Cell Line Following Induction of the
Differentiation Programme.
Replicate cultures were induced to differentiate in the presence of 10% DCS and 
samples prepared at the times indicated (see Materials and Methods). Stained 
samples were then subjected to flow cytometry and equal numbers of events 
examined at each time point. The x axis of the profile represents the DNA content 
as determined by propidium iodide staining, the fluorescence activity of the dye 
being proportional to the amount of cellular DNA. The cell number is indicated 
on the y axis.
0 hours 12 hours
4n G2/M
1023FL2H
24 hours 48 hours
o
FL2H
72 hours 96 hours
In contrast to the 3T3-L1 and Def cell lines, the Myc-expressing clones, WT6 and 
WT8, were composed of a single population representing the tetraploid (4n) cell 
type (Figures 42 and 43). Two possibilities therefore exist to explain the 
difference in ploidy. Firstly, generation of the WT cell lines from the original 
3T3-L1 stock may have resulted in the preferential selection of the tetraploid 
lineage whilst Def retained both populations. Alternatively, the 3T3-L1 line was 
originally tetraploid and the diploid population arose spontaneously following the 
generation of the WT cell lines. In this case, it is likely that the diploid population 
evident in the Def cell line arose as an independent event. To address this issue, it 
would therefore be of interest to investigate the ploidy of other cell lines 
generated during the course of this study and compare them with the master stock 
of 3T3-L1 cells originally obtained from the ECACC.
As observed with the 3T3-L1 and Def cells, the Myc-expressing lines were found 
to be growth arrested at confluence (Figures 42 and 43) confirming that they 
retained the property of contact inhibition and were not transformed (see Section 
6.9). Following treatment with the inducing hormones, the cells were seen to 
enter S phase at 24 hours demonstrating that enforced expression of c-myc in 
these cell lines did not alter their ability to undergo mitotic clonal expansion and 
that this phenomenon occurred with similar kinetics to that described for the 3T3- 
L1 cells. In addition, as previously seen in the 3T3-L1 system, hormonal 
stimulation was associated with a single round of mitosis followed by cell cycle 
exit. Subsequent serum stimulation at hormone withdrawal did not result in 
further mitoses, although the WT6 line did display a slight increase in the G2/M 
population at 48 and 72 hours when compared to 3T3-L1 and WT8. We therefore 
concluded that constitutive expression of c-myc in the 3T3-L1 preadipocyte line 
did not result in any gross alterations in cell cycle behaviour following induction 
of the differentiation programme.
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Figure 42. Cell Cycle Analysis of the WT6 Cell Line Following Induction of
the Differentiation Programme.
Replicate cultures were induced to differentiate in the presence of 10% DCS and 
samples prepared at the times indicated (see Materials and Methods). Stained 
samples were then subjected to flow cytometry and equal numbers of events 
examined at each time point. The x axis of the profile represents the DNA content 
as determined by propidium iodide staining, the fluorescence activity of the dye 
being proportional to the amount of cellular DNA. The cell number is indicated 
on the y axis.
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Figure 43. Cell Cycle Analysis of the WT8 Cell Line Following Induction of
the Differentiation Programme.
Replicate cultures were induced to differentiate in the presence of 10% DCS and 
samples prepared at the times indicated (see Materials and Methods). Stained 
samples were then subjected to flow cytometry and equal numbers of events 
examined at each time point. The x axis of the profile represents the DNA content 
as determined by propidium iodide staining, the fluorescence activity of the dye 
being proportional to the amount of cellular DNA. The cell number is indicated 
on the y axis.
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9.3 The Gd Arrest State Occurs Late in the Differentiation Programme.
Previous work had suggested that enforced expression of c-myc may inhibit 3T3- 
L1 adipogenesis by preventing entry into the Gd arrest state (Freytag, 1988). 
Whilst the nature of this growth arrest is poorly defined, it may be distinguished 
from cell cycle exit at confluence (Gs) by a number of biochemical criteria. Thus 
cells which have attained the Gd state are reported to respond to the mitogenic 
effects of MIX, whilst Gs cells are unaffected by such treatment (Wille and Scott, 
1982). In contrast, only Gs cells are responsive to mitogenic stimulation with 
30% serum (Freytag, 1988).
Following mitotic clonal expansion both the 3T3-L1 and Myc-expressing cell 
lines were seen to undergo cell cycle arrest (Figures 40, 42 and 43). However, in 
the 3T3-L1 line arrest at 72 hours was associated with morphological changes 
consistent with on-going adipogenesis whilst the WT clones retained the typical 
preadipocyte morphology. Thus, despite displaying similar cell cycle profiles the 
cell lines could be distinguished visually. To determine whether cultures attained 
the Gs or Gd state following clonal expansion, 72 hour (day 3) cultures were 
treated with either 0.5mM MIX or 30% DCS for a further 24 hours and the ability 
to undergo DNA synthesis assessed by in situ BrdU incorporation. In order to 
assess the basal level of DNA replication, control cultures were either left 
untreated or exposed to 10% DCS. As shown in Figure 44, these control cultures 
displayed relatively low levels of BrdU incorporation. However, treatment with 
either MIX or 30% serum resulted in a massive increase in the number of cells 
undergoing S phase in all of the cell lines studied. Hence, contrary to expectation, 
the biochemical criteria employed in this experiment could not distinguish 
individual growth arrest states.
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Figure 44. In Situ BrdU Labelling Following Induction of the Differentiation
Programme.
Following induction of the differentiation programme replicate day 3 cultures 
were treated as follows:
A. No treatment.
B. Growth medium supplemented with 10% DCS.
C. Growth medium supplemented with 10% DCS and 0.5mM MIX.
D. Growth medium supplemented with 30% DCS.
Cultures were incubated for 24 hours then treated with lOpM BrdU for 6 hours 
after which time they were fixed and stained as described in Materials and 
Methods. Light microscopy (x40 magnification).
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However, it is clear that at some point in the differentiation programme the 3T3- 
L1 cell line loses its responsiveness to 30% DCS since day 10 adipocytes were 
unable to incorporate BrdU following serum stimulation (data not shown). In 
contrast, day 10 cultures of Myc-expressing cells retained the ability to undergo 
DNA synthesis in response to 30% DCS. Loss of mitogenic responsiveness at the 
late stages of the differentiation programme was also found to correlate with a 
reduced plating efficiency (Figure 45). Replicate cultures were induced to 
differentiate in the presence of either 10% DCS or 10% FCS and at the times 
indicated samples trypsinised and reseeded at low density. Following incubation 
under standard growth conditions for 7 days, these cultures were then stained with 
Geimsa and the number of colonies on each dish counted. As seen in Figure 45, 
day 0, 1, 2 and 3 cultures retained their plating efficiency regardless of cell type 
and serum condition. However, in the 3T3-L1 cell line day 10 cultures had an 
obviously reduced plating efficiency. This appeared to be associated with 
terminal differentiation since the colonies were composed entirely of fibroblasts, 
indicating that mature adipocytes could not be passaged. In addition, WT6 and 
WT8 displayed a similar impairment when exposed to 10% FCS and in situ BrdU 
labelling demonstrated that Myc-expressing adipocytes were no longer responsive 
to the mitogenic effects of 30% DCS (data not shown). In contrast, the plating 
efficiency of the differentiation defective cell line was unaffected by either 
treatment, presumably reflecting the inability to undergo terminal differentiation. 
Hence, the late stages of 3T3-L1 adipogenesis appear to be associated with an 
irreversible cell cycle withdrawal which is not observed under conditions in which 
differentiation is blocked.
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Figure 45. Plating Efficiency Following Induction of the Differentiation
Programme.
Replicate cultures were induced to differentiate in the presence of either 10% DCS 
or 10% FCS. At the time points indicated, monolayers were trypsinised and 
reseeded at a concentration of 103 cells per 60 mm tissue culture dish and 
incubated under the standard growth conditions for 7 days. Cultures were then 
stained with Geimsa and the number of colonies counted manually. These values 
are presented opposite.
Panel A: Differentiation in 10% DCS. 
Panel B: Differentiation in 10% FCS.
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9.4 Inhibition of Adipogenesis is Not Associated with Aberrant Expression of 
the Cyclin-Dependent Kinase Inhibitors, p21 and p27.
Since the Go growth arrest could not be defined biochemically in our system, we 
decided to examine the expression of factors implicated in the negative regulation 
of the cell cycle machinery. Cellular proliferation is largely mediated by the 
sequential assembly and activation of cyclin/cyclin-dependent kinase (cdk) 
complexes (Pines, 1994). However, this network is also subject to negative 
regulation by cdk inhibitory proteins (CKIs), including p21, p27 and p i6 (Sherr 
and Roberts, 1995). Expression of p21 has been implicated in the terminal 
differentiation of several cell types (Missero et al, 1996; MacLeod et al, 1995; 
Billon et al, 1996) and it is likely that this protein is required to initiate the cell 
cycle withdrawal characteristic of the differentiated phenotype (Andres and 
Walsh, 1996). In addition, it was recently reported that p21 may be regulated by 
C/EBPa (Timchenko et al, 1996). Since C/EBPa is a key regulator of 
adipogenesis which has also been reported to display anti-mitotic activity, we 
postulated that this property may require the activity of p21.
We therefore examined the expression of p21 in the 3T3-L1 cell line following 
induction of the differentiation programme. Protein samples were prepared at 
various time points and subjected to Western blot analysis using the C-19 
polyclonal antibody (Santa Cruz), which was raised against residues 146-164 of 
the human protein. As shown in Figure 46, p21 could not be detected at 
confluence but was rapidly induced within 2 hours of initiating the differentiation 
programme. This expression increased steadily until 48 hours after which point 
high levels of p21 were maintained until day 10. Since C/EBPa is only expressed 
from day 2 (48 hours) of the adipogenic programme, the kinetics of p21 
expression therefore suggest that it is unlikely to be a target for C/EBPa-mediated 
transactivation in the 3T3-L1 system. A similar pattern of expression was also
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Figure 46. Western Blot Analysis of p21 Expression During the
Differentiation Programme.
Protein samples were prepared at the times indicated and equal amounts subjected 
to SDS-PAGE and Western blot analysis using the C-19 polyclonal antibody 
(1:250) and the ECL detection method.
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observed in the Myc-expressing cell lines and the differentiation defective clone 
(Figure 46). Whilst p21 was not apparent at day 10 in WT6 and WT8, it should 
be noted that this was not a consistent finding and low levels of the protein were 
generally evident at this time point. It therefore appears unlikely that p21 is 
involved in the irreversible cell cycle withdrawal associated with acquisition of 
the adipocyte phenotype.
In addition to p21, we also examined the expression pattern of p27 during 3T3-L1 
differentiation since it was previously shown that the p27 mRNA was induced 
following clonal expansion (Vaziri and Faller, 1996). Lysates were prepared at 
various times and subjected to Western blot analysis using a p27-specific 
polyclonal antibody raised against a recombinant murine protein (the generous 
gift of S. Coats, Amgen, CA, USA). Expression of p27 during 3T3-L1 
differentiation was found to be very similar to that observed with p21, with the 
exception that the protein was readily detected at confluence (Figure 47). As for 
p21, the highest level of expression was observed between 48 and 96 hours (day 
4), with a down-regulation in the fully differentiated sample (day 10). In contrast, 
reduced levels of the protein were detected in WT6 between 8 and 24 hours, with 
high levels being maintained thereafter, whilst in WT8 p27 was low between 
hours 4 and 24 (Figure 47). The differentiation defective cell line was found to 
express reduced amounts of the protein between hours 12 and 72. The functional 
significance of these findings is not clear but may relate to the clonal expansion 
phase (see Figures 41, 42 and 43). However, the fact that p27 was detected in all 
the cell lines during the late stages of the differentiation programme suggests that 
this protein is not responsible for the irreversible cell cycle withdrawal.
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Figure 47. Western Blot Analysis of p27 Expression During the
Differentiation Programme.
Protein samples were prepared at the times indicated and equal amounts subjected 
to SDS-PAGE and Western blot analysis using the p27 polyclonal antibody 
(1:5000) and the ECL detection method.
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9.5 Summary.
Examination of cell cycle profiles during induced differentiation suggested that 
inhibition of adipogenesis was not associated with an inability to arrest at 
confluence or undergo mitotic clonal expansion in response to hormonal 
stimulants. Additionally, preadipocytes did not appear to enter an irreversible 
growth arrest state prior to undergoing morphological differentiation as had 
previously been postulated, since cells which were actively undergoing shape 
changes retained the ability to respond to mitogens and did not display a reduced 
cloning efficiency. However, adipocytes lost these properties at an ill-defined 
point late in the differentiation programme and permanently withdrew from the 
cell cycle. This phenomenon was not observed in cell lines which were unable to 
differentiate. Attempts to distinguish this growth arrest by biochemical and 
molecular criteria proved somewhat disappointing but obviously represent an area 
for future study.
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CHAPTER 10: Inhibition of Adipogenesis by the c-Myc Oncoprotein.
10.1 Introduction.
The primary objective of this project was to investigate the ability of the c-Myc 
oncoprotein to inhibit the process of cellular differentiation. For this purpose we 
employed the 3T3-L1 cell line, a well-characterised in vitro model of adipocyte 
development, since enforced expression of c-myc in this system is associated with 
loss of differentiation capacity. Whilst differentiation-control remains a poorly 
understood facet of c-Myc function, several models have been proposed to account 
for the ability of this protein to inhibit adipogenesis (Section 3.9). These models 
are therefore discussed in detail below, where they are placed within the context of 
observations made during the course of this study.
10.2 Enforced Expression of c-myc in the 3T3-L1 Cell Line Does Not Result in 
Deregulated Growth Control.
Proliferation and differentiation are generally regarded as mutually exclusive 
events. It is therefore possible that c-Myc inhibits differentiation indirectly as a 
consequence of continued proliferation. However, whilst constitutive expression of 
an avian c-myc transgene in the 3T3-L1 cell line was clearly associated with a block 
to adipogenesis, there was no evidence to suggest that deregulated growth control 
had also occurred. The Myc-expressing WT clones remained contact inhibited, 
could not grow in suspension and did not exhibit an increased growth rate relative 
to the control cultures. Indeed, a single clone (WT3) that expressed high levels of 
the exogenous protein was severely retarded in its ability to grow under standard 
culture conditions. These findings were not peculiar to the avian protein since 
previous studies had concluded that neither murine (Freytag, 1988) nor human c- 
Myc (Freytag et al, 1990) were able to transform the 3T3-L1 cell line. However,
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enforced expression of these proteins was associated with a differentiation block. 
That constitutive expression of c-myc in the 3T3-L1 cell line was not associated 
with deregulated growth control was confirmed by flow cytometric analysis 
following induction of the differentiation programme. In this experiment, the cell 
cycle profiles of the Myc-expressing clones were found to be highly similar to that 
observed with the parental 3T3-L1 line. Thus, maintenance at confluence resulted 
in an accumulation of cells in the Go phase of the cell cycle. Following treatment 
with the inducing hormones, a synchronous entry into S phase was detected in all 
lines at 24 hours with the cells undergoing a single round of mitosis before 
rearresting in Go at 48 hours, despite the continued presence of the hormone 
cocktail. Additionally, removal of the hormones by changing the medium was not 
associated with further cell divisions. Hence, the continued presence of c-myc in 
the WT6 and WT8 clones was not associated with abnormal cell cycle behaviour 
during the differentiation programme.
From our observations, it is apparent that differentiation control and cellular 
transformation are separable functions of the c-Myc protein and it is therefore 
unlikely that the Myc-mediated block to adipogenesis occurs indirectly as a 
consequence of deregulated proliferation. A similar conclusion was drawn from a 
recent study by our laboratory using the primary quail myoblast system (La Rocca 
et al, 1994). In this cell line, enforced expression of c-myc resulted in both cellular 
transformation and a blockade of the myogenic programme. In contrast, the leucine 
zipper deletion mutant, c-MycA7, was unable to inhibit myogenesis. However, this 
protein retained both the ability to bind Max and transformation potential. This 
suggested that Myc-mediated differentiation control and transformation may occur 
via distinct pathways and two models were proposed to account for these 
observations. Firstly, the threshold level of Myc/Max required to elicit cellular 
transformation may differ from that needed to block differentiation. Alternatively,
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Myc may inhibit myogenesis by a Max-independent pathway. The latter model is 
particularly attractive in the light of the recent isolation of alternative Myc binding 
partners (Section 3.4). A possible candidate for this activity is YY1 (Lee et al, 
1994), which is able to simultaneously control c-myc and the muscle-specific gene, 
a-actin. Dissociation of differentiation from transformation was also observed 
when another oncogene, Ha-ras, was over-expressed in the 23A2 myoblast cell 
line. In this system, Ha -ras was found to utilise separate signal transduction 
pathways in order to both elicit transformation and inhibit myogenesis (Weyman et 
al, 1997). Thus, transformation required the activity of the MAPK pathway, whilst 
differentiation control occurred via an as yet unidentified route.
In contrast to the Myc-expressing cell lines, flow cytometric analysis of the 
differentiation-defective clone, Def, suggested that it may continue to cycle 
following hormone withdrawal. That this cell line underwent the clonal expansion 
phase at all was somewhat surprising since we had consistently failed to detect a 
significant increase in cell number following hormone stimulation, suggesting that 
it may be unresponsive to this treatment. However, maintenance at confluence was 
often associated with increased cellular debris in the medium, particularly in the 
presence of 10% FCS, which might arise as a consequence of cell death. It is 
therefore possible, but not proven, that in the differentiation defective cell line 
proliferation in response to the inducing agents may be balanced by death, thereby 
resulting in no net increase in cell number. How this would relate to the inability of 
the cell line to undergo adipogenesis is not, however, entirely clear.
A possible molecular mechanism for the differentiation block manifest in the Def 
cell line has, however, arisen from a recent study in which rapamycin was used to 
inhibit adipogenesis (Yeh et al, 1995b). The effect of this immunosuppressant on 
the 3T3-L1 cell line was found to be very similar to the phenotype of our clone
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which had spontaneously lost the ability to differentiate. Hence, rapamycin- 
mediated inhibition of differentiation resulted in an inability to accumulate 
cytoplasmic triglyceride, presumably as a consequence of the impaired expression 
of both isoforms of C/EBPa. However, of greater interest with respect to the Def 
cell line, rapamycin did not alter the expression of C/EBP8 but did cause a 
reduction in the levels of the C/EBP p protein, particularly the LIP isoform. 
Additionally, the clonal expansion phase was characterised by no net increase in 
cell number as compared to untreated controls. Rapamycin is thought to act by 
binding to specific intracellular receptors termed FKBPs, which are members of a 
family displaying peptidyl cz's-Znms-isomerase activity (Siekierka et al, 1989). This 
enzymatic activity is lost following ligand binding and rapamycin-FKBP 
complexes are then able to bind and inhibit a variety of secondary proteins involved 
in signal transduction pathways, including p70 S6 kinase (Chung et al, 1992) and 
the 110-kDa subunit of phosphatidylinositol-3-kinase (Kunz et al, 1993). It was 
therefore postulated by Yeh and co-workers (1995b) that the insulin/IGF-1 signal 
transduction pathway represented an attractive candidate for inhibition by 
rapamycin during 3T3-L1 differentiation. Thus, it is possible that the Def cell line 
is unable to undergo induced differentiation as a consequence of impaired insulin 
signalling. Interestingly, a novel FKBP has recently been identified in the 3T3-LI 
cell line that is expressed predominantly during clonal expansion, suggesting a 
specialised function during this phase of the differentiation programme (Yeh et al, 
1995c). Since the enzymatic activity of this protein was also found to be inhibited 
by rapamycin, it will doubtless be of great interest to determine the physiological 
ligands of the FKBPs as such studies might shed light on novel factors that control 
the differentiation process.
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10.3 Initiation of the Terminal Stages of the Differentiation Programme Does 
Not Require Entry into a Specific Growth Arrested State.
As described in detail in Section 1.5.4, it is widely assumed that following clonal 
expansion preadipocyte cell lines enter a specific growth arrest state, designated 
Go, which is thought to be both permissive for the terminal stages of the 
differentiation programme and irreversible. Thus, it is possible that constitutive 
expression of c-myc inhibits adipogenesis by preventing entry into this Go arrest 
state. To test this hypothesis we therefore examined cell cycle behaviour following 
the clonal expansion phase.
Flow cytometric analysis at day 3 of the differentiation programme demonstrated 
that both the Myc-expressing clones and the parental 3T3-L1 cell line were arrested 
in the Go phase of the cell cycle. However, at this time the 3T3-L1 cells were 
obviously undergoing morphological changes consistent with terminal 
differentiation whilst the WT lines retained the fibroblastic appearance 
characteristic of the preadipocyte stage. We therefore reasoned that if terminal 
differentiation did indeed require a specialised form of growth arrest, this would be 
apparent at day 3. It had previously been demonstrated that the Go state can be 
distinguished from arrest at confluence (Gs) on the basis of a differential response 
to mitogens. Hence, whilst Go cells undergo DNA synthesis in response to 0.5mM 
MIX, stimulation with 30% serum is without effect. Conversely, Gs cells are only 
able to undergo mitosis in response to 30% serum. In order to determine which of 
these arrest states the 3T3-L1 and WT clones had entered following clonal 
expansion we treated day 3 cultures with either 0.5mM MIX or 30% DCS and 
assessed the subsequent ability to synthesise nuclear DNA by in situ BrdU 
labelling. Surprisingly, all three cell lines were found to incorporate high levels of 
BrdU in response to both treatments. Hence, the biochemical criteria employed in 
this experiment were unable to distinguish separate growth arrest states. This result
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was somewhat unexpected since the study of Freytag (1988) had previously 
demonstrated that following clonal expansion 3T3-L1 cells constitutively 
expressing murine c-myc underwent DNA synthesis in response to 30% serum, 
whilst untransfected controls remained growth arrested. The inability of the 3T3- 
L1 cell line to respond to the mitogenic effects of high levels of serum was found to 
require prior treatment with the hormone cocktail since uninduced cultures 
replicated in the presence of 30% serum. Conversely, the ability to undergo mitosis 
following hormone treatment required c-myc since co-expression of a c-myc 
antisense construct abrogated this effect. On the basis of these findings, Freytag 
therefore proposed that hormone treatment/clonal expansion was necessary for cells 
to enter a differentiation-specific growth arrest state and that the continued presence 
of c-myc somehow interfered with this process thereby resulting in an inability to 
undergo adipocyte differentiation. However, it has been shown that enforced 
expression of v-myc in C2C12 myoblasts did not prevent cell cycle withdrawal 
following initiation of the myogenic programme (Crescenzi et al, 1994). As 
described for adipocyte differentiation, this growth arrest, designated 
“commitment”, is thought to be both irreversible and necessary for subsequent 
muscle-specific gene expression. Hence, in this system v-myc could inhibit the 
terminal stages of the differentiation programme without affecting the ability to exit 
the cell cycle.
Since we were unable to define the Go arrest state biochemically within our system, 
we decided to examine the expression of proteins known to play a role in growth 
arrest. It is well documented that the large isoform of C/EBPa possesses anti­
mitotic activity and it was recently suggested that this function may require 
induction of the CKI, p21(Timchenko et al, 1996), which was previously 
implicated in the growth arrest mediated by myogenic transcription factors during 
in vitro differentiation. In addition, high levels of this protein have been detected in
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a variety of post-mitotic, terminally differentiated cell types (Parker et al, 1995). 
Postulating that entry into the Go arrest state may also require the activity of p21, 
we therefore examined the expression of this protein during 3T3-L1 adipogenesis. 
Assuming that p21 did indeed represent a bona fide target for C/EBPa-mediated 
transactivation, we predicted that it would be expressed in a similar temporal 
pattern to other C/EBPa regulated genes but would be absent in the Myc- 
expressing clones, which did not express either isoform of the C/EBPa protein. 
However, contrary to these expectations p21 was found to be expressed prior to 
C/EBPa during differentiation of the 3T3-L1 cell line and a similar pattern of 
expression was observed in the WT clones. Additionally, the differentiation 
defective cell line, which also lacked C/EBPa, expressed p21 in a manner 
indistinguishable from that detected in the 3T3-L1 line. Thus, it is unlikely that 
p21 mediates the anti-mitotic effects of C/EBPa in the 3T3-L1 system or that it is 
involved in the differentiation-specific growth arrest. Similarly, expression of 
another CKI, p27, was unaltered by either Myc-mediated or spontaneous inhibition 
of differentiation. However, since such studies did not address the ability of these 
CKIs to inhibit their specific cell cycle targets, we cannot exclude the possibility 
that functional differences may exist between the various cell lines. Indeed, c-Myc 
has been shown to abrogate the activity of p27 by sequestration into an inactive 
form (Vlach et al, 1996). In addition to p21 and p27, a number of other growth 
arrest-associated genes are differentially expressed during 3T3-L1 differentiation 
(Shugart et al, 1995). One of these, gas6, is expressed towards the end of the 
clonal expansion phase, making it a plausible candidate for the mediator of the Gd 
arrest. It would therefore be of interest to examine the expression of this gene 
under conditions in which adipogenesis is blocked, for example by the constitutive 
expression of c-myc.
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What is clear from our study, however, is that acquisition of the adipocyte 
phenotype was associated with a reduced plating efficiency and fully differentiated 
cells were no longer able to respond to 30% DCS. This loss of mitogenic 
responsiveness occurred at some point between day 3 and 10 of the differentiation 
programme and followed expression of the fat-specific markers aP2 and SCD1. On 
the basis of these findings we suggest that irreversible growth arrest is not so much 
a driving force of the adipogenic programme as a consequence of it. It is therefore 
possible that the anti-mitotic effects of C/EBPa are required to maintain fully 
differentiated adipocytes in the quiescent state rather than to initiate terminal 
differentiation. In this regard, it is of interest to note that the growth arrest and 
DNA damage gene, GADD45, was found to be expressed during the terminal 
stages of 3T3-L1 differentiation with similar kinetics to the fat-specific genes 
(Constance et al, 1996). Transactivation studies using gadd45 promoter constructs 
indicated that expression of this gene was positively regulated by C/EBPa and that 
this activity could be antagonised by co-expression with c-Myc. Hence, GADD45 
represents a putative target for Myc-mediated repression late in the differentiation 
programme. Interestingly, GADD45 and p21 have been found to directly interact 
with one another and this is synergistic for growth arrest (Kearsey et al, 1995). 
Thus, the differentiation-specific cell cycle withdrawal may require the interaction 
of two or more negative regulators of cell growth. In this regard, the tumour 
suppressor pRb has been implicated in cell cycle exit during myogenesis 
(Zacksenhaus et al, 1996) and MEL cell differentiation (Zhuo et al, 1995). A 
recent study using the C2C12 myoblast system concluded that maintenance of this 
growth arrest following terminal differentiation required the activity of both pRb 
and the CKI, p i8 (Franklin and Xiong, 1996). Since lung fibroblasts derived from 
pRb null mice were unable to undergo induced adipogenesis (Chen et al, 1996a), 
this protein might also be involved in establishing the growth arrest state
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characteristic of mature adipocytes. Clearly the relationship between terminal 
differentiation and cell cycle withdrawal represents an area ripe for further study.
10.4 Enforced Expression of c-myc in the 3T3-L1 Cell Line Results in 
Repression of the Key Adipogenic Transcription Factors, C/EBPa and 
PPARy2.
Analysis of a number of markers representative of the various stages of the 
adipogenic programme demonstrated that the Myc-mediated block to 3T3-L1 
differentiation was associated with impaired expression of the late genes C/EBPa, 
PPARy2, aP2 and SCD1. This phenotype was very similar to that previously 
described when adipocyte differentiation was blocked by the cytokine TNFa, which 
is hardly surprising since it is now believed that TNFa exerts its effects on 
adipogenesis indirectly via induction of c-myc (Ninomiya-Tsuji et al, 1993). Since 
C/EBPa and PPARy2 are thought to act in concert in order to co-ordinate the 
expression of genes required for lipid metabolism, such as aP2 and SCD1, these 
observations provide a molecular mechanism for the inability of the WT cell lines 
to accumulate cytoplasmic triglyceride. We therefore propose that constitutive 
expression of c-myc in the 3T3-L1 cell line inhibits differentiation by repressing 
expression of the key adipogenic transcription factors, C/EBPa and PPARy2, 
thereby resulting in an inability to induce fat-specific gene expression and 
triglyceride biosynthesis. Indeed, repression of master transcriptional regulators 
may prove to be a common theme in oncogene-mediated differentiation control. 
Thus, inhibition of myogenesis by enforced expression of c-myc in primary quail 
myoblasts was associated with the down-regulation of both MyoD and myogenin 
(La Rocca et al, 1994), whilst co-expression of c-myc in NIH-3T3 cells suppressed 
MyoD and myogenin-initiated terminal differentiation (Miner and Wold, 1991). 
Additionally, constitutive expression of a wide range of activated oncogenes,
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including v-ras, v-src and v-jun, in primary quail myoblasts was found to severely 
impair the expression of myogenin (Russo et al, 1997).
Whilst our observations define a point at which c-Myc is repressing adipogenesis, 
they do not in themselves provide an explanation for the mechanism by which this 
occurs. Expression of C/EBPa and PPARy2 during the differentiation programme 
is thought to require the activity of C/EBPp and C/EBP8, which are themselves 
induced during the clonal expansion phase. However, Northern blot analysis 
clearly demonstrated that expression of the C/EBPp and 5 mRNAs was not altered 
in the WT cell lines. Additionally, both the LAP and LIP isoforms of C/EBPp were 
found to be expressed in response to MIX during clonal expansion. However, since 
we did not determine whether these proteins were still functional, it is possible that 
their activity was somehow impaired by the continued presence of c-Myc. Studies 
using the C/EBPp homologue, NF-IL6, have demonstrated that the ability of this 
factor to activate target genes is greatly enhanced by site-specific phosphorylation 
at serine 105 (Trautwein et al, 1993). Phosphorylation in vitro could be achieved 
by a variety of kinases including MAPK and protein kinase C but did not alter the 
ability of the protein to bind DNA. It was subsequently demonstrated that C/EBPp 
exists in a transcriptionally inert form which requires phosphorylation for 
derepression (Kowenz-Leutz et al, 1994). The inhibitory activity was found to 
reside in the N-terminus of the molecule, where two regions (CR5 and CR7) appear 
to mask the transactivation domain. This masking effect could, however, be 
relieved by phosphorylation and it is interesting to note that serine 105 is located 
within the CR5 domain. Hence, inhibition of such site-specific phosphorylation 
might restrain the transcriptional activity of C/EBPp during 3T3-L1 differentiation. 
However, it is not clear how c-Myc might exert such an effect. An alternative 
explanation is that enforced expression of c-Myc inhibits the DNA binding activity 
of C/EBP family proteins. Both the C/EBPa and PPARy2 promoters contain
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consensus C/EBP binding sites and it is assumed that C/EBPp and 8 regulate gene 
expression via these sequences. As described in Section 3.9.3, it has recently been 
demonstrated that the Myc/Max complex has the capacity to bind a consensus 
C/EBP recognition site located within the EFII enhancer of the Rous sarcoma virus 
LTR (Hann et al, 1994). It is therefore possible that c-Myc inhibits C/EBPp/8 
mediated transactivation of C/EBPa and PPARy2 by competitive binding at the 
C/EBP binding site. However, v-Myc-mediated inhibition of C/EBPa and 
C/EBPp-dependent transactivation during myelopoiesis was found to require only 
the N-terminal portion of the oncoprotein, suggesting that repression did not 
involve DNA binding (Mink et al, 1996). What is intriguing, however, is the 
observation that the alternatively translated product of c-myc, Mycl, may also bind 
the C/EBP site (Hann et al, 1994). However, in contrast to Myc2, this interaction 
was associated with increased transactivation potential rather than repression. 
Since all studies conducted thus far on the ability of c-Myc to inhibit adipogenesis 
have utilised the Myc2 protein, it would therefore be of great interest to determine 
the effect of Mycl on the differentiation programme.
It is widely assumed that the biologically active form of c-Myc comprises a 
heterodimer with Max, and that it is Max which directs the ability of the complex 
to specifically bind the E-box sequence. However, recent evidence had suggested 
that the Myc-mediated inhibition of PC 12 cell differentiation occurred in the 
absence of functional Max. Since the Max status of the 3T3-L1 cell line was 
unknown, we decided to analyse the expression of this protein during adipogenesis. 
Western blot analysis demonstrated that Max was readily detectable in this system, 
with the p21 isoform predominating. Whilst the PPARy2 promoter remains to be 
fully characterised, a canonical Myc/Max binding site has been identified in the 
proximal promoter of the C/EBPa gene. The possibility therefore exists that Myc- 
mediated repression of C/EBPa occurs through this site. Indeed, this Myc/Max
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binding motif is located in a region of the promoter enriched in negative regulatory 
elements, including the site for CUP which is proposed to inhibit expression of 
C/EBPa in the preadipocyte stage. The case for repression by the Myc/Max 
complex is strengthened by the observation that deletion of residues from the LZ 
domain of c-Myc imposed radical effects on the capacity of this protein to inhibit 
differentiation. As judged by cytoplasmic triglyceride accumulation, the removal 
of seven amino acids from the extreme C-terminus of the molecule, including 
leucine 4 of the heptad repeat, did not alter the ability to block adipogenesis. 
However, deletion of a further three residues completely abolished the inhibitory 
activity. This mutant (c-MycAlO) lacked both leucine 4 and an additional leucine 
residue, 3A, which is thought to participate in interactions which stabilise the 
zipper domain. Since we had previously demonstrated that c-MycAlO lacks the 
ability to bind Max (Crouch et al, 1993), an obvious explanation for our data is that 
inhibition of adipogenesis requires interaction with Max via an intact LZ motif. 
However, our findings cannot exclude the possibility that c-Myc inhibits 3T3-L1 
differentiation by a Max-independent pathway, which also requires the extreme C- 
terminus of the protein.
The formation of Myc/Max heterodimers is regulated primarily by the availability 
of the c-Myc protein. However, our analysis of the Myc antagonist, Madl, in the 
3T3-L1 system clearly demonstrated that high levels of this protein were present in 
the WT clones, whilst expression of the exogenous c-Myc was barely detectable. If 
Madl was indeed in excess of c-Myc in these cells then it might be envisaged that 
the equilibrium would be pushed in favour of Mad/Max complex formation, 
resulting in loss of Myc/Max binding at the E-box. However, enforced expression 
of c-Myc was obviously associated with a block to 3T3-L1 differentiation, 
suggesting that this function may not require the presence of Max or binding to the 
consensus sequence. In this regard, it was recently shown that c-Myc has the
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capacity to bind an additional DNA sequence, designated the initiator (Inr) element, 
and that binding at this site represses gene expression (Mai and Martensson, 1995). 
Interestingly, this activity required a conserved region in the N-terminus of c-Myc, 
Myc Box II (Li et al, 1994), which was previously demonstrated to be necessary for 
the Myc-mediated inhibition of adipogenesis (Freytag et al, 1990). Since the core 
promoter of the C/EBPa gene contains an Inr element, Li and co-workers (1994) 
therefore postulated that repression in the presence of c-Myc occurred via this site. 
Thus, they were able to demonstrate that enforced expression of c-myc in the 3T3- 
L1 cell line resulted in a concentration-dependent inhibition of a C/EBPa promoter 
construct. Since this construct lacked the E-box site and repression depended 
solely upon the integrity of the Inr sequence, it was concluded that c-Myc inhibited 
C/EBPa gene expression by a novel mechanism.
In addition to Max, c-Myc is able to interact with a number of additional factors 
(Section 3.4). Two of these proteins, YY-1 and TFII-I, are known to exert their 
transcriptional effects through the Inr of target genes. It is therefore of interest to 
note that interaction of c-Myc and TFII-I was associated with repression of core 
promoter constructs harbouring an Inr element (Roy et al, 1993). However, TFII-I 
may also activate such constructs when associated with the transcription factor, 
USF (Roy et al, 1991). Like c-Myc, USF is a member of the bHLH-LZ family of 
transcriptional regulators, with the capacity to bind both the E-box and Inr 
sequences. Since positive modulation of C/EBPa gene expression has been shown 
to require the activity of USF (Timchenko et al, 1995), it is therefore possible that 
c-Myc and USF have opposing functions during adipogenesis. Indeed, c-Myc was 
found to repress the USF mediated transactivation of C/EBPa promoter constructs 
in 3T3-L1 cells (Li et al, 1994). Since USF is able to inhibit cellular 
transformation arising from the co-operation of c-Myc and Ras (Luo and 
Sawadogo, 1996), it would therefore be of great interest to determine whether co­
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expression of USF in the WT clones could also abrogate the Myc-mediated block 
to adipogenesis.
10.5 Myc-Mediated Inhibition of Adipogenesis is Abrogated by Foetal Calf 
Serum.
Possibly the most unexpected finding of this study was the observation that 
differentiation in the presence of 10% FCS was sufficient to over-ride the inhibitory 
effects of c-myc in the 3T3-L1 cell line. Analysis of genetic markers of 
adipogenesis indicated that this treatment restored the expression of C/EBPa, 
PPARy2, aP2 and SCD1 and this was associated with accumulation of cytoplasmic 
triglyceride in both the WT and A7 cell lines. However, acquisition of the 
adipocyte phenotype did not affect expression of the avian c-myc 2.1 kb mRNA 
species during the differentiation programme. This was surprising since it is widely 
assumed that down-regulation of c-myc is a prerequisite for differentiation to 
proceed in a variety of cell types. However, it was previously demonstrated that 
inhibition of U-937 monoblast differentiation by enforced expression of v-myc 
could be overcome by co-stimulation with interferon-y, and that this was 
accomplished without altering either the expression or sub-cellular localisation of 
the v-Myc protein (Oberg et al, 1991). It is well documented that interferon-y 
exerts its effects on gene expression via activation of the JAK/STAT signal 
transduction pathway (Ihle and Kerr, 1995). Interestingly, it has now become 
apparent that these factors are also involved in adipocyte biology (Darnell, 1996). 
Indeed, expression of STAT 1 and STAT 5 was found to be markedly reduced 
during a TNFa-mediated differentiation block in the 3T3-L1 cell line (Stephens et 
al, 1996). Since the ability of TNFa to inhibit adipogenesis is thought to be 
mediated in part by c-Myc, it is therefore possible that the STAT family of 
transcription factors represent another target for repression by this oncoprotein.
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In contrast to TNFa, growth hormone stimulation positively modulates the activity 
of the JAK/STAT pathway during adipogenesis (Section 1.4.1). As the adipogenic 
effects of growth hormone have been well documented and FCS contains obviously 
elevated levels of this factor when compared with DCS, we therefore postulated 
that growth hormone might be the component of FCS responsible for abrogating 
the effects of c-Myc during 3T3-L1 differentiation. To test this hypothesis, we 
supplemented DCS with purified bovine pituitary growth hormone and assessed the 
ability to induce differentiation in the WT cell lines. Surprisingly, whilst WT8 
differentiated in a manner akin to that previously observed in the presence of 10% 
FCS, growth hormone treatment was without effect in the WT6 cell line. However, 
WT6 and WT8 had displayed a similar response following induction in 10% FCS. 
It should be noted, however, that when we induced differentiation in the presence 
of DCS/FCS mixtures WT6 required much higher levels of FCS than WT8 in order 
to differentiate. To fully assess the effect of growth hormone we therefore 
examined the ability of the remaining WT clones to differentiate in response to 
DCS supplemented with this factor. From this experiment it was determined that 
growth hormone could elicit a range of responses in the Myc-expressing cell lines, 
whilst treatment with 10% FCS resulted in a fairly uniform pattern of 
differentiation. One possible explanation for these results is that the individual WT 
cell lines express different numbers of growth hormone receptors on the cell 
surface. Alternatively, growth hormone signalling might be impaired in cell lines 
such as WT6. However, at present we cannot distinguish between these 
possibilities. Since adipogenesis requires the interaction of a large number of 
signal transduction pathways, we therefore suggest that the effects of FCS on the 
differentiation capacity of 3T3-L1 cell lines constitutively expressing c-myc will 
probably involve the activity of more than one serum component. Whether growth 
hormone is actually required to mediate this effect will require further 
investigation.
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10.6 Conclusions.
In summary, we have generated a number of preadipocyte cell lines which 
constitutively express c-myc and as a result are no longer able to undergo induced 
differentiation. Inhibition of adipogenesis was not found to be associated with 
either cellular transformation or abnormal cell cycle behaviour during the 
differentiation programme. However, repression of fat-specific gene expression 
and the inability to accumulate cytoplasmic triglyceride were shown to arise as a 
consequence of the inhibition of the key adipogenic transcription factors, C/EBPa 
and PPARy2. The mechanism by which c-Myc inhibits expression of these genes 
remains unclear. However, treatment with 10% FCS was found to over-ride these 
effects and restore the ability of Myc-expressing cell lines to differentiate. Thus the 
ability of c-Myc to inhibit adipogenesis in the 3T3-L1 cell line may be modulated 
by external factors.
10.7 Future Prospects.
The ability to inhibit cellular differentiation is probably one of the least understood 
biological functions of the c-Myc oncoprotein. However, the lines generated 
during the course of this study will doubtless provide a useful tool with which to 
investigate this phenomenon further. We have thus far established a point at which 
c-Myc blocks adipogenesis but the mechanism by which this occurs remains 
unclear, although reference to the literature indicates that several possibilities exist. 
To address this issue it will therefore be vital to determine whether Myc-mediated 
inhibition of 3T3-L1 differentiation is a Max-dependent or Max-independent 
phenomenon and which of the putative DNA binding sites is actually required to 
exert this effect. Secondly, further investigation is necessary to establish the mode 
of action of FCS during abrogation of the Myc block. Since FCS restores 
expression of genes known to be repressed by the continued presence of c-Myc, 
these studies may also shed light on factors that either positively or negatively
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regulate gene expression during adipogenesis. Finally, the issue of whether 
irreversible growth arrest is a prerequisite for adipocyte development and the 
identification of differentiation-specific cell cycle regulators warrants further study. 
Indeed, the recent observation that the “irreversible” growth arrest manifest in both 
mature myotubes and adipocytes may be over-come by the adenovirus El A protein 
(Crescenzi et al, 1995) suggests that such studies will be relevant not just to 
differentiation in particular but to growth control in general. It is therefore 
anticipated that by investigating the ability of c-Myc to inhibit adipogenesis we will 
further our current understanding of both the mode of action of this important 
oncoprotein and the processes that drive terminal differentiation.
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